<html lang="en" class="pb-page js" data-request-id="94d6e9573670da2e-SJC"><head data-pb-dropzone="head"><style type="text/css" nonce="94d6e9573670da2e-SJC">@font-face {font-family: "Source Sans Pro";src: url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.ttf) format("truetype"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.woff) format("woff"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.otf) format("opentype"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.eot) format("embedded-opentype");}.truste_cursor_pointer {cursor: pointer;}.truste_border_none {border: none;}.truste_accessible_link {font-family: "Source Sans Pro", sans-serif;color: #1D4ED8;font-size: 14px;font-weight: 600;text-decoration: underline;}.truste_accessible_link:hover {color: #1D4ED8;text-decoration: none !important;}.truste_accessible_link:focus-visible {outline: none;border-radius: 4px;box-shadow: 0 0 0 1px #FFFFFF, 0 0 0 4px #3699F1;}</style><script src="https://ssl-cdn.janraincapture.com/widget_data/flow.js:7h8bznq6j7bvyvzqcrwvyp8dfb:en-US:20240514181256512029:standard" type="text/javascript"></script><script src="https://cssjs.nejm.org/akamai/capture:login" type="text/javascript"></script><script src="https://ssl-widget-cdn.rpxnow.com/translations/login/en-US" type="text/javascript"></script><script type="text/javascript" id="janrainAuthWidget" src="https://cssjs.nejm.org/akamai/mms-prod.js"></script><script type="text/javascript" src="https://www.nejm.org/ZoQZhd7Ih2VGMOoI-f-8H_Lu2iZ3_XzL9EAjaNF2JDB4Cb4FtPOun88779EaE-91UsleG0tikePbqqGSh1UDMA=="></script>
            

<meta charset="UTF-8">






    
        
            
        
    
        
            
        
    
        
            
        
    
        
            
        
    
        
    
        
    
        
            
                
                
<title>Rivaroxaban in Rheumatic Heart Disease–Associated Atrial Fibrillation | New England Journal of Medicine</title>





                
            
        
    







    
        
            
        
    
        
            
        
    
        
            
                
                



                
            
        
    
        
            
        
    
        
    
        
    
        
            
        
    











    








    

    
    

    
    
    
    
        
            
                <link rel="stylesheet" type="text/css" href="/wro/1125813~article-metrics.css">
            
            
            
        
    

    
    
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_nejm_1-994b0160d1eb33dc79517ef0295aab1b.ico" type="image/x-icon">
        
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_16-4aa032aa775940f725817b7ff42f0e2c.png" type="image/png" sizes="16x16">
        
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_32-0a94fa44823476ffa0bb15bdb320fb34.png" type="image/png" sizes="32x32">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_152-d6c3522864a8e483996b7e9c132c901a.png" sizes="152x152">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_180-f2538afc53a365d4cd3f10ab73c56aad.png" sizes="180x180">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_167-8e888012bbdd31a00c3e54bc5b8ca5b6.png" sizes="167x167">
        
    

    
    
            <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/build-5b89b331018866a4a965.css" media="all">
        <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/print-5b89b331018866a4a965.css" media="print">
           <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/build-article-5b89b331018866a4a965.css" media="all" id="article-style-sheet">
    
        <script nonce="94d6e9573670da2e-SJC">
        try {
            document.documentElement.classList.add('js');
        } catch (e) {
        }
    </script>
     
    

















    
        
            
                
                
                
                    
                    <!-- TrustArc Scripts -->
<script async="async" src="https://consent.trustarc.com/notice?domain=nejm.com&amp;c=teconsent&amp;js=nj&amp;noticeType=bb&amp;gtm=1&amp;text=true&amp;pcookie" crossorigin="" id="truste_0.5051763985156195"></script>
<script src="https://consent.trustarc.com/autoblockasset/core.min.js?domain=nejm.com"></script>
<script src="https://consent.trustarc.com/autoblockoptout?domain=nejm.com"></script>
<!-- /TrustArc Scripts -->
<!-- BlueConic Scripts -->
<script src="https://bc.nejm.org/script.js"></script>
    <!-- /BlueConic Scripts -->
<!-- Printing Meta Tags -->
    <meta name="Specialties" content="Allergy/Immunology|Cardiology|Infectious Disease">
<meta name="articleType" content="Original Article">
<meta name="articleCategory" content="Research">
<meta name="topics" content="Inflammatory Disease|Valvular Heart Disease|Arrhythmias/Pacemakers/Defibrillators|Anticoagulation/Thromboembolism (Cardiology)|Autoimmune Disease|Bacterial Infections|Global Health"><script type="text/javascript">var mmsData = {"access":{"isFreeCountry":"n"},"ad":{"category":"article"},"imageChallenge":{"id":null},"article":{"doi":"10.1056/NEJMoa2209051","title":"Rivaroxaban in Rheumatic Heart Disease–Associated Atrial Fibrillation","category":"Research","type":"Original Article","topics":"Inflammatory Disease|Valvular Heart Disease|Arrhythmias/Pacemakers/Defibrillators|Anticoagulation/Thromboembolism (Cardiology)|Autoimmune Disease|Bacterial Infections|Global Health","specialties":"Allergy/Immunology|Cardiology|Infectious Disease","seriesTitle":"","viewType":"Full","age":"2Years-1990","issueDate":"2022-09-15T00:00Z","isFree":"y","broadTopics":"","perspectiveTopics":"","granularTopics":"","methodologicalArea":"","isOnlineFirst":"n","isCurrentIssue":"n","metaTags":"\u003cmeta name\u003d\"Specialties\" content\u003d\"Allergy/Immunology|Cardiology|Infectious Disease\"/\u003e\n\u003cmeta name\u003d\"articleType\" content\u003d\"Original Article\"/\u003e\n\u003cmeta name\u003d\"articleCategory\" content\u003d\"Research\"/\u003e\n\u003cmeta name\u003d\"topics\" content\u003d\"Inflammatory Disease|Valvular Heart Disease|Arrhythmias/Pacemakers/Defibrillators|Anticoagulation/Thromboembolism (Cardiology)|Autoimmune Disease|Bacterial Infections|Global Health\"/\u003e"},"page":{"activity":"showFullText","url":"www.nejm.org/doi/full/10.1056/NEJMoa2209051","viewType":"desktop","journal":"NEJM"},"user":{"ucid":null,"audienceSegment":null,"specialtyGroupCode":null,"meterCountRemaining":null,"totalMeterCount":null},"object":[{"type":"Research Summary","title":"Rivaroxaban in Rheumatic Heart Disease–Associated Atrial Fibrillation","doi":"10.1056/NEJMdo006700","issueDate":"2022-09-15T00:00Z","age":"6Months-1990","isFree":"n","topics":"Inflammatory Disease|Valvular Heart Disease|Arrhythmias/Pacemakers/Defibrillators|Anticoagulation/Thromboembolism (Cardiology)|Autoimmune Disease|Bacterial Infections|Global Health","viewType":"Full","specialties":"Allergy/Immunology|Cardiology|Infectious Disease"},{"type":"Quick Take","title":"Rivaroxaban for AF in Rheumatic Heart Disease","doi":"10.1056/NEJMdo006699","issueDate":"2022-09-15T00:00Z","age":"6Months-1990","isFree":"n","topics":"Inflammatory Disease|Valvular Heart Disease|Arrhythmias/Pacemakers/Defibrillators|Anticoagulation/Thromboembolism (Cardiology)|Autoimmune Disease|Bacterial Infections|Global Health","viewType":"Full","specialties":"Allergy/Immunology|Cardiology|Infectious Disease"}]};</script>
    <script type="text/javascript">var mmsDataAdd = {"user":{"customerType":"null","accessInstitutionID":"null"}};</script>
    <!-- Prehiding snippet for Adobe Target with asynchronous Launch deployment -->
    <!-- placeholder id=null, description=Adobe-Target-Prehiding-Snippet --><!--
  Adobe Target - Prehiding Snippet
  v2.0.0
-->
<script nonce="94d6e9573670da2e-SJC">
function tgtNoFlicker(e,n,t,o,i,c,l,r){function d(){return n.getElementsByTagName("head")[0]}function a(e,t){if(e){var o=n.getElementById(t);o&&e.removeChild(o)}}function f(e,o){!function(e,t,o){if(e){var i=n.createElement("style");i.id=t,i.innerHTML=o,e.appendChild(i)}}(d(),t,e),setTimeout(function(){a(d(),t)},o)}var m;n.location.href.indexOf(c)>-1?f(l,r):f(o,i),n.location.href.indexOf("mboxDisable")>-1?(a(d(),t),console.log("[TARGET] - Disabled, removing prehiding style")):(m=function(e){e&&(a(d(),t),console.log("[TARGET] - Blocked, removing prehiding style"))},fetch("//cdn.tt.omtrdc.net/cdn/target-vec.js",{method:"HEAD",mode:"no-cors"}).then(e=>m(!1)).catch(e=>m(!0)))}

tgtNoFlicker(window, document, 'at-body-style', 'div[data-location-name="Anonymous Module"], div[data-location-name="Anonymous Banner"], main > div.page-body > div > div > div > div.col-md-2-3.o-col.o-col--primary > div[class*="u-hide"], main > div.page-body > div > div > div > div.col-md-1-3.o-col.o-col--secondary > aside, header > h1#mainContent, a.m-article__link[href*="/10.1056/NEJMoa2116747"] > span.m-article__blurb > p, li.g-nejm-group__user-tool-secondary {opacity: 0 !important}', 3000);

tgtNoFlicker(window, document, 'at-mbox-style', '.N-ad-global-top-right, #N-ad-myNEJM-contextual-top, .N-ad-recentArticles, #N-ad-article-rightRail-1, #N-ad-siteWide-rightRail-1, #N-ad-imageChallenge-rightRail-2 {opacity: 0 !important}', 3000);
</script><!-- /Prehiding snippet for Adobe Target with asynchronous Launch deployment -->
    <!-- Launch Header Embed Code -->
    <script src="//assets.adobedtm.com/launch-ENcd6450fae3ae4870becbe6a2b01ab2e1.min.js" async="" type="ta-blocked" data-ta-blocked="1"></script>
    <!-- /Launch Header Embed Code -->

                    
                
            
        
    
        
            
                
                
                
                    
                    <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/"><meta name="citation_journal_title" content="New England Journal of Medicine"><meta name="dc.Title" content="Rivaroxaban in Rheumatic Heart Disease–Associated Atrial Fibrillation"><meta name="dc.Creator" content="Stuart J. Connolly"><meta name="dc.Creator" content="Ganesan Karthikeyan"><meta name="dc.Creator" content="Mpiko Ntsekhe"><meta name="dc.Creator" content="Abraham Haileamlak"><meta name="dc.Creator" content="Ahmed El Sayed"><meta name="dc.Creator" content="Alaa El Ghamrawy"><meta name="dc.Creator" content="Albertino Damasceno"><meta name="dc.Creator" content="Alvaro Avezum"><meta name="dc.Creator" content="Antonio M.L. Dans"><meta name="dc.Creator" content="Bernard Gitura"><meta name="dc.Creator" content="Dayi Hu"><meta name="dc.Creator" content="Emmanuel R. Kamanzi"><meta name="dc.Creator" content="Fathi Maklady"><meta name="dc.Creator" content="Golden Fana"><meta name="dc.Creator" content="J. Antonio Gonzalez-Hermosillo"><meta name="dc.Creator" content="John Musuku"><meta name="dc.Creator" content="Khawar Kazmi"><meta name="dc.Creator" content="Liesl Zühlke"><meta name="dc.Creator" content="Lillian Gondwe"><meta name="dc.Creator" content="Changsheng Ma"><meta name="dc.Creator" content="Maria Paniagua"><meta name="dc.Creator" content="Okechukwu S. Ogah"><meta name="dc.Creator" content="Onkabetse J. Molefe-Baikai"><meta name="dc.Creator" content="Peter Lwabi"><meta name="dc.Creator" content="Pilly Chillo"><meta name="dc.Creator" content="Sanjib K. Sharma"><meta name="dc.Creator" content="Tantchou T.J. Cabral"><meta name="dc.Creator" content="Wadea M. Tarhuni"><meta name="dc.Creator" content="Alexander Benz"><meta name="dc.Creator" content="Martin van Eikels"><meta name="dc.Creator" content="Amy Krol"><meta name="dc.Creator" content="Divya Pattath"><meta name="dc.Creator" content="Kumar Balasubramanian"><meta name="dc.Creator" content="Sumathy Rangarajan"><meta name="dc.Creator" content="Chinthanie Ramasundarahettige"><meta name="dc.Creator" content="Bongani Mayosi"><meta name="dc.Creator" content="Salim Yusuf"><meta name="dc.Description" content="Testing of factor Xa inhibitors for the prevention of cardiovascular events in patients with rheumatic heart disease–associated atrial fibrillation has been limited.We enrolled patients with atrial..."><meta name="Description" content="Testing of factor Xa inhibitors for the prevention of cardiovascular events in patients with rheumatic heart disease–associated atrial fibrillation has been limited.We enrolled patients with atrial..."><meta name="dc.Publisher" content="Massachusetts Medical Society"><meta name="dc.Date" scheme="WTN8601" content="2022-09-15"><meta name="dc.Type" content="research-article"><meta name="dc.Format" content="text/HTML"><meta name="dc.Identifier" scheme="doi" content="10.1056/NEJMoa2209051"><meta name="dc.Identifier" scheme="publisher-id" content="NJ202209153871107"><meta name="dc.Language" content="EN"><meta name="dc.Relation" content="10.1056/NEJMe2210187"><meta name="dc.Relation" content="YXQYoa2209051"><meta name="dc.Coverage" content="world"><meta name="dc.Rights" content="Copyright © 2022 Massachusetts Medical Society. All rights reserved.">




<link rel="meta" type="application/atom+xml" href="https://doi.org/10.1056%2FNEJMoa2209051">
<link rel="meta" type="application/rdf+json" href="https://doi.org/10.1056%2FNEJMoa2209051">
<link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1056%2FNEJMoa2209051">


                    
                
            
        
    
        
            
                
                
                
                
                
            
        
    
        
            
                
                
                
                    
                    





<meta name="robots" content="noarchive">





    





    
    
        
        <meta name="twitter:title" content="Rivaroxaban in Rheumatic Heart Disease–Associated Atrial Fibrillation | NEJM">
        <meta property="og:title" content="Rivaroxaban in Rheumatic Heart Disease–Associated Atrial Fibrillation | NEJM">
    


    <meta property="og:type" content="article">


    
    
        <meta property="og:url" content="https://www.nejm.org/doi/full/10.1056/NEJMoa2209051">
    
    


    
    
        <meta property="og:image" content="https://www.nejm.org/cms/asset/e90d5a28-e029-4528-ac8d-406ff07dcedd/nejmoa2209051_f0.jpg">
        <meta name="twitter:image" content="https://www.nejm.org/cms/asset/e90d5a28-e029-4528-ac8d-406ff07dcedd/nejmoa2209051_f0.jpg">
    



    <meta property="og:site_name" content="The New England Journal of Medicine">


    
    
        
        <meta property="og:description" content="Testing of factor Xa inhibitors for the prevention of cardiovascular events in patients
with rheumatic heart disease–associated atrial fibrillation has been limited. We enrolled
patients with atria...">
        <meta name="twitter:description" content="Testing of factor Xa inhibitors for the prevention of cardiovascular events in patients
with rheumatic heart disease–associated atrial fibrillation has been limited. We enrolled
patients with atria...">
    


    
    
        <meta property="og:image:width" content="2640">
    


    
    
        <meta property="og:image:height" content="3416">
    


    <meta name="twitter:card" content="summary">


    <meta name="twitter:site" content="@NEJM">


<meta name="viewport" content="width=device-width,initial-scale=1"><meta name="publication_doi" content="10.1056/NEJMoa2209051">


    















                    
                
            
        
    
        
    
        
    
        
            
                
                
                
                
                
            
        
    




<meta name="format-detection" content="telephone=no">

<meta http-equiv="X-UA-Compatible" content="IE=edge">
    




    
        
        
        <link rel="canonical" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2209051">
    
    







<meta name="pbContext" content=";requestedJournal:journal:nejm;page:string:Article/Chapter View;ctype:string:Journal Content;issue:issue:doi\:10.1056/nejm_2022.387.issue-11;wgroup:string:MMS NextGen Website Group;article:article:doi\:10.1056/NEJMoa2209051;pageGroup:string:Publication Pages;subPage:string:Full Text;website:website:mms-site;journal:journal:nejms">
        <link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-933-8e181dff8b36ea01dc4c.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-34-6ea546d794fb7a1cea52.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-743-ddd329e1530654ec0846.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-305-9eee37798fdfe5196307.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-388-bb098c62445f518c0b46.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-556-8e58ca05fb5497e541ef.css"><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/0-dfd243c732a07d3608f6.js"></script><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/7-10d355ba95f7ec1fddf2.js"></script><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/11-04bf2a0da30146b4a5d0.js"></script><script id="altmetric-embed-js" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/altmetric_badges-288192a491f0ad9cc434f05ea175659426f5ab0cfd6befb3f3592f96bb90b0d1.js"></script><script src="https://static.addtoany.com/menu/modules/core.pt5ow5lr.js" type="module"></script><link rel="preconnect" href="https://use.typekit.net"><meta http-equiv="P3P" content="CP=&quot;NOI DSP ADM OUR IND OTC&quot;"><link id="altmetric-embed-css" rel="stylesheet" type="text/css" href="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed-59614f5c46b49b21eeef3bb28c4fb38d1e7069e8d014752fcb66e84942556802.css"><link rel="stylesheet" href="https://quilt-cdn.janrain.com/HEAD/providers.css" type="text/css"><style type="text/css">.a2a_hide{display:none}.a2a_logo_color{background-color:#0166ff}.a2a_menu,.a2a_menu *{-moz-box-sizing:content-box;-webkit-box-sizing:content-box;box-sizing:content-box;float:none;margin:0;padding:0;position:static;height:auto;width:auto}.a2a_menu{border-radius:6px;display:none;direction:ltr;background:#FFF;font:16px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;color:#000;line-height:12px;border:1px solid #CCC;vertical-align:baseline;overflow:hidden}.a2a_mini{min-width:200px;position:absolute;width:300px;z-index:9999997}.a2a_overlay{display:none;background:#616c7deb;backdrop-filter:blur(4px);-webkit-backdrop-filter:blur(4px);position:fixed;top:0;right:0;left:0;bottom:0;z-index:9999998;-webkit-tap-highlight-color:transparent;transition:opacity .14s,backdrop-filter .14s}.a2a_full{background:#FFF;border:1px solid #FFF;box-shadow:#2a2a2a1a 0 0 20px 10px;height:auto;height:calc(320px);top:15%;left:50%;margin-left:-320px;position:fixed;text-align:center;width:640px;z-index:9999999;transition:transform .14s,opacity .14s}.a2a_full_footer,.a2a_full_header,.a2a_full_services{border:0;margin:0;padding:12px;box-sizing:border-box}.a2a_full_header{padding-bottom:8px}.a2a_full_services{height:280px;overflow-y:scroll;padding:0 12px;-webkit-overflow-scrolling:touch}.a2a_full_services .a2a_i{display:inline-block;float:none;width:181px;width:calc(33.334% - 18px)}div.a2a_full_footer{font-size:12px;text-align:center;padding:8px 14px}div.a2a_full_footer a,div.a2a_full_footer a:visited{display:inline;font-size:12px;line-height:14px;padding:8px 14px}div.a2a_full_footer a:focus,div.a2a_full_footer a:hover{background:0 0;border:0;color:#0166FF}div.a2a_full_footer a span.a2a_s_a2a,div.a2a_full_footer a span.a2a_w_a2a{background-size:14px;border-radius:3px;display:inline-block;height:14px;line-height:14px;margin:0 3px 0 0;vertical-align:top;width:14px}.a2a_modal{height:0;left:50%;margin-left:-320px;position:fixed;text-align:center;top:15%;width:640px;z-index:9999999;transition:transform .14s,opacity .14s;-webkit-tap-highlight-color:transparent}.a2a_modal_body{background:0 0;border:0;font:24px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;position:relative;height:auto;width:auto}.a2a_thanks{color:#fff;height:auto;margin-top:20px;width:auto}.a2a_thanks>div:first-child{margin:0 0 40px 0}.a2a_thanks div *{height:inherit}#a2a_copy_link{background:#FFF;border:1px solid #FFF;cursor:pointer;margin-top:15%}label.a2a_s_link#a2a_copy_link_icon,label.a2a_w_link#a2a_copy_link_icon{background-size:48px;border-radius:0;display:inline-block;height:48px;left:0;line-height:48px;margin:0 3px 0 0;position:absolute;vertical-align:top;width:48px}#a2a_modal input#a2a_copy_link_text{background-color:transparent;border:0;color:#2A2A2A;cursor:pointer;font:inherit;height:48px;left:62px;max-width:initial;min-height:auto;padding:0;position:relative;width:564px;width:calc(100% - 76px)}#a2a_copy_link_copied{background-color:#0166ff;color:#fff;display:none;font:inherit;font-size:16px;margin-top:1px;padding:3px 8px}@media (forced-colors:active){.a2a_color_buttons a,.a2a_svg{forced-color-adjust:none}}@media (prefers-color-scheme:dark){.a2a_menu a,.a2a_menu a.a2a_i,.a2a_menu a.a2a_i:visited,.a2a_menu a.a2a_more,i.a2a_i{border-color:#2a2a2a!important;color:#fff!important}.a2a_menu a.a2a_i:active,.a2a_menu a.a2a_i:focus,.a2a_menu a.a2a_i:hover,.a2a_menu a.a2a_more:active,.a2a_menu a.a2a_more:focus,.a2a_menu a.a2a_more:hover,.a2a_menu_find_container{border-color:#444!important;background-color:#444!important}.a2a_menu:not(.a2a_thanks){background-color:#2a2a2a;border-color:#2a2a2a}.a2a_menu_find{color:#fff!important}.a2a_menu label.a2a_s_find svg{background-color:transparent!important}.a2a_menu label.a2a_s_find svg path{fill:#fff!important}.a2a_full{box-shadow:#00000066 0 0 20px 10px}.a2a_overlay{background-color:#373737eb}}@media print{.a2a_floating_style,.a2a_menu,.a2a_overlay{visibility:hidden}}@keyframes a2aFadeIn{from{opacity:0}to{opacity:1}}.a2a_starting{opacity:0}.a2a_starting.a2a_full,.a2a_starting.a2a_modal{transform:scale(.8)}@media (max-width:639px){.a2a_full{border-radius:0;top:15%;left:0;margin-left:auto;width:100%}.a2a_modal{left:0;margin-left:10px;width:calc(100% - 20px)}}@media (min-width:318px) and (max-width:437px){.a2a_full .a2a_full_services .a2a_i{width:calc(50% - 18px)}}@media (max-width:317px){.a2a_full .a2a_full_services .a2a_i{width:calc(100% - 18px)}}@media (max-height:436px){.a2a_full{bottom:40px;height:auto;top:40px}}@media (max-height:550px){.a2a_modal{top:30px}}@media (max-height:360px){.a2a_modal{top:20px}.a2a_thanks>div:first-child{margin-bottom:20px}}.a2a_menu a{color:#0166FF;text-decoration:none;font:16px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;line-height:14px;height:auto;width:auto;outline:0}.a2a_menu a.a2a_i:visited,.a2a_menu a.a2a_more{color:#0166FF}.a2a_menu a.a2a_i:active,.a2a_menu a.a2a_i:focus,.a2a_menu a.a2a_i:hover,.a2a_menu a.a2a_more:active,.a2a_menu a.a2a_more:focus,.a2a_menu a.a2a_more:hover{color:#2A2A2A;border-color:#EEE;border-style:solid;background-color:#EEE;text-decoration:none}.a2a_menu label.a2a_s_find{background-size:24px;height:24px;left:8px;pointer-events:auto;position:absolute;top:7px;width:24px}.a2a_menu label.a2a_s_find svg{background-color:#FFF}.a2a_menu label.a2a_s_find svg path{fill:#CCC}#a2a_menu_container{display:inline-block}.a2a_menu_find_container{border:1px solid #CCC;border-radius:6px;padding:2px 24px 2px 0;position:relative;text-align:left}.a2a_cols_container .a2a_col1{overflow-x:hidden;overflow-y:auto;-webkit-overflow-scrolling:touch}#a2a_modal input,#a2a_modal input[type=text],.a2a_menu input,.a2a_menu input[type=text]{display:block;background-image:none;box-shadow:none;line-height:100%;margin:0;outline:0;overflow:hidden;padding:0;-moz-box-shadow:none;-webkit-box-shadow:none;-webkit-appearance:none}#a2afeed_find_container input,#a2afeed_find_container input[type=text],#a2apage_find_container input,#a2apage_find_container input[type=text]{background-color:transparent;border:0;box-sizing:content-box;color:#2A2A2A;float:none;font:inherit;font-size:16px;height:28px;line-height:20px;left:38px;outline:0;margin:0;max-width:initial;min-height:initial;padding:2px 0;position:relative;width:99%}.a2a_clear{clear:both}.a2a_svg{background-repeat:no-repeat;display:block;overflow:hidden;height:32px;line-height:32px;padding:0;pointer-events:none;width:32px}.a2a_svg svg{background-repeat:no-repeat;background-position:50% 50%;border:none;display:block;left:0;margin:0 auto;overflow:hidden;padding:0;position:relative;top:0;width:auto;height:auto}a.a2a_i,i.a2a_i{display:block;float:left;border:1px solid #FFF;line-height:24px;padding:6px 8px;text-align:left;white-space:nowrap;overflow:hidden;text-overflow:ellipsis;width:132px}a.a2a_i span,a.a2a_more span{display:inline-block;overflow:hidden;vertical-align:top}a.a2a_i .a2a_svg{margin:0 6px 0 0}a.a2a_i .a2a_svg,a.a2a_more .a2a_svg{background-size:24px;height:24px;line-height:24px;width:24px}a.a2a_sss:hover{border-left:1px solid #CCC}a.a2a_more{border-bottom:1px solid #FFF;border-left:0;border-right:0;line-height:24px;margin:6px 0 0;padding:6px;-webkit-touch-callout:none}a.a2a_more span{height:24px;margin:0 6px 0 0}.a2a_kit .a2a_svg{background-repeat:repeat}.a2a_default_style a:empty,.a2a_flex_style a:empty,.a2a_floating_style a:empty,.a2a_overlay_style a:empty{display:none}.a2a_color_buttons a,.a2a_floating_style a{text-decoration:none}.a2a_default_style:not(.a2a_flex_style) a{float:left;line-height:16px;padding:0 2px}.a2a_default_style a:hover .a2a_svg,.a2a_floating_style a:hover .a2a_svg,.a2a_overlay_style a:hover .a2a_svg svg{opacity:.7}.a2a_overlay_style.a2a_default_style a:hover .a2a_svg{opacity:1}.a2a_default_style .a2a_count,.a2a_default_style .a2a_svg,.a2a_floating_style .a2a_svg,.a2a_menu .a2a_svg,.a2a_vertical_style .a2a_count,.a2a_vertical_style .a2a_svg{border-radius:4px}.a2a_default_style .a2a_counter img,.a2a_default_style .a2a_dd,.a2a_default_style .a2a_svg{float:left}.a2a_default_style .a2a_img_text{margin-right:4px}.a2a_default_style .a2a_divider{border-left:1px solid #000;display:inline;float:left;height:16px;line-height:16px;margin:0 5px}.a2a_kit a{cursor:pointer;transition:none}.a2a_floating_style{background-color:#fff;border-radius:6px;position:fixed;z-index:9999995}.a2a_overlay_style{z-index:2147483647}.a2a_floating_style,.a2a_overlay_style{animation:a2aFadeIn .2s ease-in;padding:4px}.a2a_vertical_style:not(.a2a_flex_style) a{clear:left;display:block;overflow:hidden;padding:4px}.a2a_floating_style.a2a_default_style{bottom:0}.a2a_floating_style.a2a_default_style a,.a2a_overlay_style.a2a_default_style a{padding:4px}.a2a_count{background-color:#fff;border:1px solid #ccc;box-sizing:border-box;color:#2a2a2a;display:block;float:left;font:12px Arial,Helvetica,sans-serif;height:16px;margin-left:4px;position:relative;text-align:center;width:50px}.a2a_count:after,.a2a_count:before{border:solid transparent;border-width:4px 4px 4px 0;content:"";height:0;left:0;line-height:0;margin:-4px 0 0 -4px;position:absolute;top:50%;width:0}.a2a_count:before{border-right-color:#ccc}.a2a_count:after{border-right-color:#fff;margin-left:-3px}.a2a_count span{animation:a2aFadeIn .14s ease-in}.a2a_vertical_style .a2a_counter img{display:block}.a2a_vertical_style .a2a_count{float:none;margin-left:0;margin-top:6px}.a2a_vertical_style .a2a_count:after,.a2a_vertical_style .a2a_count:before{border:solid transparent;border-width:0 4px 4px 4px;content:"";height:0;left:50%;line-height:0;margin:-4px 0 0 -4px;position:absolute;top:0;width:0}.a2a_vertical_style .a2a_count:before{border-bottom-color:#ccc}.a2a_vertical_style .a2a_count:after{border-bottom-color:#fff;margin-top:-3px}.a2a_color_buttons .a2a_count,.a2a_color_buttons .a2a_count:after,.a2a_color_buttons .a2a_count:before,.a2a_color_buttons.a2a_vertical_style .a2a_count:after,.a2a_color_buttons.a2a_vertical_style .a2a_count:before{background-color:transparent;border:none;color:#fff;float:none;width:auto}.a2a_color_buttons.a2a_vertical_style .a2a_count{margin-top:0}.a2a_flex_style{display:flex;align-items:flex-start;gap:0}.a2a_default_style.a2a_flex_style{left:0;right:0;width:100%}.a2a_vertical_style.a2a_flex_style{flex-direction:column;top:0;bottom:0}.a2a_flex_style a{display:flex;justify-content:center;flex:1;padding:4px}.a2a_flex_style.a2a_vertical_style a{flex-direction:column}.a2a_floating_style.a2a_color_buttons,.a2a_floating_style.a2a_flex_style{border-radius:0;padding:0}.a2a_floating_style.a2a_default_style.a2a_flex_style{bottom:0}.a2a_kit.a2a_flex_style .a2a_counter img,.a2a_kit.a2a_flex_style .a2a_dd,.a2a_kit.a2a_flex_style .a2a_svg{float:none}.a2a_nowrap{white-space:nowrap}.a2a_note{margin:0 auto;padding:9px;font-size:12px;text-align:center}.a2a_note .a2a_note_note{margin:0;color:#2A2A2A}.a2a_wide a{display:block;margin-top:3px;border-top:1px solid #EEE;text-align:center}.a2a_label{position:absolute!important;clip-path:polygon(0px 0px,0px 0px,0px 0px);-webkit-clip-path:polygon(0px 0px,0px 0px,0px 0px);overflow:hidden;height:1px;width:1px}.a2a_kit,.a2a_menu,.a2a_modal,.a2a_overlay{-ms-touch-action:manipulation;touch-action:manipulation;outline:0}.a2a_dd{-webkit-user-drag:none}.a2a_dd img{border:0}.a2a_button_facebook_like iframe{max-width:none}</style></head>
    

    



    
        
        
        
            <body class="pb-ui website-mms-site loaded">
            






    
    
        





    
    
        
        
    
    
    







<input type="hidden" id="isRoMode" name="isRoMode" value="false">

        <div id="pb-page-content" data-ng-non-bindable="">
                
            <div data-pb-dropzone="main" data-pb-dropzone-name="Main">
                
                    
                        



        
        <header data-sticky="false" class="ng-header js_stickyAd"><a href="#mainContent" class="ng-skipToMainContent">Skip to main content</a><div class="ng-header_topAd"><div class="ng-header_topAd-content d-flex justify-content-center align-items-center">



        
        <div id="DTM_Position_Topbanner" class="ad">
 <!--emptycomment-->
</div>
</div></div><div class="ng-header_journal-navbar"><div class="ng-header_journal-navbar-content"><div class="container-fluid"><div class="row"><div class="ng-header_journal-navbar_left col-lg-8 col-sm-12 pr-lg-0 d-flex align-items-center"><div data-location="nejm_group_product_nav" class="ng-header_journalNavMenu">



        
        <nav data-location="nejm_group_product_nav" role="navigation" class="ng-journalNavMenu">
<ul class="ng-journalNavMenu_list">
<li class="ng-journalNavMenu_list-item"><a href="/" class="ng-journalNavMenu_mainLink active" aria-current="page" aria-label="The New England Journal of Medicine selected item"><span class="ng-journalNavMenu_mainLink-text d-lg-block d-none">The New England Journal of Medicine</span><span class="ng-journalNavMenu_mainLink-text d-lg-none d-block">NEJM</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://evidence.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Evidence</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://ai.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> AI</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://catalyst.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Catalyst</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://www.jwatch.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Journal Watch</span></a></li>
</ul>
</nav>

</div></div><div class="ng-header_journal-navbar_right col-lg-4 pl-lg-0 d-none d-xl-flex align-items-center justify-content-end"><div class="ng-header_loginBar d-xl-flex align-items-lg-center">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2209051" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div></div></div></div></div></div><div class="ng-header_instBanner d-none d-lg-block"></div><div class="ng-header_logoBar"><div class="container-fluid"><div class="row"><div data-location="logo" class="ng-header_logoBar_left col-lg-4 col-6 d-flex align-items-center justify-content-start"><a href="/" title="The New England Journal of Medicine homepage" class="ng-header_logo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/nejm-logo-166667e91992a5212bc723b03e45d39f.svg" alt="The New England Journal of Medicine homepage" width="366" height="58" class="ng-header_logo-image"></a></div><div class="ng-header_logoBar_right ng-header_navBar col-lg-8 col-sm-12 p-lg-0 align-items-center justify-content-end"><div class="ng-header_navBar-content"><div class="container-fluid"><div class="row"><div class="ng-header_instBanner-md col-12 d-block d-lg-none"></div><div class="ng-header_loginBar-md col-12 d-block d-xl-none">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2209051" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div><div class="ng-header_navBar_left col-lg-8 col-sm-12 d-flex align-items-center"><div class="ng-header_stickyLogo mr-32"><a href="/" title="The New England Journal of Medicine homepage" class="ng-header_stickyLogo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/nejm-small-logo-070df7a3f4d8cfa2e71c3c45bb4b172f.svg" alt="The New England Journal of Medicine homepage" class="ng-header_stickyLogo-image"></a></div><div class="ng-header_mainMenu">









    
    
        <div data-widget-def="menuWidget" data-widget-id="97fb3983-db63-4b0b-97dd-d9bb7929fce1" data-location="main_nav">
        



        
        <nav class="ng-menu"><ul class="ng-menu_list ng-simple-menu"><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/toc/nejm/current" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">current issue</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/toc/nejm/current" class="ng-simple-menu_list-link">VIEW CURRENT ISSUE</a></li><li class="ng-simple-menu_list-item"><a href="/toc/nejm/recently-published" class="ng-simple-menu_list-link">BROWSE RECENTLY PUBLISHED</a></li><li class="ng-simple-menu_list-item"><a href="/loi/nejm" class="ng-simple-menu_list-link">BROWSE ALL ISSUES</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/medical-specialties" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">SPECIALTIES</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/browse/specialty/cardiology" class="ng-simple-menu_list-link">Cardiology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/clinical-medicine" class="ng-simple-menu_list-link">Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/endocrinology" class="ng-simple-menu_list-link">Endocrinology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/gastroenterology" class="ng-simple-menu_list-link">Gastroenterology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/hematology-oncology" class="ng-simple-menu_list-link">Hematology/Oncology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/infectious-disease" class="ng-simple-menu_list-link">Infectious Disease</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/nephrology" class="ng-simple-menu_list-link">Nephrology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/neurology-neurosurgery" class="ng-simple-menu_list-link">Neurology/Neurosurgery</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/obstetrics-gynecology" class="ng-simple-menu_list-link">Obstetrics/Gynecology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/pediatrics" class="ng-simple-menu_list-link">Pediatrics</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/pulmonary-critical-care" class="ng-simple-menu_list-link">Pulmonary/Critical Care</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/surgery" class="ng-simple-menu_list-link">Surgery</a></li><li class="ng-simple-menu_list-item"><a href="/medical-specialties" class="ng-simple-menu_list-link">View All Specialties</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/topics" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">TOPICS</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/ai-in-medicine" class="ng-simple-menu_list-link">AI in Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/climate-change" class="ng-simple-menu_list-link">Climate Change</a></li><li class="ng-simple-menu_list-item"><a href="/coronavirus" class="ng-simple-menu_list-link">Coronavirus</a></li><li class="ng-simple-menu_list-item"><a href="/equity" class="ng-simple-menu_list-link">Efforts toward Equity</a></li><li class="ng-simple-menu_list-item"><a href="/firearm-injury-prevention" class="ng-simple-menu_list-link">Firearm Injury Prevention</a></li><li class="ng-simple-menu_list-item"><a href="/nam" class="ng-simple-menu_list-link">From the National Academy of Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/fundamentals-of-medical-ethics" class="ng-simple-menu_list-link">Fundamentals of Medical Ethics</a></li><li class="ng-simple-menu_list-item"><a href="/gray-matters" class="ng-simple-menu_list-link">Gray Matters</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/health-policy" class="ng-simple-menu_list-link">Health Policy</a></li><li class="ng-simple-menu_list-item"><a href="/medicine-and-society" class="ng-simple-menu_list-link">Medicine and Society</a></li><li class="ng-simple-menu_list-item"><a href="/nutrition-in-medicine" class="ng-simple-menu_list-link">Nutrition in Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/outbreaks" class="ng-simple-menu_list-link">Outbreaks Center</a></li><li class="ng-simple-menu_list-item"><a href="/race-and-medicine" class="ng-simple-menu_list-link">Race and Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/recognizing-historical-injustices" class="ng-simple-menu_list-link">Recognizing Historical Injustices and the Journal</a></li><li class="ng-simple-menu_list-item"><a href="/tobacco-use-reduction" class="ng-simple-menu_list-link">Tobacco Use Reduction</a></li><li class="ng-simple-menu_list-item"><a href="/topics" class="ng-simple-menu_list-link">View All Topics</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/multimedia" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">MULTIMEDIA</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/rss-feed" class="ng-simple-menu_list-link">Podcasts</a></li><li class="ng-simple-menu_list-item"><a href="/double-take" class="ng-simple-menu_list-link">Double Takes</a></li><li class="ng-simple-menu_list-item"><a href="https://illustrated-glossary.nejm.org/" class="ng-simple-menu_list-link">Illustrated Glossary</a></li><li class="ng-simple-menu_list-item"><a href="/image-challenge" class="ng-simple-menu_list-link">Image Challenge</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/images-in-clinical-medicine" class="ng-simple-menu_list-link">Images in Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/interactive-medical-case" class="ng-simple-menu_list-link">Interactive Medical Cases</a></li><li class="ng-simple-menu_list-item"><a href="/plain-language-research-summaries" class="ng-simple-menu_list-link">Plain Language/Research Summaries</a></li><li class="ng-simple-menu_list-item"><a href="/multimedia/quick-take-video" class="ng-simple-menu_list-link">Quick Takes</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/videos-in-clinical-medicine" class="ng-simple-menu_list-link">Videos in Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/multimedia" class="ng-simple-menu_list-link">View All Multimedia</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/learning" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">LEARNING/CME</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/continuing-medical-education" class="ng-simple-menu_list-link">Weekly CME</a></li><li class="ng-simple-menu_list-item"><a href="/cme-ce/obesity" class="ng-simple-menu_list-link">Obesity CME/CE</a></li><li class="ng-simple-menu_list-item"><a href="/learning" class="ng-simple-menu_list-link">VIEW ALL LEARNING/CME</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item"><a href="/author-center/home" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">AUTHOR CENTER</span></a></li></ul></nav>

        </div>
    

</div><button aria-label="Search" class="ng-header_searchBtn searchBtnNav d-block ml-24"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button></div><div class="ng-header_loginBar ng-header_loginBar-sticky col-4">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2209051" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div></div></div></div></div><div class="ng-header_logoBar_right-lg col-lg-8 col-6 d-flex align-items-center justify-content-end d-xl-none"><button aria-label="Search" class="ng-header_searchBtn d-flex justify-content-end"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button><div class="ng-header_openCloseBtns d-flex align-items-center justify-content-end"><button aria-label="Open" class="ng-header_openBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#burger"></use></svg></span></button><button aria-label="Close" class="ng-header_closeBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></button></div></div><div class="ng-header_quickSearch col-12"><div class="ng-header_quickSearch-content">



        
        <div class="ng-quick-search js-ng-quick-search"><form action="/search" method="get" class="ng-quick-search_form js-form"><div class="ng-quick-search_inputArea js-inputArea"><input type="search" name="q" placeholder="Enter keyword, author, title or citation" autocomplete="off" value="" required="required" class="ng-quick-search_allField ng-large-text-input js-allField js-allField-def-tmpl ui-autocomplete-input"><button type="submit" aria-label="Search Button" class="ng-quick-search_iconBtn d-xl-none d-block js-submitBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button><ul id="ui-id-1" tabindex="0" class="ui-menu ui-widget ui-widget-content ui-autocomplete ui-front" style="display: none;"></ul></div><div class="ng-quick-search_btnsArea d-none d-xl-flex align-items-center justify-content-end"><a href="/search/advanced" class="ng-quick-search_advSearchLink ng-btn_link js-advancedSearchLink">Advanced Search</a><button type="submit" class="ng-quick-search_textBtn ng-btn_secondary ng-btn_iconRight js-submitBtn"><span class="ng-btn_text">SEARCH</span><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-right"></use></svg></span></button></div></form></div>
</div></div></div></div></div></header><div class="ng-header_overlay"></div><div class="ng-header_after">









    
    
        <div data-widget-def="literatumAd" data-widget-id="4931ddbd-d46e-4597-b4fd-92549e9847ca" id="ad-global-banner-FULLx64-1">
        



        
        



    

    

    
        
    



        </div>
    

</div>

                    
                        



        
        <div>









    
    
        <main data-widget-def="axelPublicationContent" data-widget-id="fcdb5261-d6a2-4a9c-81d5-3a3e2304e9c1" id="mainContent">
        



        
        <div class="article-tools__savePopup"><div class="ng-save"><input type="hidden" value="/action/getSavedTags" class="getKeywordsServiceUrl"><input type="hidden" value="/action/mmsSaveItemsService?itemType=article" class="saveServiceUrl"><input type="hidden" value="article" class="saveType"><input type="hidden" value="10.1056/NEJMoa2209051" class="inputDoi"><input type="hidden" value="S.J. Connolly and Others" class="inputAuthor"><input type="hidden" value="N Engl J Med 2022;387:978-988" class="inputCitation"><input type="hidden" value="08-27-2022" class="inputEPubDate"><input type="hidden" value="September 2022" class="inputCoverDate"><input type="hidden" value="Original Article" class="inputContentType"><input type="hidden" value="Rivaroxaban in Rheumatic Heart Disease–Associated Atrial Fibrillation" class="inputArticleTitle"><input type="hidden" value="/browse/nejm-article-type/original-article" class="inputContentTypeUrl"><button type="button" id="saveArticleShowPopupBtn" aria-hidden="true" tabindex="-1" class="ng-save-btn ng-btn_secondary isLoggedOut">Save</button></div></div><div class="article-tools__articleAlertPopup"><div id="articleAlertModal" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><h5 id="articleAlertModalTitle" class="ng-modal_title modal-title">Create an E-mail Alert for This Article</h5><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body"></div></div></div></div></div><div class="ng-do-media_popup"><div id="doPopup" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body"></div></div></div></div></div><link id="build-style-article" rel="stylesheet" type="text/css" href="/products/mms-nextgen/mms/releasedAssets/css/build-article-5b89b331018866a4a965.css"><article xmlns="http://www.w3.org/1999/xhtml" data-design="pill" data-has="right-rail" data-type="research-article" vocab="http://schema.org/" typeof="ScholarlyArticle" lang="en" dir="ltr"><header data-extent="frontmatter" data-location="header_article"><div class="core-container"><div data-article-access="free" data-article-access-type="free" class="meta-panel"><div class="meta-panel__left-content"><div class="meta-panel__type"><a href="/browse/nejm-article-type/original-article">Original Article</a></div></div><div class="meta-panel__right-content"><div class="meta-panel__share">









    
    
        <div data-widget-def="UX3share" data-widget-id="eee5f139-16f2-48f8-97ea-1b114367da16" data-location="share_tools_article">
        



        
        <!-- Go to https://www.addtoany.com/buttons/customize/ to customize your tools --><script type="text/javascript" defer="defer" src="https://static.addtoany.com/menu/page.js" nonce="94d6e9573670da2e-SJC"></script><div class="share"><div class="share__block share__inline-links"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="d-flex list-unstyled a2a a2a_kit a2a_default_style mb-0 a2a_kit_size_32" style="line-height: 32px;"><li class="a2a_listitem_custom"><a role="link" title="Facebook" data-interactiontype="social" class="share__link a2a_button_facebook" target="_blank" rel="nofollow noopener" href="/#facebook"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-facebook"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="X (formerly Twitter)" data-interactiontype="social" class="share__link a2a_button_twitter" target="_blank" rel="nofollow noopener" href="/#twitter"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-twitter"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Linked In" data-interactiontype="social" class="share__link a2a_button_linkedin" target="_blank" rel="nofollow noopener" href="/#linkedin"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-linkedin"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Email" data-interactiontype="content_email_click" class="share__link a2a_button_email" target="_blank" rel="nofollow noopener" href="/#email"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-email"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Bluesky" data-interactiontype="social" class="share__link a2a_button_bluesky" target="_blank" rel="nofollow noopener" href="/#bluesky"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-bluesky"></use></svg></span></a></li><div style="clear: both;"></div></ul></div></div>

        </div>
    

</div></div></div><h1 property="name">Rivaroxaban in Rheumatic Heart Disease–Associated Atrial Fibrillation</h1><div class="core-relations my-3"></div><div class="contributors"><span class="authors"><span class="heading">Authors</span>: <span role="list"><span property="author" typeof="Person" role="listitem"><span property="givenName">Stuart J.</span> <span property="familyName">Connolly</span>, <span property="honorificSuffix">M.D.</span> <a class="orcid-id" href="https://orcid.org/0000-0002-7377-335X" property="identifier" aria-label="ORCID identifier" target="_blank">https://orcid.org/0000-0002-7377-335X</a></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Ganesan</span> <span property="familyName">Karthikeyan</span>, <span property="honorificSuffix">M.D., D.M.</span> <a class="orcid-id" href="https://orcid.org/0000-0002-2073-2917" property="identifier" aria-label="ORCID identifier" target="_blank">https://orcid.org/0000-0002-2073-2917</a></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Mpiko</span> <span property="familyName">Ntsekhe</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Abraham</span> <span property="familyName">Haileamlak</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Ahmed</span> <span property="familyName">El Sayed</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Alaa</span> <span property="familyName">El Ghamrawy</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Albertino</span> <span property="familyName">Damasceno</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span><span data-displayed-on="all">, <span data-action="reveal" tabindex="0" role="listitem">+30</span> </span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Alvaro</span> <span property="familyName">Avezum</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Antonio M.L.</span> <span property="familyName">Dans</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Bernard</span> <span property="familyName">Gitura</span>, <span property="honorificSuffix">M.Med.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Dayi</span> <span property="familyName">Hu</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Emmanuel R.</span> <span property="familyName">Kamanzi</span>, <span property="honorificSuffix">M.Med.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Fathi</span> <span property="familyName">Maklady</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Golden</span> <span property="familyName">Fana</span>, <span property="honorificSuffix">M.Med.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">J. Antonio</span> <span property="familyName">Gonzalez-Hermosillo</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">John</span> <span property="familyName">Musuku</span>, <span property="honorificSuffix">M.Med.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Khawar</span> <span property="familyName">Kazmi</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Liesl</span> <span property="familyName">Zühlke</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Lillian</span> <span property="familyName">Gondwe</span>, <span property="honorificSuffix">M.B., B.S.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Changsheng</span> <span property="familyName">Ma</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Maria</span> <span property="familyName">Paniagua</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Okechukwu S.</span> <span property="familyName">Ogah</span>, <span property="honorificSuffix">M.B., B.S., Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Onkabetse J.</span> <span property="familyName">Molefe-Baikai</span>, <span property="honorificSuffix">M.Med.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Peter</span> <span property="familyName">Lwabi</span>, <span property="honorificSuffix">M.Med.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Pilly</span> <span property="familyName">Chillo</span>, <span property="honorificSuffix">M.D.</span> <a class="orcid-id" href="https://orcid.org/0000-0001-7073-1122" property="identifier" aria-label="ORCID identifier" target="_blank">https://orcid.org/0000-0001-7073-1122</a></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Sanjib K.</span> <span property="familyName">Sharma</span>, <span property="honorificSuffix">M.D., D.M.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Tantchou T.J.</span> <span property="familyName">Cabral</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Wadea M.</span> <span property="familyName">Tarhuni</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Alexander</span> <span property="familyName">Benz</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Martin</span> <span property="familyName">van Eikels</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Amy</span> <span property="familyName">Krol</span>, <span property="honorificSuffix">B.Sc.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Divya</span> <span property="familyName">Pattath</span>, <span property="honorificSuffix">M.Sc.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Kumar</span> <span property="familyName">Balasubramanian</span>, <span property="honorificSuffix">M.Sc.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Sumathy</span> <span property="familyName">Rangarajan</span>, <span property="honorificSuffix">M.Sc.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Chinthanie</span> <span property="familyName">Ramasundarahettige</span>, <span property="honorificSuffix">M.Sc.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Bongani</span> <span property="familyName">Mayosi</span>, <span property="honorificSuffix">M.D., D.Phil.</span></span></span><span data-hidden-on="all">, and <span property="author" typeof="Person" role="listitem"><span property="givenName">Salim</span> <span property="familyName">Yusuf</span>, <span property="honorificSuffix">D.Phil.</span></span></span>, for <span property="author" typeof="Person" role="listitem">the INVICTUS Investigators<sup><a href="#fn2" role="doc-noteref">†</a></sup></span><span data-displayed-on="none" data-on-display="all" aria-hidden="true"> <span data-action="hide" tabindex="0" role="listitem">-30</span></span></span></span><a href="#tab-contributors" class="to-authors-affiliations" data-id="article-authors-viewall">Author Info &amp; Affiliations</a></div><div class="core-self-citation"><div class="core-date-published">Published <span property="datePublished">August 27, 2022</span></div><div property="isPartOf" typeof="Periodical"><span property="name">N Engl J Med</span> 2022<span property="isPartOf" typeof="PublicationVolume">;<span property="volumeNumber">387</span></span>:<span property="pageStart">978</span>-<span property="pageEnd">988</span></div><div class="doi">DOI: 10.1056/NEJMoa2209051</div><div class="core-enumeration"><a href="/toc/nejm/387/11"><span property="isPartOf" typeof="PublicationVolume">VOL. <span property="volumeNumber">387</span></span> <span property="isPartOf" typeof="PublicationIssue">NO. <span property="issueNumber">11</span></span></a></div><div><a href="#tab-information">Copyright © 2022</a></div></div><div class="info-panel"><div class="info-panel__left-content"><div class="info-panel__metrics info-panel__item"></div></div><div data-location="tools_article" class="info-panel__right-content"><div class="info-panel__article_tools info-panel__item">



        
        <div data-permission="/servlet/linkout?type=rightslink&amp;url=publisherName%3Dmassmed%26author%3DStuart%2BJ.%2BConnolly%252C%2BGanesan%2BKarthikeyan%252C%2BMpiko%2BNtsekhe%252C%2Bet%2Bal%26publication%3Dnejm%26orderBeanReset%3Dtrue%26volumeNum%3D387%26issueNum%3D11%26contentID%3D10.1056%252FNEJMoa2209051%26title%3DRivaroxaban%2Bin%2BRheumatic%2BHeart%2BDisease%25E2%2580%2593Associated%2BAtrial%2BFibrillation%26publicationDate%3D09%252F15%252F2022" class="article-tools"><button id="articleToolsAlertBtn" data-url="/action/addCitationAlert?doi=10.1056%2FNEJMoa2209051" data-toggle="" data-target="#articleAlertModal" aria-label="Sign in or create account to add an article alert" data-interactiontype="article_alert" class="article-tools__citation btn btn--slim isLoggedOut"><span title="" data-toggle="tooltip" class="d-inline-block" data-original-title="Sign in or create account to add an article alert"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#alerts"></use></svg></span></span></button><button id="articleToolsSaveBtn" data-toggle="modal" data-target="#saveArticle" aria-label="Sign in or create account to save this article" data-interactiontype="article_tools_save_click" class="article-tools__favorite btn btn--slim isLoggedOut"><span title="" data-toggle="tooltip" class="d-inline-block" data-original-title="Sign in or create account to save this article"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#bookmarkFilled"></use></svg></span></span></button><a href="/servlet/linkout?type=rightslink&amp;url=publisherName%3Dmassmed%26author%3DStuart%2BJ.%2BConnolly%252C%2BGanesan%2BKarthikeyan%252C%2BMpiko%2BNtsekhe%252C%2Bet%2Bal%26publication%3Dnejm%26orderBeanReset%3Dtrue%26volumeNum%3D387%26issueNum%3D11%26contentID%3D10.1056%252FNEJMoa2209051%26title%3DRivaroxaban%2Bin%2BRheumatic%2BHeart%2BDisease%25E2%2580%2593Associated%2BAtrial%2BFibrillation%26publicationDate%3D09%252F15%252F2022" target="_blank" title="" data-toggle="tooltip" aria-label="Permissions" data-interactiontype="article_tools_permissions_click" class="article-tools__permissions btn btn--slim" data-original-title="Permissions"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#permissions"></use></svg></span></a><a href="/about-nejm/reprints" title="" data-toggle="tooltip" aria-label="Reprints" data-interactiontype="article_tools_reprints_click" class="article-tools__reprints btn btn--slim" data-original-title="Reprints"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#reprints"></use></svg></span></a><a href="/cms/asset/381a2144-1c50-4adb-8853-dbd30a99d0cb/nejmoa2209051.pptx" target="_blank" title="" data-toggle="tooltip" aria-label="Download Slides" data-interactiontype="article_tools_slide_set_download" data-multimedia-type="Article Slideset" data-multimedia-filename="nejmoa2209051.pptx" class="article-tools__downloadSlides btn btn--slim" data-original-title="Download Slides"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#download"></use></svg></span></a><div class="article-tools__permissionsPopup"><div id="permissionsModal" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><h5 id="permissionsModalTitle" class="ng-modal_title modal-title">Permissions</h5><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body">For permission requests, please contact NEJM Reprints at <a href="mailto:reprints@nejm.org">reprints@nejm.org</a></div></div></div></div></div></div>
</div><div class="info-panel__citations info-panel__item"><a href="#tab-citations" class="btn btn--slim" aria-label="View Citations" data-toggle="tooltip" data-original-title="View Citations" data-interactiontype="article_tools_citation_download" data-multimedia-type="Citation"><i aria-hidden="true" class="icon-format_quote"></i></a></div><div class="info-panel__formats info-panel__item"><a href="https://www.nejm.org/doi/pdf/10.1056/NEJMoa2209051" class="btn btn--pdf btn--slim" aria-label="View PDF" data-toggle="tooltip" data-original-title="View PDF" data-behavior="trackDownloadEvent" data-doi="10.1056/NEJMoa2209051" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2209051.pdf"><i aria-hidden="true" class="icon-PDF"></i></a></div></div></div></div></header><div data-core-nav="header" data-extent="frontmatter"><div class="core-nav-wrapper core-container" aria-label="Article navigation"><div class="core-sections-menu"><button data-id="article-toolbar-showhide" aria-controls="article_sections_menu" aria-expanded="false" aria-label="Toggle section navigation menu" style="margin-top: 0px;"><i class="icon-list" aria-hidden="true"></i><span>Contents</span></button><nav id="article_sections_menu" aria-label="Contents" data-core-nav="article" style="margin-top: 0px;"><ul><li><a href="#summary-abstract" aria-current="true">Abstract</a></li><li><a href="#sec-1" aria-current="false">Methods</a></li><li><a href="#sec-2" aria-current="false">Results</a></li><li><a href="#sec-3" aria-current="false">Discussion</a></li><li class="bordered"><a href="#backnotes" aria-current="false">Notes</a></li><li><a href="#supplementary-materials" aria-current="false">Supplementary Material</a></li><li><a href="#bibliography" aria-current="false">References</a></li></ul></nav></div><nav id="article_collateral_menu"><ul data-core-nav="collateral" class="collateral-pill" style="margin-top: 0px;"><li><a href="#core-collateral-info" data-id="article-nav-menubar-info" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Information &amp; Authors"><i aria-hidden="true" class="icon-info"></i><span class="sr-only">Information &amp; Authors</span></a></li><li><a href="#core-collateral-metrics" data-id="article-nav-menubar-metrics" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Metrics &amp; Citations"><i aria-hidden="true" class="icon-timeline"></i><span class="sr-only">Metrics &amp; Citations</span></a></li><li><a href="#core-collateral-fulltext-options" data-id="article-nav-menubar-metrics" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="View Options"><i aria-hidden="true" class="icon-eye"></i><span class="sr-only">View Options</span></a></li><li><a href="#core-collateral-references" data-id="article-nav-menubar-references" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="References"><i aria-hidden="true" class="icon-references"></i><span class="sr-only">References</span></a></li><li><a href="#core-collateral-media" data-id="article-nav-menubar-media" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Media"><i aria-hidden="true" class="icon-photo"></i><span class="sr-only">Media</span></a></li><li><a href="#core-collateral-tables" data-id="article-nav-menubar-tables" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Tables"><i aria-hidden="true" class="icon-tables"></i><span class="sr-only">Tables</span></a></li><li><a href="#core-collateral-share" data-id="article-nav-menubar-share" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Share"><i aria-hidden="true" class="icon-share"></i><span class="sr-only">Share</span></a></li></ul></nav></div></div><div data-core-wrapper="content"><div id="abstracts" data-extent="frontmatter" data-location="articleTab_article"><div class="core-container"><section id="summary-abstract" property="abstract" typeof="Text" role="doc-abstract"><h2 property="name">Abstract</h2><section id="abs-sec-1"><h3>Background</h3><div role="paragraph">Testing of factor Xa inhibitors for the prevention of cardiovascular events in patients with rheumatic heart disease–associated atrial fibrillation has been limited.</div></section><section id="abs-sec-2"><h3>Methods</h3><div role="paragraph">We enrolled patients with atrial fibrillation and echocardiographically documented rheumatic heart disease who had any of the following: a CHA<sub>2</sub>DS<sub>2</sub>VASc score of at least 2 (on a scale from 0 to 9, with higher scores indicating a higher risk of stroke), a mitral-valve area of no more than 2 cm<sup>2</sup>, left atrial spontaneous echo contrast, or left atrial thrombus. Patients were randomly assigned to receive standard doses of rivaroxaban or dose-adjusted vitamin K antagonist. The primary efficacy outcome was a composite of stroke, systemic embolism, myocardial infarction, or death from vascular (cardiac or noncardiac) or unknown causes. We hypothesized that rivaroxaban therapy would be noninferior to vitamin K antagonist therapy. The primary safety outcome was major bleeding according to the International Society of Thrombosis and Hemostasis.</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><!-- There is no content. --><nav><a href="#f0" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2209051_f0.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f0" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2209051_f0.jpg"><img src="/cms/10.1056/NEJMoa2209051/asset/e90d5a28-e029-4528-ac8d-406ff07dcedd/assets/images/large/nejmoa2209051_f0.jpg" height="3416" width="2640" aria-labelledby="f0" loading="lazy"></a><figcaption>Download a PDF of the <a href="#ap0">Research Summary</a>.</figcaption></figure></div></section><section id="abs-sec-3"><h3>Results</h3><div role="paragraph">Of 4565 enrolled patients, 4531 were included in the final analysis. The mean age of the patients was 50.5 years, and 72.3% were women. Permanent discontinuation of trial medication was more common with rivaroxaban than with vitamin K antagonist therapy at all visits. In the intention-to-treat analysis, 560 patients in the rivaroxaban group and 446 in the vitamin K antagonist group had a primary-outcome event. Survival curves were nonproportional. The restricted mean survival time was 1599 days in the rivaroxaban group and 1675 days in the vitamin K antagonist group (difference, −76 days; 95% confidence interval [CI], −121 to −31; P&lt;0.001). A higher incidence of death occurred in the rivaroxaban group than in the vitamin K antagonist group (restricted mean survival time, 1608 days vs. 1680 days; difference, −72 days; 95% CI, −117 to −28). No significant between-group difference in the rate of major bleeding was noted.</div></section><section id="abs-sec-4"><h3>Conclusions</h3><div role="paragraph">Among patients with rheumatic heart disease–associated atrial fibrillation, vitamin K antagonist therapy led to a lower rate of a composite of cardiovascular events or death than rivaroxaban therapy, without a higher rate of bleeding. (Funded by Bayer; INVICTUS ClinicalTrials.gov number, <a href="http://clinicaltrials.gov/show/NCT02832544" target="_blank">NCT02832544</a>.)</div></section></section><div class="core-digital-object quick-take">
<div class="ng-do-media" style="border-top: 1px solid #e5e5e5; padding-top: 1.5rem;" data-location="inlineArticlePreview">
    <div class="ng-do-media_item">
        <div class="ng-do-media_item-left">
            <a href="/do/10.1056/NEJMdo006699/full/" class="ng-do-media_item-img-link">
                <img src="/cms/asset/23e9373b-11c2-42a3-9023-e228f4c798c6/media/NEJMdo006699_300x200.jpg" class="ng-do-media_item-img">
                <span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#tooltip-video"></use></svg></span>
            </a>
        </div>
        <div class="ng-do-media_item-right">
            <div class="ng-do-media_item-type">
                <a href="/browse/nejm-media-type/quick-take" class="ng-do-media_item-type-link">Quick Take</a>
            </div>
            <h6 class="ng-do-media_item-title">
                <a href="/do/10.1056/NEJMdo006699/full/" class="ng-do-media_item-title-link">Rivaroxaban for AF in Rheumatic Heart Disease</a>
            </h6>
            <div class="ng-do-media_item-duration">1m 42s</div>
        </div>
    </div>
</div>
</div></div></div><section id="bodymatter" data-extent="bodymatter" property="articleBody" typeof="Text" data-location="articleTab_article"><div class="core-container"><div role="paragraph">Atrial fibrillation may occur because of different pathophysiological conditions that lead to remodeling of the left atrium. Patients with atrial fibrillation are at increased risk for embolic stroke owing to formation of thrombus in the left atrium, which can embolize and occlude branches of the intracerebral circulation. In high-income countries, the development of atrial disease and atrial fibrillation is most often a consequence of systemic hypertension, ischemic heart disease, or advanced age. However, in low- and middle-income countries, rheumatic heart disease remains an important cause of atrial enlargement and atrial fibrillation.<sup><a href="#core-r1" role="doc-biblioref" data-xml-rid="r1 r2" id="body-ref-r2-1" href-manipulated="true">1,2</a></sup></div><div role="paragraph">Randomized trials have shown the efficacy of vitamin K antagonists for stroke prevention in patients with atrial fibrillation.<sup><a href="#core-r3" role="doc-biblioref" data-xml-rid="r3" id="body-ref-r3" href-manipulated="true" aria-label="Reference 3">3</a></sup> Because of many dietary and pharmacologic interactions, vitamin K antagonist therapy is difficult to administer, and regular blood sampling to monitor anticoagulation status with the international normalized ratio of prothrombin time (INR) is required. The need for drugs that do not require any monitoring led to the development of the direct thrombin inhibitor dabigatran and the factor Xa inhibitors rivaroxaban, apixaban, and edoxaban. Randomized clinical trials have shown that these non–vitamin K antagonist oral anticoagulants are as effective as vitamin K antagonist therapy for stroke prevention and have a lower risk of intracranial hemorrhage.<sup><a href="#core-r4" role="doc-biblioref" data-xml-rid="r4" id="body-ref-r4-1" href-manipulated="true" aria-label="Reference 4">4</a></sup> However, the randomized trials that have established the efficacy and safety of both vitamin K antagonist and non–vitamin K antagonist oral anticoagulants for stroke prevention in patients with atrial fibrillation excluded patients who had atrial fibrillation due to rheumatic heart disease.</div><div role="paragraph">Patients with atrial fibrillation due to rheumatic heart disease differ substantially from other patients with atrial fibrillation; they are usually much younger, are more often female, and often have advanced valvular disease.<sup><a href="#core-r1" role="doc-biblioref" data-xml-rid="r1 r2" id="body-ref-r2-2" href-manipulated="true">1,2</a></sup> Because of these differences and limited evidence from clinical trials, guidelines do not recommend the use of non–vitamin K antagonist oral anticoagulants for stroke prevention in patients with rheumatic heart disease–associated atrial fibrillation, and rivaroxaban is not approved for this indication in these patients.<sup><a href="#core-r5" role="doc-biblioref" data-xml-rid="r5" id="body-ref-r5" href-manipulated="true" aria-label="Reference 5">5</a></sup> However, an anticoagulant that does not require monitoring would be very useful in low- and middle-income countries, where most patients with rheumatic heart disease live and where regular INR monitoring and dose adjustment of vitamin K antagonists is often a challenge, owing to difficulties in travel and to limitations in health care resources. On the basis of these considerations, we performed a randomized, noninferiority trial to evaluate the efficacy and safety of the factor Xa inhibitor rivaroxaban, as compared with vitamin K antagonist therapy, in patients with rheumatic heart disease–associated atrial fibrillation in Africa, Asia, and Latin America.</div><section id="sec-1" data-type="methods"><h2>Methods</h2><section id="sec-1-1"><h3>Trial Organization</h3><div role="paragraph">The Investigation of Rheumatic AF Treatment Using Vitamin K Antagonists, Rivaroxaban or Aspirin Studies (INVICTUS) is an international research program in rheumatic heart disease that includes both a registry and a randomized trial in which we compared once-daily rivaroxaban (at a dose of 20 mg or 15 mg, according to renal function) with a dose-adjusted vitamin K antagonist in patients with documented rheumatic heart disease and atrial fibrillation. The trial was open-label, with blinded assessment of outcomes. The trial <a href="#ap1">protocol</a>, which is available with the full text of this article at NEJM.org, was approved by the institutional review boards and ethics committees at all the participating sites and by relevant regulatory authorities. Written informed consent was obtained from all the patients before randomization.</div><div role="paragraph">The trial was planned and led by the Population Health Research Institute, which designed, conducted, analyzed, and reported the trial results. The steering committee vouches for the accuracy and completeness of the data and made the decision to submit the manuscript for publication. The first author wrote the first draft of the manuscript. No one who is not an author contributed to writing the manuscript. The Population Health Research Institute received an unrestricted grant from Bayer to cover the costs of the trial, without any agreements regarding confidentiality. The authors vouch for the adherence of the trial to the protocol.</div></section><section id="sec-1-2"><h3>Patient Enrollment and Treatments</h3><div role="paragraph">The complete details of the patient enrollment criteria have been published previously.<sup><a href="#core-r6" role="doc-biblioref" data-xml-rid="r6" id="body-ref-r6" href-manipulated="true" aria-label="Reference 6">6</a></sup> Patients were eligible for inclusion if they were 18 years of age or older and had echocardiographically proven rheumatic heart disease and documented atrial fibrillation or atrial flutter at any time. For patients to be eligible, at least one of the following criteria was additionally required: a CHA<sub>2</sub>DS<sub>2</sub>VASc score of at least 2 (on a scale from 0 to 9, with higher scores indicating a higher risk of stroke), mitral stenosis with a mitral-valve area of no more than 2 cm<sup>2</sup>, or echocardiographic evidence of either left atrial spontaneous echo contrast or left atrial thrombus. Key exclusion criteria were the presence of a mechanical heart valve or the likelihood of receiving one within the next 6 months, the use of dual antiplatelet therapy, treatment with dual strong inhibitors of CYP3A4 and P-glycoprotein, and the presence of severe renal insufficiency (estimated glomerular filtration rate, &lt;15 ml per minute). Women of child-bearing age were excluded if they were pregnant or were not using a form of contraception that the trial had deemed to be effective.</div><div role="paragraph">Patients were randomly assigned in a 1:1 ratio, with the use of Web-based randomization system, to receive either rivaroxaban or a locally available vitamin K antagonist. Randomization was stratified according to site. Rivaroxaban was administered at a daily dose of 20 mg daily in patients with an estimated creatinine clearance of at least 50 ml per minute or at a daily dose of 15 mg in patients with an estimated creatinine clearance of less than 50 ml per minute. Patients who were assigned to the vitamin K antagonist group received any locally approved vitamin K antagonist. Dose adjustment was expected to occur with a measurement of the INR obtained no less than monthly in order to maintain the INR in the range of 2.0 to 3.0. Patients were seen in follow-up at 1 month after randomization and every 6 months thereafter.</div></section><section id="sec-1-3"><h3>Outcome Measures</h3><div role="paragraph">In the original trial design, the primary efficacy outcome was a composite of total stroke or systemic embolism. Key secondary outcomes were myocardial infarction and death from vascular (cardiac or noncardiac) causes. The primary analysis was planned as a noninferiority analysis, with potential testing for superiority; the noninferiority margin was 1.46 (upper boundary of the one-sided 97.5% confidence interval of the hazard ratio). The trial was expected to continue until the occurrence of 254 primary-outcome events. The primary safety outcome was major bleeding as defined by the International Society of Thrombosis and Hemostasis (Table S5 in the <a href="#ap2">Supplementary Appendix</a>, available at NEJM.org). Primary efficacy and safety outcomes were independently adjudicated.</div><div role="paragraph">During the course of the trial, we observed (with blinding to treatment) that the overall rate of stroke was substantially lower than the expected rate and that the overall mortality rate was much higher than expected. Because the trial was event-driven, it became clear that it would not be practical for the required number of strokes to occur in a reasonable time period in order for the trial to have the planned statistical power. On the basis of blinded review of total event rates, the steering committee decided to change the primary outcome and to adopt both the primary outcome and the noninferiority margin of the Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events (ACTIVE) W trial, which was also a noninferiority trial comparing a new treatment (clopidogrel plus aspirin) with vitamin K antagonist therapy in patients with atrial fibrillation.<sup><a href="#core-r7" role="doc-biblioref" data-xml-rid="r7 r8" id="body-ref-r8-1" href-manipulated="true">7,8</a></sup> The primary outcome in the ACTIVE W trial was a composite of stroke, systemic embolism, myocardial infarction, or death from vascular causes, and the noninferiority margin for that outcome was a hazard ratio of 1.186.<sup><a href="#core-r7" role="doc-biblioref" data-xml-rid="r7 r8" id="body-ref-r8-2" href-manipulated="true">7,8</a></sup> In our trial, death from unknown causes was added to the composite primary outcome because we reasoned that most of the deaths would have a vascular cause. The trial remained event-driven, with a target of 1079 total primary outcomes necessary for the trial to have 80% power with the revised primary outcome and noninferiority margin. Stroke or systemic embolism remained an important secondary outcome.</div><div role="paragraph">Adherence to rivaroxaban therapy was assessed by comparison of the number of pills administered to patients in this group with the pill counts made at subsequent visits. No pill counts were done for patients assigned to the vitamin K antagonist group.</div></section><section id="sec-1-4"><h3>Statistical Analysis</h3><div role="paragraph">We planned to use proportional-hazards modeling to test the primary and secondary outcomes, unless strong evidence of nonproportionality of the Kaplan–Meier survival curves was seen, in which case we would also use a restricted mean survival time analysis. Time-dependent analysis showed clear evidence of nonproportionality for the primary outcome. Therefore, we performed restricted mean survival time analyses, truncating follow-up at the time of the last follow-up visit. Because randomization was stratified according to site, both proportional-hazards and restricted mean survival time analyses with adjustment for site are presented.</div><div role="paragraph">The intention-to-treat population included all the patients who underwent randomization. The efficacy analyses were performed on the basis of the intention-to-treat principle. We also analyzed all the outcomes using the on-treatment principle, which specified that only patients who received at least one dose of trial medication would be included and that the analysis would include only events that occurred up to 5 days after permanent discontinuation of trial medication. Two interim analyses of efficacy were planned, with the use of a modified Haybittle–Peto testing approach to evaluate the possibility of greater-than-expected efficacy. A difference in favor of treatment greater than 4 SD at the first analysis or greater than 3 SD at the second analysis could lead to a recommendation to terminate the trial early for greater-than-expected efficacy. The first such formal interim analysis was performed in August 2021, and the committee recommended that the trial continue at that time. The second formal interim analysis was not done.</div><div role="paragraph">We did not correct for multiplicity when conducting tests for secondary or other outcomes; results are reported as point estimates with 95% confidence intervals. The widths of the confidence intervals have not been adjusted for multiplicity, so the intervals should not be used in place of a hypothesis test. Prespecified subgroups were defined according to the presence or absence of moderate-to-severe mitral stenosis (estimated valve area, &lt;2.0 cm<sup>2</sup>), sex, age, body weight, the calculated creatinine clearance, and time in the therapeutic range of the INR that was observed at each participating center (according to quartile).</div></section></section><section id="sec-2" data-type="results"><h2>Results</h2><section id="sec-2-1"><h3>Patient Enrollment</h3><div role="paragraph">From August 2016 through September 2019, a total of 4565 patients were enrolled from 138 trial sites across 24 countries. A total of 2292 patients were assigned to the rivaroxaban group, and 2273 to the vitamin K antagonist group. Data for 28 patients at 1 trial site were not included in any analysis because the site was closed during the trial owing to concern about data validity. The intention-to-treat analysis included 4531 patients: 2275 in the rivaroxaban group and 2256 in the vitamin K antagonist group (Fig. S1). A total of 136 patients were lost to follow-up, and 16 patients withdrew consent. Final vital status was known for 4379 patients (2194 in the rivaroxaban group and 2185 in the vitamin K antagonist group). On February 4, 2022, the data and safety monitoring board recommended that the trial be terminated because the primary question addressed by the trial had been satisfactorily answered.</div><div role="paragraph">The mean (±SD) duration of follow-up was 3.1±1.2 years. Patients were enrolled in Africa, Asia, and Latin America. Details of the ethnic groups of the patients are shown in Table S1. The baseline clinical characteristics of the patients were well balanced between the treatment groups (<a href="#t1">Table 1</a>). The mean age of the patients was 50.5 years, and 72.3% were women. Moderate-to-severe mitral stenosis (valve area, ≤2.0 cm<sup>2</sup>) was present in 81.9% of the patients. Nearly half the patients had a CHA<sub>2</sub>DS<sub>2</sub>VASc score of less than 2. Vitamin K antagonist therapy was being used before enrollment in 52.8% of the patients.</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 1</div><nav><a href="#t1" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2209051_t1.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t1" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t1" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2209051_t1.jpg"><img src="/cms/10.1056/NEJMoa2209051/asset/1126d03b-8992-41a5-80e1-d1a5bc8c8b1e/assets/images/large/nejmoa2209051_t1.jpg" height="2957" width="1999" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Characteristic</th><th class="txxx-borders">Overall<br>(N=4531)</th><th class="txxx-borders">Rivaroxaban<br>(N=2275)</th><th class="txxr-borders">Vitamin K Antagonist<br>(N=2256)</th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging04 shading" data-xml-align="left">Age — yr</td><td class="xxxx-borders shading">50.5±14.6</td><td class="xxxx-borders shading">50.7±14.8</td><td class="xxxr-borders shading">50.3±14.4</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging04" data-xml-align="left">Female sex — no. (%)</td><td class="xxxx-borders">3274 (72.3)</td><td class="xxxx-borders">1648 (72.4)</td><td class="xxxr-borders">1626 (72.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging04 shading" data-xml-align="left">Systolic blood pressure — mm Hg</td><td class="xxxx-borders shading">115.7±17.5</td><td class="xxxx-borders shading">116.0±17.7</td><td class="xxxr-borders shading">115.5±17.4</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging04" data-xml-align="left">Body-mass index<a href="#t1fn2" role="doc-noteref">†</a></td><td class="xxxx-borders">24.5±5.9</td><td class="xxxx-borders">24.4±5.7</td><td class="xxxr-borders">24.6±6.1</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging04 shading" data-xml-align="left">Creatinine clearance — ml/min</td><td class="xxxx-borders shading">80.6±30.4</td><td class="xxxx-borders shading">80.0±30.2</td><td class="xxxr-borders shading">81.1±30.7</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging04" data-xml-align="left">Congestive heart failure — no. (%)</td><td class="xxxx-borders">1745 (38.5)</td><td class="xxxx-borders">879 (38.6)</td><td class="xxxr-borders">866 (38.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging04 shading" data-xml-align="left">Hypertension — no. (%)</td><td class="xxxx-borders shading">1057 (23.3)</td><td class="xxxx-borders shading">522 (22.9)</td><td class="xxxr-borders shading">535 (23.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging04" data-xml-align="left">Diabetes mellitus — no. (%)</td><td class="xxxx-borders">290 (6.4)</td><td class="xxxx-borders">158 (6.9)</td><td class="xxxr-borders">132 (5.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging04 shading" data-xml-align="left">Stroke — no. (%)</td><td class="xxxx-borders shading">505 (11.1)</td><td class="xxxx-borders shading">248 (10.9)</td><td class="xxxr-borders shading">257 (11.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging04" data-xml-align="left">Transient ischemic attack — no. (%)</td><td class="xxxx-borders">147 (3.2)</td><td class="xxxx-borders">75 (3.3)</td><td class="xxxr-borders">72 (3.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging04 shading" data-xml-align="left">Coronary artery disease — no. (%)</td><td class="xxxx-borders shading">52 (1.1)</td><td class="xxxx-borders shading">32 (1.4)</td><td class="xxxr-borders shading">20 (0.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging04" data-xml-align="left">Percutaneous valvuloplasty — no. (%)</td><td class="xxxx-borders">506 (11.2)</td><td class="xxxx-borders">265 (11.6)</td><td class="xxxr-borders">241 (10.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging04 shading" data-xml-align="left">Mitral-valve repair — no. (%)</td><td class="xxxx-borders shading">155 (3.4)</td><td class="xxxx-borders shading">75 (3.3)</td><td class="xxxr-borders shading">80 (3.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging04" data-xml-align="left">CHA<sub>2</sub>DS<sub>2</sub>-VASc score<a href="#t1fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders">1.9±1.4</td><td class="xxxx-borders">2.0±1.4</td><td class="xxxr-borders">1.9±1.4</td></tr><tr data-type="row"><td class="xxlx-borders hanging04 shading">Inclusion criteria met — no. (%)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging14" data-xml-align="left">CHA<sub>2</sub>DS<sub>2</sub>-VASc score ≥2</td><td class="xxxx-borders">2557 (56.4)</td><td class="xxxx-borders">1295 (56.9)</td><td class="xxxr-borders">1262 (55.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging14 shading" data-xml-align="left">Moderate-to-severe mitral stenosis<a href="#t1fn4" role="doc-noteref">§</a></td><td class="xxxx-borders shading">3711 (81.9)</td><td class="xxxx-borders shading">1871 (82.2)</td><td class="xxxr-borders shading">1840 (81.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging14" data-xml-align="left">Left atrial spontaneous echo contrast</td><td class="xxxx-borders">527 (11.6)</td><td class="xxxx-borders">278 (12.2)</td><td class="xxxr-borders">249 (11.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging14 shading" data-xml-align="left">Left atrial thrombus on echocardiography</td><td class="xxxx-borders shading">304 (6.7)</td><td class="xxxx-borders shading">151 (6.6)</td><td class="xxxr-borders shading">153 (6.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging14" data-xml-align="left">CHA<sub>2</sub>DS<sub>2</sub>-VASc score ≥2 as only criterion</td><td class="xxxx-borders">697 (15.4)</td><td class="xxxx-borders">342 (15.0)</td><td class="xxxr-borders">355 (15.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging14 shading" data-xml-align="left">Moderate-to-severe mitral stenosis as only criterion</td><td class="xxxx-borders shading">1657 (36.6)</td><td class="xxxx-borders shading">827 (36.4)</td><td class="xxxr-borders shading">830 (36.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging14" data-xml-align="left">CHA<sub>2</sub>DS<sub>2</sub>-VASc score ≥2 and moderate-to-severe mitral stenosis</td><td class="xxxx-borders">1788 (39.5)</td><td class="xxxx-borders">916 (40.3)</td><td class="xxxr-borders">872 (38.7)</td></tr><tr data-type="row"><td class="xxlx-borders hanging04 shading">Echocardiographic findings — no./total no. (%)<a href="#t1fn5" role="doc-noteref">¶</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging14">Mitral-valve stenosis</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging24 shading" data-xml-align="left">Absent</td><td class="xxxx-borders shading">647/4489 (14.4)</td><td class="xxxx-borders shading">324/2255 (14.4)</td><td class="xxxr-borders shading">323/2234 (14.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging24" data-xml-align="left">Present</td><td class="xxxx-borders">3830/4489 (85.3)</td><td class="xxxx-borders">1927/2255 (85.5)</td><td class="xxxr-borders">1903/2234 (85.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging24 shading" data-xml-align="left">Valve area &lt;1.0 cm<sup>2</sup></td><td class="xxxx-borders shading">1042/3830 (27.2)</td><td class="xxxx-borders shading">506/1927 (26.3)</td><td class="xxxr-borders shading">536/1903 (28.2)</td></tr><tr data-type="row"><td class="xxlx-borders hanging14">Mitral-valve regurgitation</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging24 shading" data-xml-align="left">Absent</td><td class="xxxx-borders shading">766/4489 (17.1)</td><td class="xxxx-borders shading">390/2255 (17.3)</td><td class="xxxr-borders shading">376/2234 (16.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging24" data-xml-align="left">Present</td><td class="xxxx-borders">3709/4489 (82.6)</td><td class="xxxx-borders">1860/2255 (82.5)</td><td class="xxxr-borders">1849/2234 (82.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging34 shading" data-xml-align="left">Moderate</td><td class="xxxx-borders shading">1317/3709 (35.5)</td><td class="xxxx-borders shading">667/1860 (35.9)</td><td class="xxxr-borders shading">650/1849 (35.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging34" data-xml-align="left">Severe</td><td class="xxxx-borders">831/3709 (22.4)</td><td class="xxxx-borders">421/1860 (22.6)</td><td class="xxxr-borders">410/1849 (22.2)</td></tr><tr data-type="row"><td class="xxlx-borders hanging04 shading">Medications received — no. (%)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging14" data-xml-align="left">Any vitamin K antagonist</td><td class="xxxx-borders">2394 (52.8)</td><td class="xxxx-borders">1218 (53.5)</td><td class="xxxr-borders">1176 (52.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging14 shading" data-xml-align="left">Prophylaxis for rheumatic fever</td><td class="xxxx-borders shading">1445 (31.9)</td><td class="xxxx-borders shading">715 (31.4)</td><td class="xxxr-borders shading">730 (32.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging14" data-xml-align="left">Beta-blocker</td><td class="xxxx-borders">3276 (72.3)</td><td class="xxxx-borders">1612 (70.9)</td><td class="xxxr-borders">1664 (73.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging14 shading" data-xml-align="left">ACE inhibitor or ARB</td><td class="xxxx-borders shading">1283 (28.3)</td><td class="xxxx-borders shading">651 (28.6)</td><td class="xxxr-borders shading">632 (28.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging14" data-xml-align="left">Digoxin</td><td class="xxxx-borders">1925 (42.5)</td><td class="xxxx-borders">991 (43.6)</td><td class="xxxr-borders">934 (41.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging14 shading" data-xml-align="left">Calcium-channel blocker</td><td class="xxxx-borders shading">267 (5.9)</td><td class="xxxx-borders shading">136 (6.0)</td><td class="xxxr-borders shading">131 (5.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging14" data-xml-align="left">Diuretic</td><td class="xxxx-borders">3825 (84.4)</td><td class="xxxx-borders">1931 (84.9)</td><td class="xxxr-borders">1894 (84.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging14 shading" data-xml-align="left">Treatment for HIV infection or AIDS</td><td class="xbxx-borders shading">58 (1.3)</td><td class="xbxx-borders shading">25 (1.1)</td><td class="xbxr-borders shading">33 (1.5)</td></tr></tbody></table></div><figcaption><div class="caption">Characteristics of the Patients at Baseline.<a href="#t1fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t1fn1" role="paragraph">Plus–minus values are means ±SD. ACE denotes angiotensin-converting enzyme, AIDS acquired immunodeficiency syndrome, ARB angiotensin-receptor blocker, and HIV human immunodeficiency virus.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="t1fn2" role="paragraph">The body-mass index is the weight in kilograms divided by the square of the height in meters.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="t1fn3" role="paragraph">CHA<sub>2</sub>DS<sub>2</sub>-VASc scores (an assessment of the risk of stroke among patients with atrial fibrillation) range from 0 to 9, with higher scores indicating a higher risk of stroke.</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="t1fn4" role="paragraph">Moderate-to-severe mitral stenosis was defined as a valve area of less than 2.0 cm<sup>2</sup>.</div></div><div role="doc-footnote" data-has="label"><div class="label">¶</div><div id="t1fn5" role="paragraph">With regard to echocardiographic findings, results on mitral-valve stenosis were unknown for four patients in the rivaroxaban group and for eight in the vitamin K antagonist group; results on mitral-valve regurgitation were unknown for five and nine, respectively.</div></div></div></figcaption></figure></div></section><section id="sec-2-2"><h3>Delivery of Trial Treatment</h3><div role="paragraph">In the vitamin K antagonist group, warfarin was used predominantly (in 79 to 85% of the patients, with the percentage varying between visits), and acenocoumarol was used in almost all the other patients. The INR that was recorded immediately before trial enrollment was in the therapeutic range (2.0 to 3.0) in 33.2% of the patients in the vitamin K antagonist group, and the INR that was recorded at trial visits was in the therapeutic range in 56.1% of the patients at 6 months, in 59.0% at 1 year, in 65.3% at 2 years, in 65.1% at 3 years, and in 64.1% at 4 years.</div><div role="paragraph">The percentage of patients with permanent discontinuation of trial medication was higher in the rivaroxaban group than in the vitamin K antagonist group. Detailed reasons for permanent discontinuation are shown in Table S2. The most common reasons for permanent discontinuation in the two trial groups were hospitalization for valve surgery and decision by the patient. Of the 513 patients who discontinued rivaroxaban permanently, 161 (31.4%) stopped rivaroxaban owing to an indication for valve-replacement surgery that required the use of a vitamin K antagonist. Many patients who discontinued rivaroxaban subsequently received a vitamin K antagonist, whereas those who discontinued vitamin K antagonist therapy did not usually receive an oral anticoagulant thereafter. At the trial visits, the percentages of patients in the vitamin K antagonist group receiving trial medication (not permanently or temporarily discontinued) were 98.0% at 1 year, 97.7% at 2 years, 97.1% at 3 years, and 96.4% at 4 years; in the rivaroxaban group, the corresponding percentages were 88.7%, 84.4%, 81.2%, and 79.0%. At the trial visits, the percentages of patients in the rivaroxaban group who either were receiving rivaroxaban or had switched to a vitamin K antagonist were 94.9% at 1 year, 92.4% at 2 years, 91.5% at 3 years, and 87.5% at 4 years. Reasons for permanent discontinuation of rivaroxaban, in a comparison of patients who subsequently started a vitamin K antagonist with those who did not, are shown in Table S3. On the basis of the expected number of pills administered and the pills returned, the mean adherence to rivaroxaban therapy was 83.7±16.5%.</div></section><section id="sec-2-3"><h3>Efficacy and Safety Outcomes</h3><div role="paragraph">A primary-outcome event (stroke, systemic embolism, myocardial infarction, or death from vascular or unknown causes) occurred in 560 of 2275 patients in the rivaroxaban group and in 446 of 2256 patients in the vitamin K antagonist group (proportional-hazards ratio, 1.25; 95% confidence interval [CI], 1.10 to 1.41) (<a href="#t2">Table 2</a> and <a href="#f1">Figure 1</a>). The restricted mean survival time was 1599 days in the rivaroxaban group and 1675 days in the vitamin K antagonist group (difference, −76 days; 95% CI, −121 to −31 days; P&lt;0.001 for superiority). More patients in the rivaroxaban group than in the vitamin K antagonist group had a stroke (90 vs. 65 patients), a finding that was almost entirely due to a higher rate of ischemic stroke in the rivaroxaban group. A total of 552 patients in the rivaroxaban group and in 442 in the vitamin K antagonist group died (difference in restricted mean survival time, −72 days; 95% CI, −117 to −28). The difference in mortality was almost entirely due to lower rates of sudden cardiac death and of death due to mechanical or pump failure in the vitamin K antagonist group than in the rivaroxaban group (<a href="#f2">Figure 2</a>). No between-group differences in the rate of hospitalization for heart failure were observed. The rates of valve-replacement surgery or mitral valvuloplasty did not differ significantly between the two groups. The between-group differences in the rates of stroke and death were similar in the on-treatment analyses and the intention-to-treat analyses (<a href="#t3">Table 3</a>). A competing-risk analysis of the primary outcome showed a result that was similar to that of the primary analysis (Table S4). Rates of major bleeding did not differ significantly between the treatment groups (<a href="#t3">Table 3</a>). However, the rate of fatal bleeding was lower with rivaroxaban than with vitamin K antagonists. No significant interactions were found for effect of the intervention on the primary outcome according to the prespecified subgroups.</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Figure 1</div><nav><a href="#f1" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2209051_f1.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f1" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f1" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2209051_f1.jpg"><img src="/cms/10.1056/NEJMoa2209051/asset/3eb90917-d9a9-4166-abfd-80f3c1860f7b/assets/images/large/nejmoa2209051_f1.jpg" height="1768" width="2231" aria-labelledby="f1" loading="lazy"></a><figcaption><div class="caption">Cumulative Incidence of the Composite of Stroke, Systemic Embolism, Myocardial Infarction, or Death from Vascular or Unknown Causes (Primary Outcome).</div><div class="notes"><div role="doc-footnote">Vascular causes could be cardiac or noncardiac. The inset shows the same data on an expanded y axis. VKA denotes vitamin K antagonist.</div></div></figcaption></figure></div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Figure 2</div><nav><a href="#f2" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2209051_f2.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f2" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f2" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2209051_f2.jpg"><img src="/cms/10.1056/NEJMoa2209051/asset/9278e3cb-d519-462f-b517-ed012b940adf/assets/images/large/nejmoa2209051_f2.jpg" height="3417" width="2231" aria-labelledby="f2" loading="lazy"></a><figcaption><div class="caption">Cumulative Incidences of Stroke or Systemic Embolism and of Death.</div><div class="notes"><div role="doc-footnote">The insets show the same data on expanded y axes.</div></div></figcaption></figure></div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 2</div><nav><a href="#t2" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2209051_t2.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t2" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t2" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2209051_t2.jpg"><img src="/cms/10.1056/NEJMoa2209051/asset/78e137be-9006-4191-a2e6-64d4f0d32dc6/assets/images/large/nejmoa2209051_t2.jpg" height="1818" width="2615" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Outcome</th><th class="txxx-borders" colspan="3"><span>Rivaroxaban<br>(N=2275)</span></th><th class="txxx-borders" colspan="3"><span>Vitamin K Antagonist<br>(N=2256)</span></th><th class="txxx-borders">Proportional-Hazards<br>Ratio (95% CI)</th><th class="txxx-borders">Difference in RMST<br>(95% CI)</th><th class="txxr-borders">P Value</th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">No. of Patients</th><th class="xxxx-borders">Rate</th><th class="xxxx-borders">RMST</th><th class="xxxx-borders">No. of Patients</th><th class="xxxx-borders">Rate</th><th class="xxxx-borders">RMST</th><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr class="head3" data-type="row head3"><td class="xxlx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><th class="xxxx-borders">%/yr</th><th class="xxxx-borders">days</th><td class="xxxx-borders">&nbsp;</td><th class="xxxx-borders">%/yr</th><th class="xxxx-borders">days</th><td class="xxxx-borders">&nbsp;</td><th class="xxxx-borders">days</th><td class="xxxr-borders">&nbsp;</td></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">Stroke, systemic embolism, myocardial infarction, or death from vascular or unknown causes</td><td class="xxxx-borders shading">560</td><td class="xxxx-borders shading">8.21</td><td class="xxxx-borders shading">1599</td><td class="xxxx-borders shading">446</td><td class="xxxx-borders shading">6.49</td><td class="xxxx-borders shading">1675</td><td class="xxxx-borders shading">1.25 (1.10 to 1.41)</td><td class="xxxx-borders shading">−76 (−121 to −31)</td><td class="xxxr-borders shading">&lt;0.001</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03" data-xml-align="left">Stroke</td><td class="xxxx-borders">90</td><td class="xxxx-borders">1.32</td><td class="xxxx-borders">1929</td><td class="xxxx-borders">65</td><td class="xxxx-borders">0.94</td><td class="xxxx-borders">1950</td><td class="xxxx-borders">1.37 (1.00 to 1.89)</td><td class="xxxx-borders">−21 (−40 to −2)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">Ischemic stroke</td><td class="xxxx-borders shading">74</td><td class="xxxx-borders shading">1.08</td><td class="xxxx-borders shading">1941</td><td class="xxxx-borders shading">48</td><td class="xxxx-borders shading">0.70</td><td class="xxxx-borders shading">1963</td><td class="xxxx-borders shading">1.53 (1.06 to 2.20)</td><td class="xxxx-borders shading">−23 (−40 to −6)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03" data-xml-align="left">Hemorrhagic stroke</td><td class="xxxx-borders">7</td><td class="xxxx-borders">0.10</td><td class="xxxx-borders">1995</td><td class="xxxx-borders">7</td><td class="xxxx-borders">0.10</td><td class="xxxx-borders">1994</td><td class="xxxx-borders">1.00 (0.35 to 2.86)</td><td class="xxxx-borders">0.3 (−6 to 6)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">Stroke of uncertain cause</td><td class="xxxx-borders shading">12</td><td class="xxxx-borders shading">0.17</td><td class="xxxx-borders shading">1991</td><td class="xxxx-borders shading">10</td><td class="xxxx-borders shading">0.14</td><td class="xxxx-borders shading">1993</td><td class="xxxx-borders shading">1.21 (0.52 to 2.79)</td><td class="xxxx-borders shading">−1 (−8 to 5)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03" data-xml-align="left">Systemic embolism</td><td class="xxxx-borders">6</td><td class="xxxx-borders">0.09</td><td class="xxxx-borders">1995</td><td class="xxxx-borders">10</td><td class="xxxx-borders">0.14</td><td class="xxxx-borders">1992</td><td class="xxxx-borders">0.59 (0.22 to 1.63)</td><td class="xxxx-borders">4 (−3 to 10)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">Stroke or systemic embolism</td><td class="xxxx-borders shading">94</td><td class="xxxx-borders shading">1.38</td><td class="xxxx-borders shading">1926</td><td class="xxxx-borders shading">75</td><td class="xxxx-borders shading">1.09</td><td class="xxxx-borders shading">1942</td><td class="xxxx-borders shading">1.24 (0.92 to 1.68)</td><td class="xxxx-borders shading">−16 (−36 to 4)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03" data-xml-align="left">Myocardial infarction</td><td class="xxxx-borders">5</td><td class="xxxx-borders">0.07</td><td class="xxxx-borders">1996</td><td class="xxxx-borders">3</td><td class="xxxx-borders">0.04</td><td class="xxxx-borders">1998</td><td class="xxxx-borders">1.67 (0.40 to 6.97)</td><td class="xxxx-borders">−1 (−5 to 3)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">Death</td><td class="xxxx-borders shading">552</td><td class="xxxx-borders shading">7.95</td><td class="xxxx-borders shading">1608</td><td class="xxxx-borders shading">442</td><td class="xxxx-borders shading">6.35</td><td class="xxxx-borders shading">1680</td><td class="xxxx-borders shading">1.23 (1.09 to 1.40)</td><td class="xxxx-borders shading">−72 (−117 to −28)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Death due to vascular causes<a href="#t2fn2" role="doc-noteref">†</a></td><td class="xxxx-borders">439</td><td class="xxxx-borders">6.33</td><td class="xxxx-borders">1683</td><td class="xxxx-borders">337</td><td class="xxxx-borders">4.84</td><td class="xxxx-borders">1751</td><td class="xxxx-borders">1.29 (1.12 to 1.49)</td><td class="xxxx-borders">−68 (−110 to −26)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">Sudden cardiac death</td><td class="xxxx-borders shading">141</td><td class="xxxx-borders shading">2.03</td><td class="xxxx-borders shading">1894</td><td class="xxxx-borders shading">94</td><td class="xxxx-borders shading">1.35</td><td class="xxxx-borders shading">1929</td><td class="xxxx-borders shading">1.51 (1.16 to 1.96)</td><td class="xxxx-borders shading">−36 (−58 to −13)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Death due to mechanical or pump failure</td><td class="xxxx-borders">237</td><td class="xxxx-borders">3.42</td><td class="xxxx-borders">1817</td><td class="xxxx-borders">174</td><td class="xxxx-borders">2.50</td><td class="xxxx-borders">1862</td><td class="xxxx-borders">1.35 (1.11 to 1.64)</td><td class="xxxx-borders">−45 (−83 to −8)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Death due to nonvascular causes</td><td class="xxxx-borders shading">46</td><td class="xxxx-borders shading">0.66</td><td class="xxxx-borders shading">1962</td><td class="xxxx-borders shading">36</td><td class="xxxx-borders shading">0.52</td><td class="xxxx-borders shading">1971</td><td class="xxxx-borders shading">1.26 (0.81 to 1.94)</td><td class="xxxx-borders shading">−9 (−25 to 7)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Death due to unknown cause</td><td class="xxxx-borders">67</td><td class="xxxx-borders">0.97</td><td class="xxxx-borders">1941</td><td class="xxxx-borders">69</td><td class="xxxx-borders">0.99</td><td class="xxxx-borders">1946</td><td class="xxxx-borders">0.96 (0.69 to 1.35)</td><td class="xxxx-borders">−4 (−26 to 17)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">Any hospitalization</td><td class="xxxx-borders shading">687</td><td class="xxxx-borders shading">11.71</td><td class="xxxx-borders shading">1432</td><td class="xxxx-borders shading">622</td><td class="xxxx-borders shading">10.44</td><td class="xxxx-borders shading">1467</td><td class="xxxx-borders shading">1.08 (0.97 to 1.21)</td><td class="xxxx-borders shading">−36 (−80 to 9)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Hospitalization for heart failure</td><td class="xxxx-borders">240</td><td class="xxxx-borders">3.61</td><td class="xxxx-borders">1779</td><td class="xxxx-borders">219</td><td class="xxxx-borders">3.28</td><td class="xxxx-borders">1794</td><td class="xxxx-borders">1.08 (0.89 to 1.29)</td><td class="xxxx-borders">−16 (−47 to 16)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Valve surgery</td><td class="xxxx-borders shading">187</td><td class="xxxx-borders shading">2.85</td><td class="xxxx-borders shading">1852</td><td class="xxxx-borders shading">157</td><td class="xxxx-borders shading">2.36</td><td class="xxxx-borders shading">1873</td><td class="xxxx-borders shading">1.19 (0.97 to 1.48)</td><td class="xxxx-borders shading">−21 (−50 to 9)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging13" data-xml-align="left">Valve surgery or valvuloplasty</td><td class="xbxx-borders">205</td><td class="xbxx-borders">3.14</td><td class="xbxx-borders">1838</td><td class="xbxx-borders">175</td><td class="xbxx-borders">2.65</td><td class="xbxx-borders">1859</td><td class="xbxx-borders">1.17 (0.95 to 1.43)</td><td class="xbxx-borders">−21 (−52 to 10)</td><td class="xbxr-borders">&nbsp;</td></tr></tbody></table></div><figcaption><div class="caption">Intention-to-Treat Analysis of Efficacy Outcomes.<a href="#t2fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t2fn1" role="paragraph">The intention-to-treat population included all the patients who underwent randomization, except for 34 patients, whose data were excluded owing to duplicate randomization, potentially fraudulent data, or inability to obtain required re-consent. The widths of the confidence intervals have not been adjusted for multiplicity, so the intervals should not be used in place of a hypothesis test. RMST denotes restricted mean survival time.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="t2fn2" role="paragraph">Vascular causes could be cardiac or noncardiac. Deaths due to vascular causes other than sudden death or death due to mechanical or pump failure occurred in 61 patients in the rivaroxaban group and in 69 in the vitamin K antagonist group.</div></div></div></figcaption></figure></div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 3</div><nav><a href="#t3" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2209051_t3.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t3" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t3" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2209051_t3.jpg"><img src="/cms/10.1056/NEJMoa2209051/asset/975afcba-7553-49bd-ba79-253ab4b4ba56/assets/images/large/nejmoa2209051_t3.jpg" height="1763" width="2615" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Outcome</th><th class="txxx-borders" colspan="3"><span>Rivaroxaban<br>(N=2265)</span></th><th class="txxx-borders" colspan="3"><span>Vitamin K Antagonist<br>(N=2251)</span></th><th class="txxx-borders">Proportional-Hazards<br>Ratio (95% CI)</th><th class="txxx-borders">Difference in RMST<br>(95% CI)</th><th class="txxr-borders">P Value</th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">No. of<br>Patients</th><th class="xxxx-borders">Rate</th><th class="xxxx-borders">RMST</th><th class="xxxx-borders">No. of<br>Patients</th><th class="xxxx-borders">Rate</th><th class="xxxx-borders">RMST</th><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr class="head3" data-type="row head3"><td class="xxlx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><th class="xxxx-borders">%/yr</th><th class="xxxx-borders">days</th><td class="xxxx-borders">&nbsp;</td><th class="xxxx-borders">%/yr</th><th class="xxxx-borders">days</th><td class="xxxx-borders">&nbsp;</td><th class="xxxx-borders">days</th><td class="xxxr-borders">&nbsp;</td></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging02 shading"><b>Safety outcomes</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Major bleeding</td><td class="xxxx-borders">40</td><td class="xxxx-borders">0.67</td><td class="xxxx-borders">1965</td><td class="xxxx-borders">56</td><td class="xxxx-borders">0.83</td><td class="xxxx-borders">1954</td><td class="xxxx-borders">0.76 (0.51 to 1.15)</td><td class="xxxx-borders">11 (−5 to 28)</td><td class="xxxr-borders">0.18</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Fatal bleeding</td><td class="xxxx-borders shading">4</td><td class="xxxx-borders shading">0.07</td><td class="xxxx-borders shading">1996</td><td class="xxxx-borders shading">15</td><td class="xxxx-borders shading">0.22</td><td class="xxxx-borders shading">1988</td><td class="xxxx-borders shading">0.29 (0.10 to 0.88)</td><td class="xxxx-borders shading">8 (1 to 16)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Bleeding in a critical area or organ</td><td class="xxxx-borders">2</td><td class="xxxx-borders">0.03</td><td class="xxxx-borders">1998</td><td class="xxxx-borders">4</td><td class="xxxx-borders">0.06</td><td class="xxxx-borders">1997</td><td class="xxxx-borders">0.52 (0.09 to 2.81)</td><td class="xxxx-borders">2 (−3 to 6)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Intracranial hemorrhage</td><td class="xxxx-borders shading">8</td><td class="xxxx-borders shading">0.13</td><td class="xxxx-borders shading">1993</td><td class="xxxx-borders shading">14</td><td class="xxxx-borders shading">0.21</td><td class="xxxx-borders shading">1989</td><td class="xxxx-borders shading">0.63 (0.26 to 1.50)</td><td class="xxxx-borders shading">4 (−3 to 12)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Life-threatening bleeding</td><td class="xxxx-borders">22</td><td class="xxxx-borders">0.36</td><td class="xxxx-borders">1981</td><td class="xxxx-borders">31</td><td class="xxxx-borders">0.46</td><td class="xxxx-borders">1975</td><td class="xxxx-borders">0.77 (0.44 to 1.32)</td><td class="xxxx-borders">6 (−6 to 18)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Clinically relevant nonmajor bleeding</td><td class="xxxx-borders shading">65</td><td class="xxxx-borders shading">1.09</td><td class="xxxx-borders shading">1943</td><td class="xxxx-borders shading">71</td><td class="xxxx-borders shading">1.06</td><td class="xxxx-borders shading">1942</td><td class="xxxx-borders shading">0.96 (0.68 to 1.34)</td><td class="xxxx-borders shading">1 (−18 to 20)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Major or clinically relevant nonmajor bleeding</td><td class="xxxx-borders">102</td><td class="xxxx-borders">1.72</td><td class="xxxx-borders">1912</td><td class="xxxx-borders">120</td><td class="xxxx-borders">1.81</td><td class="xxxx-borders">1901</td><td class="xxxx-borders">0.89 (0.68 to 1.16)</td><td class="xxxx-borders">10 (−14 to 35)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading"><b>Selected efficacy outcomes</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Stroke, systemic embolism, myocardial infarction, or death from vascular or unknown causes</td><td class="xxxx-borders">481</td><td class="xxxx-borders">8.06</td><td class="xxxx-borders">1619</td><td class="xxxx-borders">426</td><td class="xxxx-borders">6.33</td><td class="xxxx-borders">1686</td><td class="xxxx-borders">1.26 (1.10 to 1.43)</td><td class="xxxx-borders">−67 (−110 to −24)</td><td class="xxxr-borders">0.002</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Stroke</td><td class="xxxx-borders shading">83</td><td class="xxxx-borders shading">1.39</td><td class="xxxx-borders shading">1926</td><td class="xxxx-borders shading">59</td><td class="xxxx-borders shading">0.87</td><td class="xxxx-borders shading">1955</td><td class="xxxx-borders shading">1.54 (1.10 to 2.16)</td><td class="xxxx-borders shading">−29 (−49 to −9)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Systemic embolism</td><td class="xxxx-borders">6</td><td class="xxxx-borders">0.10</td><td class="xxxx-borders">1995</td><td class="xxxx-borders">9</td><td class="xxxx-borders">0.13</td><td class="xxxx-borders">1993</td><td class="xxxx-borders">0.71 (0.25 to 2.01)</td><td class="xxxx-borders">2 (−4 to 9)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Myocardial infarction</td><td class="xxxx-borders shading">5</td><td class="xxxx-borders shading">0.08</td><td class="xxxx-borders shading">1996</td><td class="xxxx-borders shading">3</td><td class="xxxx-borders shading">0.04</td><td class="xxxx-borders shading">1998</td><td class="xxxx-borders shading">1.85 (0.44 to 7.77)</td><td class="xxxx-borders shading">−2 (−6 to 3)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Death from vascular causes</td><td class="xxxx-borders">362</td><td class="xxxx-borders">5.98</td><td class="xxxx-borders">1712</td><td class="xxxx-borders">319</td><td class="xxxx-borders">4.68</td><td class="xxxx-borders">1761</td><td class="xxxx-borders">1.26 (1.08 to 1.47)</td><td class="xxxx-borders">−49 (−87 to −10)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Death from unknown cause</td><td class="xxxx-borders shading">58</td><td class="xxxx-borders shading">0.96</td><td class="xxxx-borders shading">1941</td><td class="xxxx-borders shading">65</td><td class="xxxx-borders shading">0.95</td><td class="xxxx-borders shading">1948</td><td class="xxxx-borders shading">1.00 (0.70 to 1.42)</td><td class="xxxx-borders shading">−7 (−30 to 16)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Death</td><td class="xxxx-borders">459</td><td class="xxxx-borders">7.58</td><td class="xxxx-borders">1638</td><td class="xxxx-borders">416</td><td class="xxxx-borders">6.10</td><td class="xxxx-borders">1694</td><td class="xxxx-borders">1.23 (1.08 to 1.40)</td><td class="xxxx-borders">−57 (−98 to −15)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Any hospitalization</td><td class="xxxx-borders shading">627</td><td class="xxxx-borders shading">11.49</td><td class="xxxx-borders shading">1447</td><td class="xxxx-borders shading">606</td><td class="xxxx-borders shading">10.35</td><td class="xxxx-borders shading">1473</td><td class="xxxx-borders shading">1.06 (0.95 to 1.19)</td><td class="xxxx-borders shading">−26 (−71 to 19)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Hospitalization for heart failure</td><td class="xxxx-borders">222</td><td class="xxxx-borders">3.80</td><td class="xxxx-borders">1775</td><td class="xxxx-borders">214</td><td class="xxxx-borders">3.27</td><td class="xxxx-borders">1795</td><td class="xxxx-borders">1.09 (0.90 to 1.32)</td><td class="xxxx-borders">−20 (−52 to 13)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging12 shading" data-xml-align="left">Valve surgery or valvuloplasty</td><td class="xbxx-borders shading">172</td><td class="xbxx-borders shading">2.87</td><td class="xbxx-borders shading">1853</td><td class="xbxx-borders shading">173</td><td class="xbxx-borders shading">2.67</td><td class="xbxx-borders shading">1858</td><td class="xbxx-borders shading">1.06 (0.86 to 1.31)</td><td class="xbxx-borders shading">−5 (−36 to 26)</td><td class="xbxr-borders shading">&nbsp;</td></tr></tbody></table></div><figcaption><div class="caption">On-Treatment Analysis of Safety Outcomes and Selected Efficacy Outcomes.<a href="#t3fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t3fn1" role="paragraph">The on-treatment population included all the patients who received at least one dose of trial medication, and the on-treatment analysis included only events that occurred up to 5 days after permanent discontinuation of trial medication. The widths of the confidence intervals have not been adjusted for multiplicity, so the intervals should not be used in place of a hypothesis test.</div></div></div></figcaption></figure></div></section></section><section id="sec-3" data-type="discussion"><h2>Discussion</h2><div role="paragraph">In patients with atrial fibrillation not related to rheumatic heart disease, treatment with rivaroxaban or other factor Xa inhibitors has been shown to be noninferior to warfarin therapy for stroke prevention, with large reduction in the risk of hemorrhagic stroke.<sup><a href="#core-r4" role="doc-biblioref" data-xml-rid="r4" id="body-ref-r4-2" href-manipulated="true" aria-label="Reference 4">4</a></sup> The patients in the present trial were much younger (mean age, 50.5 years) and more likely to be women (72% of the patients) than in recent trials including only patients without rheumatic heart disease.<sup><a href="#core-r4" role="doc-biblioref" data-xml-rid="r4" id="body-ref-r4-3" href-manipulated="true" aria-label="Reference 4">4</a></sup> A lower percentage of patients in this trial had hypertension (23%) than in previous trials. However, on the basis of previous trials, we expected to find a similar or higher risk of stroke because mitral stenosis has been associated with a high risk of stroke. We expected generally similar results in the present trial on the basis of the expectation that, despite a different underlying cardiac condition, the underlying stroke mechanism of embolism of left atrial thrombus would be similar in rheumatic heart disease as in other types of atrial fibrillation. We did not expect to observe a difference in mortality. The phase 3 trials confirming the safety and efficacy of the new oral anticoagulants, which included patients with atrial fibrillation not due to rheumatic heart disease and which compared non–vitamin K antagonist oral anticoagulants with vitamin K antagonists, showed consistent effects between patients with (nonrheumatic) valvular heart disease and those without such disease.<sup><a href="#core-r9" role="doc-biblioref" data-xml-rid="r9" id="body-ref-r9" href-manipulated="true" aria-label="Reference 9">9</a></sup> A randomized trial comparing rivaroxaban with vitamin K antagonist therapy in patients with atrial fibrillation and bioprosthetic mitral valves showed a lower risk with rivaroxaban of stroke at 1 year of follow-up and no significant difference in mortality.<sup><a href="#core-r10" role="doc-biblioref" data-xml-rid="r10" id="body-ref-r10" href-manipulated="true" aria-label="Reference 10">10</a></sup> Thus, the results of the present trial were unexpected.</div><div role="paragraph">Possible explanations for these findings include the reduced power of this trial for the outcome of stroke, because the rates of stroke in the two groups were lower than expected; in addition, the difference in the rate of stroke was modest, which suggests that the difference could be due to chance. The rate of the composite outcome of stroke or systemic embolism, which is widely accepted in trials of stroke prevention in patients with atrial fibrillation, did not differ between the two treatment groups. However, the difference in mortality was large and is therefore unlikely to be due to chance. Patients in the vitamin K antagonist group had more physician interactions than those in the rivaroxaban group because of the need for monthly monitoring of INR control. This situation could have resulted in better overall care and fewer strokes and deaths. It is possible that adherence to rivaroxaban therapy was worse than to vitamin K antagonist therapy because patients in the rivaroxaban group knew that they were not having the INR monitored. The difference in stroke rates between the two groups could also be, in part, related to the higher incidence of discontinuation of rivaroxaban, even though many of the patients who discontinued rivaroxaban then received a vitamin K antagonist. The most common reasons given for the discontinuation of rivaroxaban were hospitalization for valve surgery and patient decision. Some patients in the rivaroxaban group received mechanical valves, which necessitated a switch to vitamin K antagonist therapy to prevent valve thrombosis. However, the discontinuation of rivaroxaban does not explain the observed benefit of vitamin K antagonist therapy because the on-treatment analysis, which excluded any events that occurred more than 5 days after the discontinuation of trial treatment, showed results that were almost identical to those of the intention-to-treat analysis.</div><div role="paragraph">A mortality difference in favor of either treatment was not expected. In a meta-analysis of trials of non–vitamin K antagonist anticoagulants as compared with warfarin, mortality was 10% lower with non–vitamin K antagonist anticoagulants.<sup><a href="#core-r4" role="doc-biblioref" data-xml-rid="r4" id="body-ref-r4-4" href-manipulated="true" aria-label="Reference 4">4</a></sup> This difference appears to be driven mostly by the large reductions in the risk of hemorrhagic stroke with the newer agents. The effect of vitamin K antagonist therapy on mortality in the present trial appears to be mostly unrelated to stroke prevention. The absolute number of strokes prevented was small (25 strokes), as compared with the absolute number of deaths prevented (110 deaths). The lower mortality that was observed with vitamin K antagonist therapy than with rivaroxaban therapy in this trial is also clearly not related to any effect on bleeding, given that bleeding was not less common with vitamin K antagonist therapy than with rivaroxaban therapy. Treatment with a vitamin K antagonist does not appear to have slowed the progression of heart-valve deterioration, because rates of valve replacement surgery or valvuloplasty were similar in the two groups. The use of a vitamin K antagonist led to a lower rate of death from vascular causes than rivaroxaban therapy, with lower rates of both sudden cardiac death and death from mechanical or pump failure. Thus, the lower rates of sudden cardiac death and of death from mechanical or pump failure with vitamin K antagonist therapy than with rivaroxaban therapy are not readily explained by effects on stroke, bleeding, or valve deterioration.</div><div role="paragraph">During the first 12 to 18 months of follow-up, little difference was seen between the vitamin K antagonist group and the rivaroxaban group (Figs. <a href="#f1">Figure 1</a> and <a href="#f2">Figure 2</a>). After that, a lower rate of the primary composite outcome in the vitamin K antagonist group than in the rivaroxaban group became evident and was substantial beyond 3 years. We speculate that a delayed effect could be occurring, in part owing to improvement in the management of vitamin K antagonist therapy during the initial phase of the trial. It is also possible that there was a delay in the onset of the benefit from a vitamin K antagonist over rivaroxaban that is independent of INR control.</div><div role="paragraph">A delay in the onset of a benefit of vitamin K antagonist therapy was also seen in the Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) trial.<sup><a href="#core-r11" role="doc-biblioref" data-xml-rid="r11" id="body-ref-r11" href-manipulated="true" aria-label="Reference 11">11</a></sup> The WARCEF trial tested whether warfarin therapy would lead to a lower rate of death or stroke than aspirin among patients with heart failure due to a reduced ejection fraction without atrial fibrillation. The trial showed no benefit overall, but a time-varying Cox analysis showed a benefit of warfarin therapy that emerged only later in follow-up, as in the INVICTUS trial. The hazard ratio in favor of vitamin K antagonist therapy decreased by a factor of 0.89 per year (95% CI, 0.80 to 0.998; P=0.046) and became significant by year 4 (hazard ratio, 0.76; P=0.04).</div><div role="paragraph">No evidence suggests that rivaroxaban therapy increases mortality among patients with other heart conditions. Treatment with rivaroxaban reduces mortality substantially among patients with atherosclerotic vascular disease.<sup><a href="#core-r12" role="doc-biblioref" data-xml-rid="r12" id="body-ref-r12" href-manipulated="true" aria-label="Reference 12">12</a></sup> Thus, our data support the hypothesis that vitamin K antagonist therapy reduces the risk of death from vascular causes among patients with rheumatic heart disease; this effect appears to be independent of the prevention of atrial fibrillation–related stroke and suggests a direct effect on the disease process of rheumatic heart disease. Our trial showed that as compared with rivaroxaban, vitamin K antagonist therapy led to a lower rate of ischemic stroke among patients with rheumatic heart disease–associated atrial fibrillation and lower mortality due to vascular causes, without significantly increasing the rate of major bleeding. The results of this trial support current guidelines, which recommend vitamin K antagonist therapy for the prevention of stroke in patients with rheumatic heart disease in whom atrial fibrillation develops.</div></section>



        
        
</div></section><section id="backmatter" data-extent="backmatter" data-location="articleTab_article"><div class="core-container"><section id="backnotes" data-location="notes_article"><h2>Notes</h2><div data-type="published/updated" role="paragraph">This article was published on August 28, 2022, at NEJM.org.</div><div data-type="data-sharing" role="paragraph">A <a href="#ap4">data sharing statement</a> provided by the authors is available with the full text of this article at NEJM.org.</div><div role="paragraph">Supported by a nonrestricted grant from <span class="named-content" data-type="funder">Bayer</span> to the Population Health Research Institute.</div><div role="paragraph"><a href="#ap3">Disclosure forms</a> provided by the authors are available with the full text of this article at NEJM.org.</div><div data-type="dedication" role="paragraph">This article is dedicated to the memory of Dr. Bongani Mayosi, of the University of Cape Town, who was the initial principal investigator of the INVICTUS trial, for which he played a pivotal role in the design and initiation. We were saddened by his untimely death on July 27, 2018.</div></section><section id="supplementary-materials" class="core-supplementary-materials"><h2>Supplementary Material</h2><div role="list"><div id="ap0" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Research Summary</span> <span class="core-filename">(nejmoa2209051_research-summary.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2209051/suppl_file/nejmoa2209051_research-summary.pdf" download="nejmoa2209051_research-summary.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2209051_research-summary.pdf" data-doi="10.1056/NEJMoa2209051">Download</a></li><li>374.31 KB</li></ul></div></div><div id="ap1" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Protocol</span> <span class="core-filename">(nejmoa2209051_protocol.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2209051/suppl_file/nejmoa2209051_protocol.pdf" download="nejmoa2209051_protocol.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2209051_protocol.pdf" data-doi="10.1056/NEJMoa2209051">Download</a></li><li>2.00 MB</li></ul></div></div><div id="ap2" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Supplementary Appendix</span> <span class="core-filename">(nejmoa2209051_appendix.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2209051/suppl_file/nejmoa2209051_appendix.pdf" download="nejmoa2209051_appendix.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2209051_appendix.pdf" data-doi="10.1056/NEJMoa2209051">Download</a></li><li>394.14 KB</li></ul></div></div><div id="ap3" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Disclosure Forms</span> <span class="core-filename">(nejmoa2209051_disclosures.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2209051/suppl_file/nejmoa2209051_disclosures.pdf" download="nejmoa2209051_disclosures.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2209051_disclosures.pdf" data-doi="10.1056/NEJMoa2209051">Download</a></li><li>739.08 KB</li></ul></div></div><div id="ap4" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Data Sharing Statement</span> <span class="core-filename">(nejmoa2209051_data-sharing.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2209051/suppl_file/nejmoa2209051_data-sharing.pdf" download="nejmoa2209051_data-sharing.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2209051_data-sharing.pdf" data-doi="10.1056/NEJMoa2209051">Download</a></li><li>69.84 KB</li></ul></div></div></div></section><section id="bibliography" class="core-reference-list" role="doc-bibliography" data-location="references_article"><h2>References</h2><div role="list" data-method="clamp" id="collapsible-text"><div role="listitem" data-has="label"><div class="label">1.</div><div id="r1" class="citations"><div class="citation"><div class="citation-content">Iung B, Leenhardt A, Extramiana F. Management of atrial fibrillation in patients with rheumatic mitral stenosis. <em>Heart</em> 2018;104:1062-1068.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r1" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1136/heartjnl-2017-311425" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29453328/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000438038400006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Management+of+atrial+fibrillation+in+patients+with+rheumatic+mitral+stenosis.&amp;publication_year=2018&amp;journal=Heart&amp;pages=1062-1068&amp;doi=10.1136%2Fheartjnl-2017-311425&amp;pmid=29453328" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r1" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r2-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] atrial enlargement and atrial fibrillation. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r2-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] and often have advanced valvular disease. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">2.</div><div id="r2" class="citations"><div class="citation"><div class="citation-content">Stambler BS, Ngunga LM. Atrial fibrillation in Sub-Saharan Africa: epidemiology, unmet needs, and treatment options. <em>Int J Gen Med</em> 2015;8:231-242.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r2" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.2147/IJGM.S84537" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26261423/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Atrial+fibrillation+in+Sub-Saharan+Africa%3A+epidemiology%2C+unmet+needs%2C+and+treatment+options.&amp;publication_year=2015&amp;journal=Int+J+Gen+Med&amp;pages=231-242&amp;doi=10.2147%2FIJGM.S84537&amp;pmid=26261423" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r2" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r2-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] atrial enlargement and atrial fibrillation. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r2-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] and often have advanced valvular disease. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">3.</div><div id="r3" class="citations"><div class="citation"><div class="citation-content">Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. <em>Ann Intern Med</em> 2007;146:857-867.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r3"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.7326/0003-4819-146-12-200706190-00007" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/17577005/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000247347100004" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Meta-analysis%3A+antithrombotic+therapy+to+prevent+stroke+in+patients+who+have+nonvalvular+atrial+fibrillation.&amp;publication_year=2007&amp;journal=Ann+Intern+Med&amp;pages=857-867&amp;doi=10.7326%2F0003-4819-146-12-200706190-00007&amp;pmid=17577005" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">4.</div><div id="r4" class="citations"><div class="citation"><div class="citation-content">Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. <em>Lancet</em> 2014;383:955-962.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r4" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(13)62343-0" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24315724/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000333520700026" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Comparison+of+the+efficacy+and+safety+of+new+oral+anticoagulants+with+warfarin+in+patients+with+atrial+fibrillation%3A+a+meta-analysis+of+randomised+trials.&amp;publication_year=2014&amp;journal=Lancet&amp;pages=955-962&amp;doi=10.1016%2FS0140-6736%2813%2962343-0&amp;pmid=24315724" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r4" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r4-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] a lower risk of intracranial hemorrhage. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r4-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] in the risk of hemorrhagic stroke. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r4-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] patients without rheumatic heart disease. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r4-4" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>d [...] non–vitamin K antagonist anticoagulants. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">5.</div><div id="r5" class="citations"><div class="citation"><div class="citation-content">January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. <em>J Am Coll Cardiol</em> 2019;74:104-132.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r5"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.jacc.2019.01.011" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30703431/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000473259200015" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=2019+AHA%2FACC%2FHRS+focused+update+of+the+2014+AHA%2FACC%2FHRS+guideline+for+the+management+of+patients+with+atrial+fibrillation%3A+a+report+of+the+American+College+of+Cardiology%2FAmerican+Heart+Association+Task+Force+on+Clinical+Practice+Guidelines+and+the+Heart+Rhythm+Society.&amp;publication_year=2019&amp;journal=J+Am+Coll+Cardiol&amp;pages=104-132&amp;doi=10.1016%2Fj.jacc.2019.01.011&amp;pmid=30703431" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">6.</div><div id="r6" class="citations"><div class="citation"><div class="citation-content">Karthikeyan G, Connolly SJ, Ntsekhe M, et al. The INVICTUS rheumatic heart disease research program: rationale, design and baseline characteristics of a randomized trial of rivaroxaban compared to vitamin K antagonists in rheumatic valvular disease and atrial fibrillation. <em>Am Heart J</em> 2020;225:69-77.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r6"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.ahj.2020.03.018" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32474206/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000541737100010" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+INVICTUS+rheumatic+heart+disease+research+program%3A+rationale%2C+design+and+baseline+characteristics+of+a+randomized+trial+of+rivaroxaban+compared+to+vitamin+K+antagonists+in+rheumatic+valvular+disease+and+atrial+fibrillation.&amp;publication_year=2020&amp;journal=Am+Heart+J&amp;pages=69-77&amp;doi=10.1016%2Fj.ahj.2020.03.018&amp;pmid=32474206" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">7.</div><div id="r7" class="citations"><div class="citation"><div class="citation-content">The Active Steering Committee. Rationale and design of ACTIVE: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events. <em>Am Heart J</em> 2006;151:1187-1193.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r7" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.ahj.2005.06.026" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/16781218/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000238614600008" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Rationale+and+design+of+ACTIVE%3A+the+atrial+fibrillation+clopidogrel+trial+with+irbesartan+for+prevention+of+vascular+events.&amp;publication_year=2006&amp;journal=Am+Heart+J&amp;pages=1187-1193&amp;doi=10.1016%2Fj.ahj.2005.06.026&amp;pmid=16781218" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r7" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r8-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] in patients with atrial fibrillation. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r8-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] that outcome was a hazard ratio of 1.186. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">8.</div><div id="r8" class="citations"><div class="citation"><div class="citation-content">The ACTIVE Writing Group on behalf of the ACTIVE Investigators. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. <em>Lancet</em> 2006;367:1903-1912.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r8" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(06)68845-4" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/16765759/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000238194400029" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Clopidogrel+plus+aspirin+versus+oral+anticoagulation+for+atrial+fibrillation+in+the+Atrial+fibrillation+Clopidogrel+Trial+with+Irbesartan+for+prevention+of+Vascular+Events+%28ACTIVE+W%29%3A+a+randomised+controlled+trial.&amp;publication_year=2006&amp;journal=Lancet&amp;pages=1903-1912&amp;doi=10.1016%2FS0140-6736%2806%2968845-4&amp;pmid=16765759" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r8" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r8-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] in patients with atrial fibrillation. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r8-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] that outcome was a hazard ratio of 1.186. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">9.</div><div id="r9" class="citations"><div class="citation"><div class="citation-content">Pan K-L, Singer DE, Ovbiagele B, Wu Y-L, Ahmed MA, Lee M. Effects of non-vitamin K antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and valvular heart disease: a systematic review and meta-analysis. <em>J Am Heart Assoc</em> 2017;6(7):e005835-e005835.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r9"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1161/JAHA.117.005835" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28720644/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000406278900050" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Effects+of+non-vitamin+K+antagonist+oral+anticoagulants+versus+warfarin+in+patients+with+atrial+fibrillation+and+valvular+heart+disease%3A+a+systematic+review+and+meta-analysis.&amp;publication_year=2017&amp;journal=J+Am+Heart+Assoc&amp;pages=e005835-e005835&amp;doi=10.1161%2FJAHA.117.005835&amp;pmid=28720644" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">10.</div><div id="r10" class="citations"><div class="citation"><div class="citation-content">Guimarães HP, de Barros E Silva PGM, Liporace IL, et al. A randomized clinical trial to evaluate the efficacy and safety of rivaroxaban in patients with bioprosthetic mitral valve and atrial fibrillation or flutter: rationale and design of the RIVER trial. <em>Am Heart J</em> 2021;231:128-136.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r10"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.ahj.2020.10.001" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33045224/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000604578300017" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+randomized+clinical+trial+to+evaluate+the+efficacy+and+safety+of+rivaroxaban+in+patients+with+bioprosthetic+mitral+valve+and+atrial+fibrillation+or+flutter%3A+rationale+and+design+of+the+RIVER+trial.&amp;publication_year=2021&amp;journal=Am+Heart+J&amp;pages=128-136&amp;doi=10.1016%2Fj.ahj.2020.10.001&amp;pmid=33045224" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">11.</div><div id="r11" class="citations"><div class="citation"><div class="citation-content">Homma S, Thompson JLP, Pullicino PM, et al. Warfarin and aspirin in patients with heart failure and sinus rhythm. <em>N Engl J Med</em> 2012;366:1859-1869.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r11"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_12_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2209051&amp;key=10.1056%2FNEJMoa1202299&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/22551105/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000304083000005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Warfarin+and+aspirin+in+patients+with+heart+failure+and+sinus+rhythm.&amp;publication_year=2012&amp;journal=N+Engl+J+Med&amp;pages=1859-1869&amp;doi=10.1056%2FNEJMoa1202299&amp;pmid=22551105" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">12.</div><div id="r12" class="citations"><div class="citation"><div class="citation-content">Eikelboom JW, Connolly SJ, Bosch J, et al. Rivaroxaban with or without aspirin in stable cardiovascular disease. <em>N Engl J Med</em> 2017;377:1319-1330.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r12"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_13_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2209051&amp;key=10.1056%2FNEJMoa1709118&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28844192/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000412375000012" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Rivaroxaban+with+or+without+aspirin+in+stable+cardiovascular+disease.&amp;publication_year=2017&amp;journal=N+Engl+J+Med&amp;pages=1319-1330&amp;doi=10.1056%2FNEJMoa1709118&amp;pmid=28844192" target="_blank">Google Scholar</a></div></div></div></div></div></div><div class="citations-truncation"><button data-label-expand="Show all references" data-label-collapse="Show fewer" data-label-remaining="references remaining" class="btn btn--secondary" aria-expanded="false" aria-controls="collapsible-text"><span>Show all references</span></button></div></section></div></section></div><div class="core-collateral"><div id="core-collateral-info" role="tabpanel" data-core-tabs="core-collateral-info" tabindex="-1" aria-labelledby="pane-core-collateral-info"><header><h2 id="pane-core-collateral-info"><i class="icon-info" aria-hidden="true"></i>Information &amp; Authors</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-information" role="tab" id="tab-information-label" aria-selected="true" class="active">Information</button><button aria-controls="tab-contributors" role="tab" id="tab-contributors-label" tabindex="-1" aria-selected="false">Authors</button></div><section id="tab-information" aria-labelledby="tab-information-label" role="tabpanel" tabindex="0"><h3>Information</h3><section class="core-self-citation"><h4>Published In</h4><div class="core-journal-presentation"><div class="core-journal-description"><div property="isPartOf" typeof="Periodical"><span property="name">New England Journal of Medicine</span></div><div class="core-enumeration"><a href="/toc/nejm/387/11"><span property="isPartOf" typeof="PublicationVolume">Volume <span property="volumeNumber">387</span></span> • <span property="isPartOf" typeof="PublicationIssue">Number <span property="issueNumber">11</span></span> • <span property="datePublished">September 15, 2022</span></a></div><div class="core-pagination"><span class="heading">Pages</span>: <span class="content"><span property="pageStart">978</span>-<span property="pageEnd">988</span></span></div></div></div></section><section class="core-copyright"><h4>Copyright</h4><div role="paragraph">Copyright © 2022 Massachusetts Medical Society. All rights reserved.</div><div>For personal use only. Any commercial reuse of NEJM Group content requires <a href="mailto:permissions@nejm.org">permission</a>.</div></section><section data-translation="YXQYoa2209051" class="core-component-translation"><h4>Translation</h4><div role="paragraph"><a target="_blank" href="https://nejmqianyan.cn/article/YXQYoa2209051?sg=AbW1N">Chinese Translation 中文翻译</a></div></section><section class="core-history"><h4>History</h4><div><b class="core-label">Published online</b>: August 27, 2022</div><div><b class="core-label">Published in issue</b>: September 15, 2022</div></section><section data-location="recirc_topics_article" class="core-classifications"><h4>Topics</h4><div class="keywords"><ol><li><a href="/browse/topic/anticoagulation-thromboembolism-cardiology" alt="View article keyword Anticoagulation/Thromboembolism (Cardiology)" data-interactiontype="article_recirculation_click">Anticoagulation/Thromboembolism (Cardiology)</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li><li><a href="/browse/topic/arrhythmias-pacemakers-defibrillators" alt="View article keyword Arrhythmias/Pacemakers/Defibrillators" data-interactiontype="article_recirculation_click">Arrhythmias/Pacemakers/Defibrillators</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li><li><a href="/browse/topic/autoimmune-disease" alt="View article keyword Autoimmune Disease" data-interactiontype="article_recirculation_click">Autoimmune Disease</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li><li><a href="/browse/topic/bacterial-infections" alt="View article keyword Bacterial Infections" data-interactiontype="article_recirculation_click">Bacterial Infections</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li><li><a href="/browse/topic/global-health" alt="View article keyword Global Health" data-interactiontype="article_recirculation_click">Global Health</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li><li><a href="/browse/topic/inflammatory-disease" alt="View article keyword Inflammatory Disease" data-interactiontype="article_recirculation_click">Inflammatory Disease</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li><li><a href="/browse/topic/valvular-heart-disease" alt="View article keyword Valvular Heart Disease" data-interactiontype="article_recirculation_click">Valvular Heart Disease</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li></ol></div></section></section><section id="tab-contributors" aria-labelledby="tab-contributors-label" role="tabpanel" tabindex="-1"><h3>Authors</h3><section class="core-authors"><h4>Authors</h4><div role="paragraph"><span property="author" typeof="Person"><span property="givenName">Stuart J.</span> <span property="familyName">Connolly</span>, <span property="honorificSuffix">M.D.</span> <a class="orcid-id" href="https://orcid.org/0000-0002-7377-335X" property="identifier" aria-label="ORCID identifier" target="_blank">https://orcid.org/0000-0002-7377-335X</a></span>, <span property="author" typeof="Person"><span property="givenName">Ganesan</span> <span property="familyName">Karthikeyan</span>, <span property="honorificSuffix">M.D., D.M.</span> <a class="orcid-id" href="https://orcid.org/0000-0002-2073-2917" property="identifier" aria-label="ORCID identifier" target="_blank">https://orcid.org/0000-0002-2073-2917</a></span>, <span property="author" typeof="Person"><span property="givenName">Mpiko</span> <span property="familyName">Ntsekhe</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Abraham</span> <span property="familyName">Haileamlak</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Ahmed</span> <span property="familyName">El Sayed</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Alaa</span> <span property="familyName">El Ghamrawy</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Albertino</span> <span property="familyName">Damasceno</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Alvaro</span> <span property="familyName">Avezum</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Antonio M.L.</span> <span property="familyName">Dans</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Bernard</span> <span property="familyName">Gitura</span>, <span property="honorificSuffix">M.Med.</span></span>, <span property="author" typeof="Person"><span property="givenName">Dayi</span> <span property="familyName">Hu</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Emmanuel R.</span> <span property="familyName">Kamanzi</span>, <span property="honorificSuffix">M.Med.</span></span>, <span property="author" typeof="Person"><span property="givenName">Fathi</span> <span property="familyName">Maklady</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Golden</span> <span property="familyName">Fana</span>, <span property="honorificSuffix">M.Med.</span></span>, <span property="author" typeof="Person"><span property="givenName">J. Antonio</span> <span property="familyName">Gonzalez-Hermosillo</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">John</span> <span property="familyName">Musuku</span>, <span property="honorificSuffix">M.Med.</span></span>, <span property="author" typeof="Person"><span property="givenName">Khawar</span> <span property="familyName">Kazmi</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Liesl</span> <span property="familyName">Zühlke</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Lillian</span> <span property="familyName">Gondwe</span>, <span property="honorificSuffix">M.B., B.S.</span></span>, <span property="author" typeof="Person"><span property="givenName">Changsheng</span> <span property="familyName">Ma</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Maria</span> <span property="familyName">Paniagua</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Okechukwu S.</span> <span property="familyName">Ogah</span>, <span property="honorificSuffix">M.B., B.S., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Onkabetse J.</span> <span property="familyName">Molefe-Baikai</span>, <span property="honorificSuffix">M.Med.</span></span>, <span property="author" typeof="Person"><span property="givenName">Peter</span> <span property="familyName">Lwabi</span>, <span property="honorificSuffix">M.Med.</span></span>, <span property="author" typeof="Person"><span property="givenName">Pilly</span> <span property="familyName">Chillo</span>, <span property="honorificSuffix">M.D.</span> <a class="orcid-id" href="https://orcid.org/0000-0001-7073-1122" property="identifier" aria-label="ORCID identifier" target="_blank">https://orcid.org/0000-0001-7073-1122</a></span>, <span property="author" typeof="Person"><span property="givenName">Sanjib K.</span> <span property="familyName">Sharma</span>, <span property="honorificSuffix">M.D., D.M.</span></span>, <span property="author" typeof="Person"><span property="givenName">Tantchou T.J.</span> <span property="familyName">Cabral</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Wadea M.</span> <span property="familyName">Tarhuni</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Alexander</span> <span property="familyName">Benz</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Martin</span> <span property="familyName">van Eikels</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Amy</span> <span property="familyName">Krol</span>, <span property="honorificSuffix">B.Sc.</span></span>, <span property="author" typeof="Person"><span property="givenName">Divya</span> <span property="familyName">Pattath</span>, <span property="honorificSuffix">M.Sc.</span></span>, <span property="author" typeof="Person"><span property="givenName">Kumar</span> <span property="familyName">Balasubramanian</span>, <span property="honorificSuffix">M.Sc.</span></span>, <span property="author" typeof="Person"><span property="givenName">Sumathy</span> <span property="familyName">Rangarajan</span>, <span property="honorificSuffix">M.Sc.</span></span>, <span property="author" typeof="Person"><span property="givenName">Chinthanie</span> <span property="familyName">Ramasundarahettige</span>, <span property="honorificSuffix">M.Sc.</span></span>, <span property="author" typeof="Person"><span property="givenName">Bongani</span> <span property="familyName">Mayosi</span>, <span property="honorificSuffix">M.D., D.Phil.</span></span>, and <span property="author" typeof="Person"><span property="givenName">Salim</span> <span property="familyName">Yusuf</span>, <span property="honorificSuffix">D.Phil.</span></span>, for <span property="author" typeof="Person">the INVICTUS Investigators<sup><a href="#fn2" role="doc-noteref">†</a></sup></span></div></section><section class="core-affiliations"><h4>Affiliations</h4><div property="affiliation" typeof="Organization"><span property="name">From the Population Health Research Institute, McMaster University, Hamilton, ON, Canada (S.J.C., A.B., A.K., D.P., K.B., S.R., C.R., S.Y.); the All India Institute of Medical Sciences, New Delhi (G.K.); the Division of Cardiology, Faculty of Health Sciences, University of Cape Town (M.N., B.M.), and the South African Medical Research Council (L.Z.) — both in Cape Town, South Africa; Jimma University Medical Center, Jimma, Ethiopia (A.H.); the University of Gazira, Wad Madani, Sudan (A.E.S.); Mahalla Heart Center, El Mahalla El Kubra (A.E.G.), and Suez Canal University Hospital, Ismailia (F.M.) — both in Egypt; the Faculty of Medicine, Eduardo Mondlane University, Maputo, Mozambique (A.D.); the International Research Center, Hospital Alemão Oswaldo Cruz, São Paulo (A.A.); the College of Medicine, University of the Philippines, Manila (A.M.L.D.); Kenyatta National Hospital, Nairobi (B.G.); the People’s Hospital of Peking University (D.H.) and the Beijing Anzhen Hospital (C.M.) — both in Beijing; the University Teaching Hospital of Kigali, Kigali, Rwanda (E.R.K.); the University of Zimbabwe, College of Health Sciences, Harare (G.F.); Instituto Nacional de Cardiología Ignacio Chávez, Mexico City (J.A.G.-H.); the University Teaching Hospital, Lusaka, Zambia (J.M.); the National Institute of Cardiovascular Diseases, Karachi, Pakistan (K.K.); Kamuzu Central Hospital, Lilongwe, Malawi (L.G.); Barrio Obrero Hospital, Asuncion, Paraguay (M.P.); the Department of Medicine, University of Ibadan–College Hospital, Ibadan, Nigeria (O.S.O.); Princess Marina Hospital, University of Botswana, Gaborone (O.J.M.-B.); Uganda Heart Institute, Kampala (P.L.); Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania (P.C.); the B.P. Koirala Institute of Health Sciences, Dharan, Nepal (S.K.S.); St. Elizabeth Catholic General Hospital, Kumbo, Cameroon (T.T.J.C.); the Department of Medicine, University of Saskatchewan, Saskatoon, the Department of Medicine, Western University, London, ON, and the Windsor Cardiac Centre, Windsor, ON — all in Canada (W.M.T.); the Department of Cardiology, Cardiology I, University Medical Center Mainz, Johannes Gutenberg University, Mainz (A.B.), and Bayer, Berlin (M.E.) — both in Germany.</span></div></section><section class="core-authors-notes"><h4>Notes</h4><div role="doc-footnote">Dr. Connolly can be contacted at <a href="mailto:connostu@phri.ca">connostu@phri.ca</a> or at the Population Health Research Institute, 30 Birge St., Hamilton, ON L8L 0A6, Canada.</div><div role="doc-footnote"><div id="fn1" role="paragraph">Bongani Mayosi, M.D., D.Phil., is deceased.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="fn2" role="paragraph">A complete list of the INVICTUS investigators is provided in the <a href="#ap2">Supplementary Appendix</a>, available at NEJM.org.</div></div></section></section></div><div id="core-collateral-metrics" role="tabpanel" data-core-tabs="core-collateral-metrics" tabindex="-1" aria-labelledby="pane-core-collateral-metrics"><header><h2 id="pane-core-collateral-metrics"><i class="icon-timeline" aria-hidden="true"></i>Metrics &amp; Citations</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-metrics-inner" role="tab" id="tab-metrics-inner-label" aria-selected="true" class="active" data-interactiontype="article_tab" data-tabname="metricsWindow">Metrics</button><button aria-controls="tab-citations" role="tab" id="tab-citations-label" tabindex="-1" aria-selected="false" data-interactiontype="article_tab" data-tabname="metricsWindow">Citations<span class="citations-count">152</span></button></div><section id="tab-metrics-inner" aria-labelledby="tab-metrics-inner-label" role="tabpanel" tabindex="0"><h3>Metrics</h3><section>









    
    
        <div data-widget-def="UX3HTMLWidget" data-widget-id="95ea9f58-ec0e-4db2-b2ab-280fc876af53" data-location="article_metrics_article">
        



        
            <h4 class="">
                Altmetrics
            </h4>
        
        <div data-badge-details="right" data-badge-type="large-donut" data-doi="10.1056/NEJMoa2209051" data-hide-no-mentions="true" data-link-target="_blank" class="altmetric-embed" data-uuid="50bcf46c-4c8a-20fa-aa65-1780f85c6842"><div style="overflow:hidden;">
    <div class="altmetric-normal-legend">
        <a target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=135066721" style="display:inline-block;">
                <img alt="Article has an altmetric score of 434" src="https://badges.altmetric.com/?size=320&amp;score=434&amp;types=mbcrtwf1" width="180" height="180" style="border:0; margin:0; max-width: none;">
        </a>
        <p class="altmetric-see-more-details" style="padding-top: 10px; text-align: center;"><a target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=135066721">See more details</a></p>
    </div>
    <div id="_altmetric_popover_el_50bcf46c-4c8a-20fa-aa65-1780f85c6842" class="altmetric-embed right" style="margin:0; padding:0; display:inline-block; float:left; position:relative;">
        <div class="altmetric_container">
            <div class="altmetric-embed altmetric-popover-inner right">
                <div style="padding:0; margin: 0;" class="altmetric-embed altmetric-popover-content">
                        <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #FF0000;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=135066721&amp;tab=news">
          Picked up by <b>13</b> news outlets
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #ffd140;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=135066721&amp;tab=blogs">
          Blogged by <b>2</b>
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #74CFED;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=135066721&amp;tab=twitter">
          Posted by <b>522</b> X users
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #2445bd;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=135066721&amp;tab=facebook">
          On <b>6</b> Facebook pages
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #958899;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=135066721&amp;tab=wikipedia">
          Referenced in <b>1</b> Wikipedia pages
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #D5E8F0;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=135066721&amp;tab=reddit">
          Reddited by <b>1</b>
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #F4006E;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=135066721&amp;tab=research-highlights">
          Highlighted by <b>1</b> platforms
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #A1E3E4;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=135066721&amp;tab=guidelines">
          Referenced in <b>2</b> clinical guideline sources
      </a>
    </div>

    <div class="altmetric-embed readers" style="margin-top: 10px;">
          <div class="altmetric-embed tip_mendeley" style="padding-left: 10px; line-height:18px; border-left: 16px solid #A60000;">
              <b>269</b> readers on Mendeley
          </div>
    </div>

                </div>
            </div>
        </div>
    </div>
</div></div>
<script async="" type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" nonce="94d6e9573670da2e-SJC"></script>

        </div>
    

</section></section><section id="tab-citations" aria-labelledby="tab-citations-label" role="tabpanel" tabindex="-1"><h3>Citations</h3><section>



        
            <h4 class="">
                Export citation
            </h4>
        
        <div class="citation-download cd-sec">
<p class="citation-download_msg">Select the format you want to export the citation of this publication.</p>
<form action="/action/downloadCitation" name="frmCitmgr" method="post" target="_self" class="citation-download_form"><input type="hidden" name="doi" value="10.1056/NEJMoa2209051"> <input type="hidden" name="downloadFileName" value="csp_387_"> <input type="hidden" name="include" value="abs">
<div class="dropdown dropdown-selectable dropdown-selectable--form-control"><input type="hidden" name="format" value=""> <label class="form-label">Format*</label> <button id="slct_format" type="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" class="btn dropdown-toggle d-flex align-items-center justify-content-between">Please Select </button>
<div aria-labelledby="slct_format" role="listbox" class="dropdown-menu"><a href="#" data-value="ris" class="dropdown-item">RIS (ProCite, Reference Manager)</a><a href="#" data-value="endnote" class="dropdown-item">EndNote</a><a href="#" data-value="bibtex" class="dropdown-item">BibTex</a><a href="#" data-value="medlars" class="dropdown-item">Medlars</a><a href="#" data-value="refworks" class="dropdown-item">RefWorks</a></div>
<div class="invalid-feedback">Please select an item in the list</div>
</div>
<div class="citation-download_checkbox"><label class="checkbox--primary"><input type="checkbox" name="direct" value="true"><span class="checkbox--primary-icons"><span class="checkbox--primary-unchecked"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#toggles-checboxUnchecked"></use></svg></span></span><span class="checkbox--primary-checked"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#toggles-checboxChecked"></use></svg></span></span></span><span class="checkbox--primary-label"><span class="checkbox--primary-label-text">Direct Import</span></span></label></div>
<div class="citation-download_btn"><button type="submit" name="submit" value="Download" class="ng-btn_default ng-btn_iconLeft" data-interactiontype="article_tools_citation_download" data-multimedia-type="Citation"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#citations"></use></svg></span><span class="ng-btn_text">Export citation</span></button></div>
</form></div>
</section><section>









    
    
        <div data-widget-def="UX3CitedByWidget" data-widget-id="efb4df9a-8e1a-47f9-bfb7-271959277a9f" data-location="citedby_article">
        



        
            <h4 class="">
                Cited by
            </h4>
        
        <section id="cited-by" class="cited-by"><div class="cited-by__wrapper"><div id="cited-by__content" class="cited-by__content"><ol data-source="/pb/widgets/citedBy?page=1&amp;widgetId=efb4df9a-8e1a-47f9-bfb7-271959277a9f&amp;pbContext=%3BrequestedJournal%3Ajournal%3Anejm%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3Adoi%5C%3A10.1056%2Fnejm_2022.387.issue-11%3Bwgroup%3Astring%3AMMS+NextGen+Website+Group%3Barticle%3Aarticle%3Adoi%5C%3A10.1056%2FNEJMoa2209051%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bwebsite%3Awebsite%3Amms-site%3Bjournal%3Ajournal%3Anejms" data-lazyload="false" data-total="152" class="cited-by__list list-unstyled"><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Niveditha Devasenapathy, </li><li class="list-inline-item cited-by__entry__author">Shyamashree Biswas, </li><li class="list-inline-item cited-by__entry__author">Prayaag Kini, </li><li class="list-inline-item cited-by__entry__author">Santhosh Satheesh, </li><li class="list-inline-item cited-by__entry__author">Mohit D. Gupta, </li><li class="list-inline-item cited-by__entry__author">Girish MP, </li><li class="list-inline-item cited-by__entry__author">Rishi Sethi, </li><li class="list-inline-item cited-by__entry__author">Satyavir Yadav, </li><li class="list-inline-item cited-by__entry__author">Sanjeev Asotra, </li><li class="list-inline-item cited-by__entry__author">Arun Gopalakrishnan, </li><li class="list-inline-item cited-by__entry__author">Sudeep Gupta, </li><li class="list-inline-item cited-by__entry__author">Aditya Kapoor, </li><li class="list-inline-item cited-by__entry__author">Chandra Bhan Meena, </li><li class="list-inline-item cited-by__entry__author">Ravi S. Math, </li><li class="list-inline-item cited-by__entry__author">Shanmugam Krishnan, </li><li class="list-inline-item cited-by__entry__author">Sandeep Bansal, </li><li class="list-inline-item cited-by__entry__author">Nagendra Boopathy, </li><li class="list-inline-item cited-by__entry__author">Romika Jhajhria, </li><li class="list-inline-item cited-by__entry__author">Birbal Kaushik, </li><li class="list-inline-item cited-by__entry__author">Nitya Wadhwa, </li><li class="list-inline-item cited-by__entry__author">Manoj Soni, </li><li class="list-inline-item cited-by__entry__author">Aman Rastogi, </li><li class="list-inline-item cited-by__entry__author">Arpita Ghosh, </li><li class="list-inline-item cited-by__entry__author">Vivekanand Jha, </li><li class="list-inline-item cited-by__entry__author">Ganesan Karthikeyan, </li></ul><span class="cited-by__entry__title">Digoxin in rheumatic heart disease: Rationale and design of a multicenter, placebo-controlled double-blind randomized controlled trial (Dig-RHD trial), </span><span class="cited-by__entry__series-title">American Heart Journal, </span><span class="cited-by__entry__volume"><strong>289</strong>, </span><span class="cited-by__entry__page-range">(38-47), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.ahj.2025.05.005" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.ahj.2025.05.005</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.ahj.2025.05.005" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Alessandra Ida Celia, </li><li class="list-inline-item cited-by__entry__author">Giovanni Maria Vescovo, </li><li class="list-inline-item cited-by__entry__author">Gianmarco Sarto, </li><li class="list-inline-item cited-by__entry__author">Cristiano Alessandri, </li><li class="list-inline-item cited-by__entry__author">Antonio Iaconelli, </li><li class="list-inline-item cited-by__entry__author">Domenico D’Amario, </li><li class="list-inline-item cited-by__entry__author">Giacomo Frati, </li><li class="list-inline-item cited-by__entry__author">Fabrizio Conti, </li><li class="list-inline-item cited-by__entry__author">Sebastiano Sciarretta, </li><li class="list-inline-item cited-by__entry__author">Dominick J Angiolillo, </li><li class="list-inline-item cited-by__entry__author">Andrea Fava, </li><li class="list-inline-item cited-by__entry__author">Michelle A Petri, </li><li class="list-inline-item cited-by__entry__author">Behnood Bikdeli, </li><li class="list-inline-item cited-by__entry__author">Mattia Galli, </li></ul><span class="cited-by__entry__title">Direct oral anticoagulants versus Vitamin K antagonists in antiphospholipid syndrome: A systematic review and meta-analysis, </span><span class="cited-by__entry__series-title">Seminars in Arthritis and Rheumatism, </span><span class="cited-by__entry__volume"><strong>73</strong>, </span><span class="cited-by__entry__page-range">(152741), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.semarthrit.2025.152741" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.semarthrit.2025.152741</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.semarthrit.2025.152741" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Sonia Sawant, </li><li class="list-inline-item cited-by__entry__author">Gabrielle Freedman, </li><li class="list-inline-item cited-by__entry__author">Ana Garcia, </li><li class="list-inline-item cited-by__entry__author">Sally Terrett, </li><li class="list-inline-item cited-by__entry__author">Chinmay Khandkar, </li><li class="list-inline-item cited-by__entry__author">Anosh Sivashanmugarajah, </li><li class="list-inline-item cited-by__entry__author">Angus Baumann, </li></ul><span class="cited-by__entry__title">Anticoagulation use in rheumatic heart disease-associated atrial fibrillation: a study of real-world practice in Central Australia, </span><span class="cited-by__entry__series-title">IJC Heart &amp; Vasculature, </span><span class="cited-by__entry__volume"><strong>59</strong>, </span><span class="cited-by__entry__page-range">(101711), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.ijcha.2025.101711" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.ijcha.2025.101711</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.ijcha.2025.101711" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Amir Askarinejad, </li><li class="list-inline-item cited-by__entry__author">Deirdre A. Lane, </li><li class="list-inline-item cited-by__entry__author">Parham Sadeghipour, </li><li class="list-inline-item cited-by__entry__author">Majid Haghjoo, </li><li class="list-inline-item cited-by__entry__author">Gregory Y. H. Lip, </li></ul><span class="cited-by__entry__title">Stroke prevention in atrial fibrillation: A narrative review of current evidence and emerging strategies, </span><span class="cited-by__entry__series-title">European Journal of Clinical Investigation, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1111/eci.70082" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1111/eci.70082</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1111/eci.70082" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Dandan Feng, </li><li class="list-inline-item cited-by__entry__author">Jianchun Wang, </li></ul><span class="cited-by__entry__title">Factor XI inhibitors are the novel promising anticoagulants in the treatment of age related thrombotic disease, </span><span class="cited-by__entry__series-title">Frontiers in Cardiovascular Medicine, </span><span class="cited-by__entry__volume"><strong>12</strong>, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.3389/fcvm.2025.1498826" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.3389/fcvm.2025.1498826</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.3389/fcvm.2025.1498826" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Mattia Galli, </li><li class="list-inline-item cited-by__entry__author">Dominick J. Angiolillo, </li></ul><span class="cited-by__entry__title">Direct oral anticoagulants in stroke prevention of atrial fibrillation patients: can we rely on them in all clinical scenarios?, </span><span class="cited-by__entry__series-title">Future Cardiology, </span><span class="cited-by__entry__page-range">(1-3), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1080/14796678.2025.2506915" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1080/14796678.2025.2506915</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1080/14796678.2025.2506915" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Zainab Aslam Castro-Vidal, </li><li class="list-inline-item cited-by__entry__author">Asad Gandapur, </li><li class="list-inline-item cited-by__entry__author">Rohit Prakash, </li><li class="list-inline-item cited-by__entry__author">Khaled Azab, </li><li class="list-inline-item cited-by__entry__author">Khushi Nayyar, </li><li class="list-inline-item cited-by__entry__author">Fnu Rinkoo, </li><li class="list-inline-item cited-by__entry__author">Sravani Kommuru, </li><li class="list-inline-item cited-by__entry__author">Youssef Elsoussi, </li><li class="list-inline-item cited-by__entry__author">Nagavenakta Lova Surya Vamsi Avinash Bojanki, </li><li class="list-inline-item cited-by__entry__author">Anil Kumar Yennam, </li><li class="list-inline-item cited-by__entry__author">Syeed Mahmud Nishat, </li><li class="list-inline-item cited-by__entry__author">Jatin Motwani, </li></ul><span class="cited-by__entry__title">Anticoagulation strategies for stroke prevention in atrial fibrillation: a comprehensive review of current literature, </span><span class="cited-by__entry__series-title">Annals of Medicine &amp; Surgery, </span><span class="cited-by__entry__volume"><strong>87</strong>, </span><span class="cited-by__entry__issue">6, </span><span class="cited-by__entry__page-range">(3691-3699), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1097/MS9.0000000000003364" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1097/MS9.0000000000003364</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1097/MS9.0000000000003364" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Amiliana Mardiani Soesanto, </li><li class="list-inline-item cited-by__entry__author">Prima Almazini, </li><li class="list-inline-item cited-by__entry__author">Rina Ariani, </li><li class="list-inline-item cited-by__entry__author">Estu Rudiktyo, </li><li class="list-inline-item cited-by__entry__author">Tengku Winda Ardini, </li><li class="list-inline-item cited-by__entry__author">Hasanah Mumpuni, </li><li class="list-inline-item cited-by__entry__author">Achmad Lefi, </li><li class="list-inline-item cited-by__entry__author">Aussie Fitriani Ghaznawie, </li><li class="list-inline-item cited-by__entry__author">Ni Made Ayu Wulan Sari, </li><li class="list-inline-item cited-by__entry__author">Mefri Yanni, </li><li class="list-inline-item cited-by__entry__author">Niniek Purwaningtyas, </li><li class="list-inline-item cited-by__entry__author">Rille Puspitoadhi Harjoko, </li><li class="list-inline-item cited-by__entry__author">Melawati Hasan, </li><li class="list-inline-item cited-by__entry__author">Siti Elkana Nauli, </li><li class="list-inline-item cited-by__entry__author">Fitranti Suciati Laitupa, </li><li class="list-inline-item cited-by__entry__author">Novita Muchtar, </li><li class="list-inline-item cited-by__entry__author">Wella Karolina, </li><li class="list-inline-item cited-by__entry__author">Indah Puspita, </li><li class="list-inline-item cited-by__entry__author">Gratiani Eben Haezer Reppi, </li><li class="list-inline-item cited-by__entry__author">Dyna Evalina Syahlul, </li><li class="list-inline-item cited-by__entry__author">Nia Dyah Rahmianti, </li><li class="list-inline-item cited-by__entry__author">Rinelia Minaswary, </li><li class="list-inline-item cited-by__entry__author">Yasmina Hanifah, </li><li class="list-inline-item cited-by__entry__author">Ario Soeryo Kuncoro, </li></ul><span class="cited-by__entry__title">Characteristics and Problems of Rheumatic Heart Disease in Indonesia, </span><span class="cited-by__entry__series-title">JACC: Asia, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.jacasi.2025.03.010" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.jacasi.2025.03.010</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.jacasi.2025.03.010" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Arnar B. Ingason, </li><li class="list-inline-item cited-by__entry__author">Brynja R. Gudmundsdottir, </li><li class="list-inline-item cited-by__entry__author">Ragnar Palsson, </li><li class="list-inline-item cited-by__entry__author">Johann P. Hreinsson, </li><li class="list-inline-item cited-by__entry__author">Sigrun H. Lund, </li><li class="list-inline-item cited-by__entry__author">Loic R. Letertre, </li><li class="list-inline-item cited-by__entry__author">Edward Rumba, </li><li class="list-inline-item cited-by__entry__author">Arnar S. Agustsson, </li><li class="list-inline-item cited-by__entry__author">Einar S. Bjornsson, </li><li class="list-inline-item cited-by__entry__author">Pall T. Onundarson, </li></ul><span class="cited-by__entry__title">Low incidence of thromboembolism with Fiix-monitored warfarin compared to conventional warfarin and DOACs in patients with AF, </span><span class="cited-by__entry__series-title">Blood Vessels, Thrombosis &amp; Hemostasis, </span><span class="cited-by__entry__volume"><strong>2</strong>, </span><span class="cited-by__entry__issue">2, </span><span class="cited-by__entry__page-range">(100056), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.bvth.2025.100056" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.bvth.2025.100056</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.bvth.2025.100056" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Qurat Ul Ain Yasin, </li><li class="list-inline-item cited-by__entry__author">Rabia Sattar, </li><li class="list-inline-item cited-by__entry__author">Muhammad Amin, </li></ul><span class="cited-by__entry__title">Green Synthesis of Silver Oxide Nanoparticles using Zingiber officinale Extract: Catalytic and Antibacterial Potentials of 2-Phenyl Benzimidazole Derivatives, </span><span class="cited-by__entry__series-title">Conclusions in Engineering, </span><span class="cited-by__entry__page-range">(124-131), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.71107/ve4msa83" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.71107/ve4msa83</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.71107/ve4msa83" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry--see-more"><a href="javascript:void(0)" data-source="/pb/widgets/citedBy?page=1&amp;widgetId=efb4df9a-8e1a-47f9-bfb7-271959277a9f&amp;pbContext=%3BrequestedJournal%3Ajournal%3Anejm%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3Adoi%5C%3A10.1056%2Fnejm_2022.387.issue-11%3Bwgroup%3Astring%3AMMS+NextGen+Website+Group%3Barticle%3Aarticle%3Adoi%5C%3A10.1056%2FNEJMoa2209051%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bwebsite%3Awebsite%3Amms-site%3Bjournal%3Ajournal%3Anejms" class="cited-by__see-more">See more</a></li></ol></div><div class="cited-by__spinner justify-content-center align-items-center d-none"><div role="status" class="spinner-border text-gray"><span class="sr-only">Loading...</span></div></div></div></section>

        </div>
    

</section></section></div><div id="core-collateral-fulltext-options" role="tabpanel" data-core-tabs="core-collateral-fulltext-options" tabindex="-1" aria-labelledby="pane-core-collateral-fulltext-options"><header><h2 id="pane-core-collateral-fulltext-options"><i class="icon-eye" aria-hidden="true"></i>View Options</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div class="section--wrapper"><h3>View options</h3><section class="format--pdf"><h4> <abbr title="Portable Document Format">PDF</abbr></h4><a href="https://www.nejm.org/doi/pdf/10.1056/NEJMoa2209051" class="btn btn--pdf" aria-label="View PDF" data-behavior="trackDownloadEvent" data-doi="10.1056/NEJMoa2209051" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2209051.pdf"><i aria-hidden="true" class="icon-pdf"></i><span>View PDF</span></a></section></div><!-- Its needed to duplicate this for PB check Collateral.js as well--></div><div id="core-collateral-media" role="tabpanel" data-core-tabs="core-collateral-media" tabindex="-1" aria-labelledby="pane-core-collateral-media"><header><h2 id="pane-core-collateral-media"><i class="icon-photo" aria-hidden="true"></i>Media</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-figures" role="tab" id="tab-figures-label" aria-selected="true" class="active">Figures</button><button aria-controls="tab-other" role="tab" id="tab-other-label" tabindex="-1" aria-selected="false" class="inactive" aria-disabled="true">Other</button></div><section id="tab-figures" aria-labelledby="tab-figures-label" role="tabpanel" tabindex="0"><h3>Figures</h3><div class="text-right"><a class="btn btn--inverse  open-in-viewer" href="#figures"><span>Open all in viewer</span><i class="icon-open_in_new" aria-hidden="true"></i></a></div><div id="core-f0"><figure class="graphic"><a class="open-in-viewer" href="#f0" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2209051_f0.jpg"><img src="/cms/10.1056/NEJMoa2209051/asset/e90d5a28-e029-4528-ac8d-406ff07dcedd/assets/images/large/nejmoa2209051_f0.jpg" height="3416" width="2640" aria-labelledby="f0" loading="lazy"></a><figcaption>Download a PDF of the <a href="#ap0">Research Summary</a>.</figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f0"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2209051_f0.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-f1"><figure class="graphic"><a class="open-in-viewer" href="#f1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2209051_f1.jpg"><img src="/cms/10.1056/NEJMoa2209051/asset/3eb90917-d9a9-4166-abfd-80f3c1860f7b/assets/images/large/nejmoa2209051_f1.jpg" height="1768" width="2231" aria-labelledby="f1" loading="lazy"></a><figcaption><div class="caption">Cumulative Incidence of the Composite of Stroke, Systemic Embolism, Myocardial Infarction, or Death from Vascular or Unknown Causes (Primary Outcome).</div><div class="notes"><div role="doc-footnote">Vascular causes could be cardiac or noncardiac. The inset shows the same data on an expanded y axis. VKA denotes vitamin K antagonist.</div></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f1"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f1" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2209051_f1.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-f2"><figure class="graphic"><a class="open-in-viewer" href="#f2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2209051_f2.jpg"><img src="/cms/10.1056/NEJMoa2209051/asset/9278e3cb-d519-462f-b517-ed012b940adf/assets/images/large/nejmoa2209051_f2.jpg" height="3417" width="2231" aria-labelledby="f2" loading="lazy"></a><figcaption><div class="caption">Cumulative Incidences of Stroke or Systemic Embolism and of Death.</div><div class="notes"><div role="doc-footnote">The insets show the same data on expanded y axes.</div></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f2"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f2" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2209051_f2.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div></section><section id="tab-other" aria-labelledby="tab-other-label" role="tabpanel" tabindex="-1"><h3>Other</h3></section></div><div id="core-collateral-tables" role="tabpanel" data-core-tabs="core-collateral-tables" tabindex="-1" aria-labelledby="pane-core-collateral-tables"><header><h2 id="pane-core-collateral-tables"><i class="icon-tables" aria-hidden="true"></i>Tables</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><!-- There is no content. --><div class="section--wrapper"><div class="text-right"><a class="btn btn--inverse  open-in-viewer" href="#tables"><span>Open all in viewer</span><i class="icon-open_in_new" aria-hidden="true"></i></a></div><div id="core-t1"><figure class="table"><a class="open-in-viewer" href="#t1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2209051_t1.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa2209051/asset/1126d03b-8992-41a5-80e1-d1a5bc8c8b1e/assets/images/large/nejmoa2209051_t1.jpg" height="2957" width="1999" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Characteristic</th><th class="txxx-borders">Overall<br>(N=4531)</th><th class="txxx-borders">Rivaroxaban<br>(N=2275)</th><th class="txxr-borders">Vitamin K Antagonist<br>(N=2256)</th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging04 shading" data-xml-align="left">Age — yr</td><td class="xxxx-borders shading">50.5±14.6</td><td class="xxxx-borders shading">50.7±14.8</td><td class="xxxr-borders shading">50.3±14.4</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging04" data-xml-align="left">Female sex — no. (%)</td><td class="xxxx-borders">3274 (72.3)</td><td class="xxxx-borders">1648 (72.4)</td><td class="xxxr-borders">1626 (72.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging04 shading" data-xml-align="left">Systolic blood pressure — mm Hg</td><td class="xxxx-borders shading">115.7±17.5</td><td class="xxxx-borders shading">116.0±17.7</td><td class="xxxr-borders shading">115.5±17.4</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging04" data-xml-align="left">Body-mass index<a href="#core-t1fn2" role="doc-noteref">†</a></td><td class="xxxx-borders">24.5±5.9</td><td class="xxxx-borders">24.4±5.7</td><td class="xxxr-borders">24.6±6.1</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging04 shading" data-xml-align="left">Creatinine clearance — ml/min</td><td class="xxxx-borders shading">80.6±30.4</td><td class="xxxx-borders shading">80.0±30.2</td><td class="xxxr-borders shading">81.1±30.7</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging04" data-xml-align="left">Congestive heart failure — no. (%)</td><td class="xxxx-borders">1745 (38.5)</td><td class="xxxx-borders">879 (38.6)</td><td class="xxxr-borders">866 (38.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging04 shading" data-xml-align="left">Hypertension — no. (%)</td><td class="xxxx-borders shading">1057 (23.3)</td><td class="xxxx-borders shading">522 (22.9)</td><td class="xxxr-borders shading">535 (23.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging04" data-xml-align="left">Diabetes mellitus — no. (%)</td><td class="xxxx-borders">290 (6.4)</td><td class="xxxx-borders">158 (6.9)</td><td class="xxxr-borders">132 (5.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging04 shading" data-xml-align="left">Stroke — no. (%)</td><td class="xxxx-borders shading">505 (11.1)</td><td class="xxxx-borders shading">248 (10.9)</td><td class="xxxr-borders shading">257 (11.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging04" data-xml-align="left">Transient ischemic attack — no. (%)</td><td class="xxxx-borders">147 (3.2)</td><td class="xxxx-borders">75 (3.3)</td><td class="xxxr-borders">72 (3.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging04 shading" data-xml-align="left">Coronary artery disease — no. (%)</td><td class="xxxx-borders shading">52 (1.1)</td><td class="xxxx-borders shading">32 (1.4)</td><td class="xxxr-borders shading">20 (0.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging04" data-xml-align="left">Percutaneous valvuloplasty — no. (%)</td><td class="xxxx-borders">506 (11.2)</td><td class="xxxx-borders">265 (11.6)</td><td class="xxxr-borders">241 (10.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging04 shading" data-xml-align="left">Mitral-valve repair — no. (%)</td><td class="xxxx-borders shading">155 (3.4)</td><td class="xxxx-borders shading">75 (3.3)</td><td class="xxxr-borders shading">80 (3.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging04" data-xml-align="left">CHA<sub>2</sub>DS<sub>2</sub>-VASc score<a href="#core-t1fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders">1.9±1.4</td><td class="xxxx-borders">2.0±1.4</td><td class="xxxr-borders">1.9±1.4</td></tr><tr data-type="row"><td class="xxlx-borders hanging04 shading">Inclusion criteria met — no. (%)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging14" data-xml-align="left">CHA<sub>2</sub>DS<sub>2</sub>-VASc score ≥2</td><td class="xxxx-borders">2557 (56.4)</td><td class="xxxx-borders">1295 (56.9)</td><td class="xxxr-borders">1262 (55.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging14 shading" data-xml-align="left">Moderate-to-severe mitral stenosis<a href="#core-t1fn4" role="doc-noteref">§</a></td><td class="xxxx-borders shading">3711 (81.9)</td><td class="xxxx-borders shading">1871 (82.2)</td><td class="xxxr-borders shading">1840 (81.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging14" data-xml-align="left">Left atrial spontaneous echo contrast</td><td class="xxxx-borders">527 (11.6)</td><td class="xxxx-borders">278 (12.2)</td><td class="xxxr-borders">249 (11.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging14 shading" data-xml-align="left">Left atrial thrombus on echocardiography</td><td class="xxxx-borders shading">304 (6.7)</td><td class="xxxx-borders shading">151 (6.6)</td><td class="xxxr-borders shading">153 (6.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging14" data-xml-align="left">CHA<sub>2</sub>DS<sub>2</sub>-VASc score ≥2 as only criterion</td><td class="xxxx-borders">697 (15.4)</td><td class="xxxx-borders">342 (15.0)</td><td class="xxxr-borders">355 (15.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging14 shading" data-xml-align="left">Moderate-to-severe mitral stenosis as only criterion</td><td class="xxxx-borders shading">1657 (36.6)</td><td class="xxxx-borders shading">827 (36.4)</td><td class="xxxr-borders shading">830 (36.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging14" data-xml-align="left">CHA<sub>2</sub>DS<sub>2</sub>-VASc score ≥2 and moderate-to-severe mitral stenosis</td><td class="xxxx-borders">1788 (39.5)</td><td class="xxxx-borders">916 (40.3)</td><td class="xxxr-borders">872 (38.7)</td></tr><tr data-type="row"><td class="xxlx-borders hanging04 shading">Echocardiographic findings — no./total no. (%)<a href="#core-t1fn5" role="doc-noteref">¶</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging14">Mitral-valve stenosis</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging24 shading" data-xml-align="left">Absent</td><td class="xxxx-borders shading">647/4489 (14.4)</td><td class="xxxx-borders shading">324/2255 (14.4)</td><td class="xxxr-borders shading">323/2234 (14.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging24" data-xml-align="left">Present</td><td class="xxxx-borders">3830/4489 (85.3)</td><td class="xxxx-borders">1927/2255 (85.5)</td><td class="xxxr-borders">1903/2234 (85.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging24 shading" data-xml-align="left">Valve area &lt;1.0 cm<sup>2</sup></td><td class="xxxx-borders shading">1042/3830 (27.2)</td><td class="xxxx-borders shading">506/1927 (26.3)</td><td class="xxxr-borders shading">536/1903 (28.2)</td></tr><tr data-type="row"><td class="xxlx-borders hanging14">Mitral-valve regurgitation</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging24 shading" data-xml-align="left">Absent</td><td class="xxxx-borders shading">766/4489 (17.1)</td><td class="xxxx-borders shading">390/2255 (17.3)</td><td class="xxxr-borders shading">376/2234 (16.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging24" data-xml-align="left">Present</td><td class="xxxx-borders">3709/4489 (82.6)</td><td class="xxxx-borders">1860/2255 (82.5)</td><td class="xxxr-borders">1849/2234 (82.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging34 shading" data-xml-align="left">Moderate</td><td class="xxxx-borders shading">1317/3709 (35.5)</td><td class="xxxx-borders shading">667/1860 (35.9)</td><td class="xxxr-borders shading">650/1849 (35.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging34" data-xml-align="left">Severe</td><td class="xxxx-borders">831/3709 (22.4)</td><td class="xxxx-borders">421/1860 (22.6)</td><td class="xxxr-borders">410/1849 (22.2)</td></tr><tr data-type="row"><td class="xxlx-borders hanging04 shading">Medications received — no. (%)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging14" data-xml-align="left">Any vitamin K antagonist</td><td class="xxxx-borders">2394 (52.8)</td><td class="xxxx-borders">1218 (53.5)</td><td class="xxxr-borders">1176 (52.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging14 shading" data-xml-align="left">Prophylaxis for rheumatic fever</td><td class="xxxx-borders shading">1445 (31.9)</td><td class="xxxx-borders shading">715 (31.4)</td><td class="xxxr-borders shading">730 (32.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging14" data-xml-align="left">Beta-blocker</td><td class="xxxx-borders">3276 (72.3)</td><td class="xxxx-borders">1612 (70.9)</td><td class="xxxr-borders">1664 (73.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging14 shading" data-xml-align="left">ACE inhibitor or ARB</td><td class="xxxx-borders shading">1283 (28.3)</td><td class="xxxx-borders shading">651 (28.6)</td><td class="xxxr-borders shading">632 (28.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging14" data-xml-align="left">Digoxin</td><td class="xxxx-borders">1925 (42.5)</td><td class="xxxx-borders">991 (43.6)</td><td class="xxxr-borders">934 (41.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging14 shading" data-xml-align="left">Calcium-channel blocker</td><td class="xxxx-borders shading">267 (5.9)</td><td class="xxxx-borders shading">136 (6.0)</td><td class="xxxr-borders shading">131 (5.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging14" data-xml-align="left">Diuretic</td><td class="xxxx-borders">3825 (84.4)</td><td class="xxxx-borders">1931 (84.9)</td><td class="xxxr-borders">1894 (84.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging14 shading" data-xml-align="left">Treatment for HIV infection or AIDS</td><td class="xbxx-borders shading">58 (1.3)</td><td class="xbxx-borders shading">25 (1.1)</td><td class="xbxr-borders shading">33 (1.5)</td></tr></tbody></table></div><figcaption><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t1fn1" role="paragraph" data-to-manipulate="true">Plus–minus values are means ±SD. ACE denotes angiotensin-converting enzyme, AIDS acquired immunodeficiency syndrome, ARB angiotensin-receptor blocker, and HIV human immunodeficiency virus.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="core-t1fn2" role="paragraph" data-to-manipulate="true">The body-mass index is the weight in kilograms divided by the square of the height in meters.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="core-t1fn3" role="paragraph" data-to-manipulate="true">CHA<sub>2</sub>DS<sub>2</sub>-VASc scores (an assessment of the risk of stroke among patients with atrial fibrillation) range from 0 to 9, with higher scores indicating a higher risk of stroke.</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="core-t1fn4" role="paragraph" data-to-manipulate="true">Moderate-to-severe mitral stenosis was defined as a valve area of less than 2.0 cm<sup>2</sup>.</div></div><div role="doc-footnote" data-has="label"><div class="label">¶</div><div id="core-t1fn5" role="paragraph" data-to-manipulate="true">With regard to echocardiographic findings, results on mitral-valve stenosis were unknown for four patients in the rivaroxaban group and for eight in the vitamin K antagonist group; results on mitral-valve regurgitation were unknown for five and nine, respectively.</div></div></div></figcaption></a><figcaption><div class="caption">Characteristics of the Patients at Baseline.<a href="#core-t1fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t1"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t1" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2209051_t1.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-t2"><figure class="table"><a class="open-in-viewer" href="#t2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2209051_t2.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa2209051/asset/78e137be-9006-4191-a2e6-64d4f0d32dc6/assets/images/large/nejmoa2209051_t2.jpg" height="1818" width="2615" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Outcome</th><th class="txxx-borders" colspan="3"><span>Rivaroxaban<br>(N=2275)</span></th><th class="txxx-borders" colspan="3"><span>Vitamin K Antagonist<br>(N=2256)</span></th><th class="txxx-borders">Proportional-Hazards<br>Ratio (95% CI)</th><th class="txxx-borders">Difference in RMST<br>(95% CI)</th><th class="txxr-borders">P Value</th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">No. of Patients</th><th class="xxxx-borders">Rate</th><th class="xxxx-borders">RMST</th><th class="xxxx-borders">No. of Patients</th><th class="xxxx-borders">Rate</th><th class="xxxx-borders">RMST</th><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr class="head3" data-type="row head3"><td class="xxlx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><th class="xxxx-borders">%/yr</th><th class="xxxx-borders">days</th><td class="xxxx-borders">&nbsp;</td><th class="xxxx-borders">%/yr</th><th class="xxxx-borders">days</th><td class="xxxx-borders">&nbsp;</td><th class="xxxx-borders">days</th><td class="xxxr-borders">&nbsp;</td></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">Stroke, systemic embolism, myocardial infarction, or death from vascular or unknown causes</td><td class="xxxx-borders shading">560</td><td class="xxxx-borders shading">8.21</td><td class="xxxx-borders shading">1599</td><td class="xxxx-borders shading">446</td><td class="xxxx-borders shading">6.49</td><td class="xxxx-borders shading">1675</td><td class="xxxx-borders shading">1.25 (1.10 to 1.41)</td><td class="xxxx-borders shading">−76 (−121 to −31)</td><td class="xxxr-borders shading">&lt;0.001</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03" data-xml-align="left">Stroke</td><td class="xxxx-borders">90</td><td class="xxxx-borders">1.32</td><td class="xxxx-borders">1929</td><td class="xxxx-borders">65</td><td class="xxxx-borders">0.94</td><td class="xxxx-borders">1950</td><td class="xxxx-borders">1.37 (1.00 to 1.89)</td><td class="xxxx-borders">−21 (−40 to −2)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">Ischemic stroke</td><td class="xxxx-borders shading">74</td><td class="xxxx-borders shading">1.08</td><td class="xxxx-borders shading">1941</td><td class="xxxx-borders shading">48</td><td class="xxxx-borders shading">0.70</td><td class="xxxx-borders shading">1963</td><td class="xxxx-borders shading">1.53 (1.06 to 2.20)</td><td class="xxxx-borders shading">−23 (−40 to −6)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03" data-xml-align="left">Hemorrhagic stroke</td><td class="xxxx-borders">7</td><td class="xxxx-borders">0.10</td><td class="xxxx-borders">1995</td><td class="xxxx-borders">7</td><td class="xxxx-borders">0.10</td><td class="xxxx-borders">1994</td><td class="xxxx-borders">1.00 (0.35 to 2.86)</td><td class="xxxx-borders">0.3 (−6 to 6)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">Stroke of uncertain cause</td><td class="xxxx-borders shading">12</td><td class="xxxx-borders shading">0.17</td><td class="xxxx-borders shading">1991</td><td class="xxxx-borders shading">10</td><td class="xxxx-borders shading">0.14</td><td class="xxxx-borders shading">1993</td><td class="xxxx-borders shading">1.21 (0.52 to 2.79)</td><td class="xxxx-borders shading">−1 (−8 to 5)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03" data-xml-align="left">Systemic embolism</td><td class="xxxx-borders">6</td><td class="xxxx-borders">0.09</td><td class="xxxx-borders">1995</td><td class="xxxx-borders">10</td><td class="xxxx-borders">0.14</td><td class="xxxx-borders">1992</td><td class="xxxx-borders">0.59 (0.22 to 1.63)</td><td class="xxxx-borders">4 (−3 to 10)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">Stroke or systemic embolism</td><td class="xxxx-borders shading">94</td><td class="xxxx-borders shading">1.38</td><td class="xxxx-borders shading">1926</td><td class="xxxx-borders shading">75</td><td class="xxxx-borders shading">1.09</td><td class="xxxx-borders shading">1942</td><td class="xxxx-borders shading">1.24 (0.92 to 1.68)</td><td class="xxxx-borders shading">−16 (−36 to 4)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03" data-xml-align="left">Myocardial infarction</td><td class="xxxx-borders">5</td><td class="xxxx-borders">0.07</td><td class="xxxx-borders">1996</td><td class="xxxx-borders">3</td><td class="xxxx-borders">0.04</td><td class="xxxx-borders">1998</td><td class="xxxx-borders">1.67 (0.40 to 6.97)</td><td class="xxxx-borders">−1 (−5 to 3)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">Death</td><td class="xxxx-borders shading">552</td><td class="xxxx-borders shading">7.95</td><td class="xxxx-borders shading">1608</td><td class="xxxx-borders shading">442</td><td class="xxxx-borders shading">6.35</td><td class="xxxx-borders shading">1680</td><td class="xxxx-borders shading">1.23 (1.09 to 1.40)</td><td class="xxxx-borders shading">−72 (−117 to −28)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Death due to vascular causes<a href="#core-t2fn2" role="doc-noteref">†</a></td><td class="xxxx-borders">439</td><td class="xxxx-borders">6.33</td><td class="xxxx-borders">1683</td><td class="xxxx-borders">337</td><td class="xxxx-borders">4.84</td><td class="xxxx-borders">1751</td><td class="xxxx-borders">1.29 (1.12 to 1.49)</td><td class="xxxx-borders">−68 (−110 to −26)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">Sudden cardiac death</td><td class="xxxx-borders shading">141</td><td class="xxxx-borders shading">2.03</td><td class="xxxx-borders shading">1894</td><td class="xxxx-borders shading">94</td><td class="xxxx-borders shading">1.35</td><td class="xxxx-borders shading">1929</td><td class="xxxx-borders shading">1.51 (1.16 to 1.96)</td><td class="xxxx-borders shading">−36 (−58 to −13)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Death due to mechanical or pump failure</td><td class="xxxx-borders">237</td><td class="xxxx-borders">3.42</td><td class="xxxx-borders">1817</td><td class="xxxx-borders">174</td><td class="xxxx-borders">2.50</td><td class="xxxx-borders">1862</td><td class="xxxx-borders">1.35 (1.11 to 1.64)</td><td class="xxxx-borders">−45 (−83 to −8)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Death due to nonvascular causes</td><td class="xxxx-borders shading">46</td><td class="xxxx-borders shading">0.66</td><td class="xxxx-borders shading">1962</td><td class="xxxx-borders shading">36</td><td class="xxxx-borders shading">0.52</td><td class="xxxx-borders shading">1971</td><td class="xxxx-borders shading">1.26 (0.81 to 1.94)</td><td class="xxxx-borders shading">−9 (−25 to 7)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Death due to unknown cause</td><td class="xxxx-borders">67</td><td class="xxxx-borders">0.97</td><td class="xxxx-borders">1941</td><td class="xxxx-borders">69</td><td class="xxxx-borders">0.99</td><td class="xxxx-borders">1946</td><td class="xxxx-borders">0.96 (0.69 to 1.35)</td><td class="xxxx-borders">−4 (−26 to 17)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">Any hospitalization</td><td class="xxxx-borders shading">687</td><td class="xxxx-borders shading">11.71</td><td class="xxxx-borders shading">1432</td><td class="xxxx-borders shading">622</td><td class="xxxx-borders shading">10.44</td><td class="xxxx-borders shading">1467</td><td class="xxxx-borders shading">1.08 (0.97 to 1.21)</td><td class="xxxx-borders shading">−36 (−80 to 9)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Hospitalization for heart failure</td><td class="xxxx-borders">240</td><td class="xxxx-borders">3.61</td><td class="xxxx-borders">1779</td><td class="xxxx-borders">219</td><td class="xxxx-borders">3.28</td><td class="xxxx-borders">1794</td><td class="xxxx-borders">1.08 (0.89 to 1.29)</td><td class="xxxx-borders">−16 (−47 to 16)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Valve surgery</td><td class="xxxx-borders shading">187</td><td class="xxxx-borders shading">2.85</td><td class="xxxx-borders shading">1852</td><td class="xxxx-borders shading">157</td><td class="xxxx-borders shading">2.36</td><td class="xxxx-borders shading">1873</td><td class="xxxx-borders shading">1.19 (0.97 to 1.48)</td><td class="xxxx-borders shading">−21 (−50 to 9)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging13" data-xml-align="left">Valve surgery or valvuloplasty</td><td class="xbxx-borders">205</td><td class="xbxx-borders">3.14</td><td class="xbxx-borders">1838</td><td class="xbxx-borders">175</td><td class="xbxx-borders">2.65</td><td class="xbxx-borders">1859</td><td class="xbxx-borders">1.17 (0.95 to 1.43)</td><td class="xbxx-borders">−21 (−52 to 10)</td><td class="xbxr-borders">&nbsp;</td></tr></tbody></table></div><figcaption><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t2fn1" role="paragraph" data-to-manipulate="true">The intention-to-treat population included all the patients who underwent randomization, except for 34 patients, whose data were excluded owing to duplicate randomization, potentially fraudulent data, or inability to obtain required re-consent. The widths of the confidence intervals have not been adjusted for multiplicity, so the intervals should not be used in place of a hypothesis test. RMST denotes restricted mean survival time.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="core-t2fn2" role="paragraph" data-to-manipulate="true">Vascular causes could be cardiac or noncardiac. Deaths due to vascular causes other than sudden death or death due to mechanical or pump failure occurred in 61 patients in the rivaroxaban group and in 69 in the vitamin K antagonist group.</div></div></div></figcaption></a><figcaption><div class="caption">Intention-to-Treat Analysis of Efficacy Outcomes.<a href="#core-t2fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t2"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t2" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2209051_t2.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-t3"><figure class="table"><a class="open-in-viewer" href="#t3" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2209051_t3.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa2209051/asset/975afcba-7553-49bd-ba79-253ab4b4ba56/assets/images/large/nejmoa2209051_t3.jpg" height="1763" width="2615" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Outcome</th><th class="txxx-borders" colspan="3"><span>Rivaroxaban<br>(N=2265)</span></th><th class="txxx-borders" colspan="3"><span>Vitamin K Antagonist<br>(N=2251)</span></th><th class="txxx-borders">Proportional-Hazards<br>Ratio (95% CI)</th><th class="txxx-borders">Difference in RMST<br>(95% CI)</th><th class="txxr-borders">P Value</th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">No. of<br>Patients</th><th class="xxxx-borders">Rate</th><th class="xxxx-borders">RMST</th><th class="xxxx-borders">No. of<br>Patients</th><th class="xxxx-borders">Rate</th><th class="xxxx-borders">RMST</th><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr class="head3" data-type="row head3"><td class="xxlx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><th class="xxxx-borders">%/yr</th><th class="xxxx-borders">days</th><td class="xxxx-borders">&nbsp;</td><th class="xxxx-borders">%/yr</th><th class="xxxx-borders">days</th><td class="xxxx-borders">&nbsp;</td><th class="xxxx-borders">days</th><td class="xxxr-borders">&nbsp;</td></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging02 shading"><b>Safety outcomes</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Major bleeding</td><td class="xxxx-borders">40</td><td class="xxxx-borders">0.67</td><td class="xxxx-borders">1965</td><td class="xxxx-borders">56</td><td class="xxxx-borders">0.83</td><td class="xxxx-borders">1954</td><td class="xxxx-borders">0.76 (0.51 to 1.15)</td><td class="xxxx-borders">11 (−5 to 28)</td><td class="xxxr-borders">0.18</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Fatal bleeding</td><td class="xxxx-borders shading">4</td><td class="xxxx-borders shading">0.07</td><td class="xxxx-borders shading">1996</td><td class="xxxx-borders shading">15</td><td class="xxxx-borders shading">0.22</td><td class="xxxx-borders shading">1988</td><td class="xxxx-borders shading">0.29 (0.10 to 0.88)</td><td class="xxxx-borders shading">8 (1 to 16)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Bleeding in a critical area or organ</td><td class="xxxx-borders">2</td><td class="xxxx-borders">0.03</td><td class="xxxx-borders">1998</td><td class="xxxx-borders">4</td><td class="xxxx-borders">0.06</td><td class="xxxx-borders">1997</td><td class="xxxx-borders">0.52 (0.09 to 2.81)</td><td class="xxxx-borders">2 (−3 to 6)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Intracranial hemorrhage</td><td class="xxxx-borders shading">8</td><td class="xxxx-borders shading">0.13</td><td class="xxxx-borders shading">1993</td><td class="xxxx-borders shading">14</td><td class="xxxx-borders shading">0.21</td><td class="xxxx-borders shading">1989</td><td class="xxxx-borders shading">0.63 (0.26 to 1.50)</td><td class="xxxx-borders shading">4 (−3 to 12)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Life-threatening bleeding</td><td class="xxxx-borders">22</td><td class="xxxx-borders">0.36</td><td class="xxxx-borders">1981</td><td class="xxxx-borders">31</td><td class="xxxx-borders">0.46</td><td class="xxxx-borders">1975</td><td class="xxxx-borders">0.77 (0.44 to 1.32)</td><td class="xxxx-borders">6 (−6 to 18)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Clinically relevant nonmajor bleeding</td><td class="xxxx-borders shading">65</td><td class="xxxx-borders shading">1.09</td><td class="xxxx-borders shading">1943</td><td class="xxxx-borders shading">71</td><td class="xxxx-borders shading">1.06</td><td class="xxxx-borders shading">1942</td><td class="xxxx-borders shading">0.96 (0.68 to 1.34)</td><td class="xxxx-borders shading">1 (−18 to 20)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Major or clinically relevant nonmajor bleeding</td><td class="xxxx-borders">102</td><td class="xxxx-borders">1.72</td><td class="xxxx-borders">1912</td><td class="xxxx-borders">120</td><td class="xxxx-borders">1.81</td><td class="xxxx-borders">1901</td><td class="xxxx-borders">0.89 (0.68 to 1.16)</td><td class="xxxx-borders">10 (−14 to 35)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading"><b>Selected efficacy outcomes</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Stroke, systemic embolism, myocardial infarction, or death from vascular or unknown causes</td><td class="xxxx-borders">481</td><td class="xxxx-borders">8.06</td><td class="xxxx-borders">1619</td><td class="xxxx-borders">426</td><td class="xxxx-borders">6.33</td><td class="xxxx-borders">1686</td><td class="xxxx-borders">1.26 (1.10 to 1.43)</td><td class="xxxx-borders">−67 (−110 to −24)</td><td class="xxxr-borders">0.002</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Stroke</td><td class="xxxx-borders shading">83</td><td class="xxxx-borders shading">1.39</td><td class="xxxx-borders shading">1926</td><td class="xxxx-borders shading">59</td><td class="xxxx-borders shading">0.87</td><td class="xxxx-borders shading">1955</td><td class="xxxx-borders shading">1.54 (1.10 to 2.16)</td><td class="xxxx-borders shading">−29 (−49 to −9)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Systemic embolism</td><td class="xxxx-borders">6</td><td class="xxxx-borders">0.10</td><td class="xxxx-borders">1995</td><td class="xxxx-borders">9</td><td class="xxxx-borders">0.13</td><td class="xxxx-borders">1993</td><td class="xxxx-borders">0.71 (0.25 to 2.01)</td><td class="xxxx-borders">2 (−4 to 9)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Myocardial infarction</td><td class="xxxx-borders shading">5</td><td class="xxxx-borders shading">0.08</td><td class="xxxx-borders shading">1996</td><td class="xxxx-borders shading">3</td><td class="xxxx-borders shading">0.04</td><td class="xxxx-borders shading">1998</td><td class="xxxx-borders shading">1.85 (0.44 to 7.77)</td><td class="xxxx-borders shading">−2 (−6 to 3)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Death from vascular causes</td><td class="xxxx-borders">362</td><td class="xxxx-borders">5.98</td><td class="xxxx-borders">1712</td><td class="xxxx-borders">319</td><td class="xxxx-borders">4.68</td><td class="xxxx-borders">1761</td><td class="xxxx-borders">1.26 (1.08 to 1.47)</td><td class="xxxx-borders">−49 (−87 to −10)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Death from unknown cause</td><td class="xxxx-borders shading">58</td><td class="xxxx-borders shading">0.96</td><td class="xxxx-borders shading">1941</td><td class="xxxx-borders shading">65</td><td class="xxxx-borders shading">0.95</td><td class="xxxx-borders shading">1948</td><td class="xxxx-borders shading">1.00 (0.70 to 1.42)</td><td class="xxxx-borders shading">−7 (−30 to 16)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Death</td><td class="xxxx-borders">459</td><td class="xxxx-borders">7.58</td><td class="xxxx-borders">1638</td><td class="xxxx-borders">416</td><td class="xxxx-borders">6.10</td><td class="xxxx-borders">1694</td><td class="xxxx-borders">1.23 (1.08 to 1.40)</td><td class="xxxx-borders">−57 (−98 to −15)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Any hospitalization</td><td class="xxxx-borders shading">627</td><td class="xxxx-borders shading">11.49</td><td class="xxxx-borders shading">1447</td><td class="xxxx-borders shading">606</td><td class="xxxx-borders shading">10.35</td><td class="xxxx-borders shading">1473</td><td class="xxxx-borders shading">1.06 (0.95 to 1.19)</td><td class="xxxx-borders shading">−26 (−71 to 19)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Hospitalization for heart failure</td><td class="xxxx-borders">222</td><td class="xxxx-borders">3.80</td><td class="xxxx-borders">1775</td><td class="xxxx-borders">214</td><td class="xxxx-borders">3.27</td><td class="xxxx-borders">1795</td><td class="xxxx-borders">1.09 (0.90 to 1.32)</td><td class="xxxx-borders">−20 (−52 to 13)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging12 shading" data-xml-align="left">Valve surgery or valvuloplasty</td><td class="xbxx-borders shading">172</td><td class="xbxx-borders shading">2.87</td><td class="xbxx-borders shading">1853</td><td class="xbxx-borders shading">173</td><td class="xbxx-borders shading">2.67</td><td class="xbxx-borders shading">1858</td><td class="xbxx-borders shading">1.06 (0.86 to 1.31)</td><td class="xbxx-borders shading">−5 (−36 to 26)</td><td class="xbxr-borders shading">&nbsp;</td></tr></tbody></table></div><figcaption><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t3fn1" role="paragraph" data-to-manipulate="true">The on-treatment population included all the patients who received at least one dose of trial medication, and the on-treatment analysis included only events that occurred up to 5 days after permanent discontinuation of trial medication. The widths of the confidence intervals have not been adjusted for multiplicity, so the intervals should not be used in place of a hypothesis test.</div></div></div></figcaption></a><figcaption><div class="caption">On-Treatment Analysis of Safety Outcomes and Selected Efficacy Outcomes.<a href="#core-t3fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t3"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t3" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2209051_t3.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div></div></div><div id="core-collateral-share" role="tabpanel" data-core-tabs="core-collateral-share" tabindex="-1" aria-labelledby="pane-core-collateral-share"><header><h2 id="pane-core-collateral-share"><i class="icon-share" aria-hidden="true"></i>Share</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><h3>Share</h3><div class="section--wrapper"><section><h4>CONTENT LINK</h4><div id="share-self"><p data-id="article-share-self-link" class="share-self__source">https://www.nejm.org/doi/full/10.1056/NEJMoa2209051</p><button data-id="article-share-access" aria-label="CONTENT LINK" class="share-self__action btn btn--inverse"><i aria-hidden="true" class="icon-copy-o"></i><span>Copy Link</span></button><div aria-live="polite" class="share-self__status"><p class="share-self__success"><i aria-hidden="true" class="icon-check_circle"></i><span>Copied!</span></p><p class="share-self__failed"><i aria-hidden="true" class="icon-x_btnclose"></i><span>Copying failed.</span></p></div></div></section><section data-location="share_tools_article"><h4>Share</h4><div class="share-buttons a2a a2a_kit" style="line-height: 16px;"><a href="/#facebook" aria-label="Share on Facebook" data-id="article-share-facebook" rel="nofollow noopener" role="link" target="_blank" title="Share on Facebook" class="btn btn--facebook a2a_button_facebook" data-interactiontype="social"><i aria-hidden="true" class="icon-facebook"></i><span>Facebook</span></a><a href="/#twitter" aria-label="Share on X (formerly Twitter)" data-id="article-share-twitter" rel="nofollow noopener" role="link" target="_blank" title="Share on X (formerly Twitter)" class="btn btn--twitter a2a_button_twitter" data-interactiontype="social"><i aria-hidden="true" class="icon-twitter"></i><span>X (formerly Twitter)</span></a><a href="/#linkedin" aria-label="Share on LinkedIn" data-id="article-share-linkedin" rel="nofollow noopener" role="link" target="_blank" title="Share on LinkedIn" class="btn btn--linkedin a2a_button_linkedin" data-interactiontype="social"><i aria-hidden="true" class="icon-linkedin"></i><span>LinkedIn</span></a><a href="/#email" aria-label="Share on email" data-id="article-share-email" rel="nofollow noopener" role="link" target="_blank" title="Share on email" class="btn btn--email a2a_button_email" data-interactiontype="content_email_click"><i aria-hidden="true" class="icon-mail"></i><span>email</span></a><a href="/#bluesky" aria-label="Share on Bluesky" data-id="article-share-bluesky" rel="nofollow noopener" role="link" target="_blank" title="Share on Bluesky" class="btn btn--bluesky a2a_button_bluesky" data-interactiontype="social"><i aria-hidden="true" class="icon-bluesky"></i><span>Bluesky</span></a></div></section></div></div><div data-location="references_article" id="core-collateral-references" role="tabpanel" aria-labelledby="pane-core-collateral-references" data-core-tabs="core-collateral-references" tabindex="-1"><header><h2 id="pane-core-collateral-references"><i aria-hidden="true" class="icon-references"></i>References</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><h3>References</h3><div role="list" class="section--wrapper"><div role="listitem" data-has="label"><div class="label">1.</div><div id="core-r1" class="citations"><div class="citation"><div class="citation-content">Iung B, Leenhardt A, Extramiana F. Management of atrial fibrillation in patients with rheumatic mitral stenosis. <em>Heart</em> 2018;104:1062-1068.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r1-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1136/heartjnl-2017-311425" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29453328/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000438038400006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Management+of+atrial+fibrillation+in+patients+with+rheumatic+mitral+stenosis.&amp;publication_year=2018&amp;journal=Heart&amp;pages=1062-1068&amp;doi=10.1136%2Fheartjnl-2017-311425&amp;pmid=29453328" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r1-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r2-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] atrial enlargement and atrial fibrillation. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r2-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] and often have advanced valvular disease. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">2.</div><div id="core-r2" class="citations"><div class="citation"><div class="citation-content">Stambler BS, Ngunga LM. Atrial fibrillation in Sub-Saharan Africa: epidemiology, unmet needs, and treatment options. <em>Int J Gen Med</em> 2015;8:231-242.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r2-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.2147/IJGM.S84537" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26261423/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Atrial+fibrillation+in+Sub-Saharan+Africa%3A+epidemiology%2C+unmet+needs%2C+and+treatment+options.&amp;publication_year=2015&amp;journal=Int+J+Gen+Med&amp;pages=231-242&amp;doi=10.2147%2FIJGM.S84537&amp;pmid=26261423" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r2-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r2-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] atrial enlargement and atrial fibrillation. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r2-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] and often have advanced valvular disease. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">3.</div><div id="core-r3" class="citations"><div class="citation"><div class="citation-content">Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. <em>Ann Intern Med</em> 2007;146:857-867.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r3"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.7326/0003-4819-146-12-200706190-00007" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/17577005/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000247347100004" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Meta-analysis%3A+antithrombotic+therapy+to+prevent+stroke+in+patients+who+have+nonvalvular+atrial+fibrillation.&amp;publication_year=2007&amp;journal=Ann+Intern+Med&amp;pages=857-867&amp;doi=10.7326%2F0003-4819-146-12-200706190-00007&amp;pmid=17577005" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">4.</div><div id="core-r4" class="citations"><div class="citation"><div class="citation-content">Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. <em>Lancet</em> 2014;383:955-962.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r4-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(13)62343-0" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24315724/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000333520700026" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Comparison+of+the+efficacy+and+safety+of+new+oral+anticoagulants+with+warfarin+in+patients+with+atrial+fibrillation%3A+a+meta-analysis+of+randomised+trials.&amp;publication_year=2014&amp;journal=Lancet&amp;pages=955-962&amp;doi=10.1016%2FS0140-6736%2813%2962343-0&amp;pmid=24315724" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r4-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r4-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] a lower risk of intracranial hemorrhage. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r4-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] in the risk of hemorrhagic stroke. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r4-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] patients without rheumatic heart disease. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r4-4" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>d [...] non–vitamin K antagonist anticoagulants. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">5.</div><div id="core-r5" class="citations"><div class="citation"><div class="citation-content">January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. <em>J Am Coll Cardiol</em> 2019;74:104-132.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r5"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.jacc.2019.01.011" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30703431/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000473259200015" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=2019+AHA%2FACC%2FHRS+focused+update+of+the+2014+AHA%2FACC%2FHRS+guideline+for+the+management+of+patients+with+atrial+fibrillation%3A+a+report+of+the+American+College+of+Cardiology%2FAmerican+Heart+Association+Task+Force+on+Clinical+Practice+Guidelines+and+the+Heart+Rhythm+Society.&amp;publication_year=2019&amp;journal=J+Am+Coll+Cardiol&amp;pages=104-132&amp;doi=10.1016%2Fj.jacc.2019.01.011&amp;pmid=30703431" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">6.</div><div id="core-r6" class="citations"><div class="citation"><div class="citation-content">Karthikeyan G, Connolly SJ, Ntsekhe M, et al. The INVICTUS rheumatic heart disease research program: rationale, design and baseline characteristics of a randomized trial of rivaroxaban compared to vitamin K antagonists in rheumatic valvular disease and atrial fibrillation. <em>Am Heart J</em> 2020;225:69-77.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r6"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.ahj.2020.03.018" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32474206/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000541737100010" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+INVICTUS+rheumatic+heart+disease+research+program%3A+rationale%2C+design+and+baseline+characteristics+of+a+randomized+trial+of+rivaroxaban+compared+to+vitamin+K+antagonists+in+rheumatic+valvular+disease+and+atrial+fibrillation.&amp;publication_year=2020&amp;journal=Am+Heart+J&amp;pages=69-77&amp;doi=10.1016%2Fj.ahj.2020.03.018&amp;pmid=32474206" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">7.</div><div id="core-r7" class="citations"><div class="citation"><div class="citation-content">The Active Steering Committee. Rationale and design of ACTIVE: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events. <em>Am Heart J</em> 2006;151:1187-1193.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r7-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.ahj.2005.06.026" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/16781218/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000238614600008" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Rationale+and+design+of+ACTIVE%3A+the+atrial+fibrillation+clopidogrel+trial+with+irbesartan+for+prevention+of+vascular+events.&amp;publication_year=2006&amp;journal=Am+Heart+J&amp;pages=1187-1193&amp;doi=10.1016%2Fj.ahj.2005.06.026&amp;pmid=16781218" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r7-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r8-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] in patients with atrial fibrillation. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r8-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] that outcome was a hazard ratio of 1.186. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">8.</div><div id="core-r8" class="citations"><div class="citation"><div class="citation-content">The ACTIVE Writing Group on behalf of the ACTIVE Investigators. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. <em>Lancet</em> 2006;367:1903-1912.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r8-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(06)68845-4" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/16765759/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000238194400029" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Clopidogrel+plus+aspirin+versus+oral+anticoagulation+for+atrial+fibrillation+in+the+Atrial+fibrillation+Clopidogrel+Trial+with+Irbesartan+for+prevention+of+Vascular+Events+%28ACTIVE+W%29%3A+a+randomised+controlled+trial.&amp;publication_year=2006&amp;journal=Lancet&amp;pages=1903-1912&amp;doi=10.1016%2FS0140-6736%2806%2968845-4&amp;pmid=16765759" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r8-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r8-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] in patients with atrial fibrillation. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r8-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] that outcome was a hazard ratio of 1.186. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">9.</div><div id="core-r9" class="citations"><div class="citation"><div class="citation-content">Pan K-L, Singer DE, Ovbiagele B, Wu Y-L, Ahmed MA, Lee M. Effects of non-vitamin K antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and valvular heart disease: a systematic review and meta-analysis. <em>J Am Heart Assoc</em> 2017;6(7):e005835-e005835.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r9"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1161/JAHA.117.005835" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28720644/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000406278900050" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Effects+of+non-vitamin+K+antagonist+oral+anticoagulants+versus+warfarin+in+patients+with+atrial+fibrillation+and+valvular+heart+disease%3A+a+systematic+review+and+meta-analysis.&amp;publication_year=2017&amp;journal=J+Am+Heart+Assoc&amp;pages=e005835-e005835&amp;doi=10.1161%2FJAHA.117.005835&amp;pmid=28720644" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">10.</div><div id="core-r10" class="citations"><div class="citation"><div class="citation-content">Guimarães HP, de Barros E Silva PGM, Liporace IL, et al. A randomized clinical trial to evaluate the efficacy and safety of rivaroxaban in patients with bioprosthetic mitral valve and atrial fibrillation or flutter: rationale and design of the RIVER trial. <em>Am Heart J</em> 2021;231:128-136.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r10"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.ahj.2020.10.001" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33045224/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000604578300017" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+randomized+clinical+trial+to+evaluate+the+efficacy+and+safety+of+rivaroxaban+in+patients+with+bioprosthetic+mitral+valve+and+atrial+fibrillation+or+flutter%3A+rationale+and+design+of+the+RIVER+trial.&amp;publication_year=2021&amp;journal=Am+Heart+J&amp;pages=128-136&amp;doi=10.1016%2Fj.ahj.2020.10.001&amp;pmid=33045224" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">11.</div><div id="core-r11" class="citations"><div class="citation"><div class="citation-content">Homma S, Thompson JLP, Pullicino PM, et al. Warfarin and aspirin in patients with heart failure and sinus rhythm. <em>N Engl J Med</em> 2012;366:1859-1869.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r11"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_12_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2209051&amp;key=10.1056%2FNEJMoa1202299&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/22551105/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000304083000005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Warfarin+and+aspirin+in+patients+with+heart+failure+and+sinus+rhythm.&amp;publication_year=2012&amp;journal=N+Engl+J+Med&amp;pages=1859-1869&amp;doi=10.1056%2FNEJMoa1202299&amp;pmid=22551105" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">12.</div><div id="core-r12" class="citations"><div class="citation"><div class="citation-content">Eikelboom JW, Connolly SJ, Bosch J, et al. Rivaroxaban with or without aspirin in stable cardiovascular disease. <em>N Engl J Med</em> 2017;377:1319-1330.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r12"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_13_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2209051&amp;key=10.1056%2FNEJMoa1709118&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28844192/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000412375000012" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Rivaroxaban+with+or+without+aspirin+in+stable+cardiovascular+disease.&amp;publication_year=2017&amp;journal=N+Engl+J+Med&amp;pages=1319-1330&amp;doi=10.1056%2FNEJMoa1709118&amp;pmid=28844192" target="_blank">Google Scholar</a></div></div></div></div></div></div></div></div><aside data-core-aside="right-rail">



        
        <div id="DTM_Position_MedRectangle" class="ad">
 <!--emptycomment-->
</div>




        
        <div class="ng-page_layout-sidebarSpacing"></div>










    
    
        <div data-widget-def="relatedArticlesWidget" data-widget-id="8206d5cd-cb8c-4ff9-8c46-3d22e0dee215" data-location="recirc_curatedRelated_article">
        



        
        <div class="ng-related-articles"><h3 class="ng-subsection-title"><span class="ng-subsection-title_text">Related articles</span></h3><ul class="ng-related-articles_list"><li class="ng-related-articles_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/editorial" class="issue-item_type">Editorial</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Aug 27, 2022</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMe2210187" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Anticoagulation in Atrial Fibrillation and Rheumatic Heart Disease</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">G.Y. Lip</span></div></div></div></div></div></li><li class="ng-related-articles_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/correspondence" class="issue-item_type">Correspondence</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Nov 30, 2022</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMc2213437" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Rivaroxaban in Rheumatic Heart Disease–Associated Atrial Fibrillation</a></h4><div class="issue-item_authors-and-text"></div></div></div></div></div></li></ul></div>

        </div>
    





        
        <div class="ng-page_layout-sidebarSpacing"></div>




        
        <div id="nejm_jobs" class="nejm_jobs"> <!-- top red rectangle --><div id="nejm-widget" class="nejm-widget" style="display: block;"><div class="nejm-widget_logo">	<a target="nejm-win" href="https://www.nejmcareercenter.org/?query=fjw">		<img alt="CareerCenter" src="https://apps1.nejmcareercenter.org/images/nejmCCID-JobsWidget.gif" width="140" height="36">	</a></div><div class="nejm-widget_cont"> <!-- content --><div class="nejm-widget_title">PHYSICIAN JOBS</div><div class="nejm-widget_date">June 10, 2025</div><div class="nejm-widget_item"><div><span> Salem, New Hampshire</span></div><div><span>Gastroenterology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/888915/gastroenterologist-salem-nh/?query=fjwp&amp;rid=428606">Gastroenterologist, Salem, NH</a></div></div><div class="nejm-widget_item"><div><span> Port Jefferson, New York</span></div><div><span>Cardiology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/880182/chair-department-of-cardiology-mather-hospital-northwell-health/?query=fjwp&amp;rid=3059">Chair, Department of Cardiology - Mather Hospital, Northwell Health</a></div></div><div class="nejm-widget_item"><div><span> Providence, Rhode Island</span></div><div><span>Psychiatry</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/886237/adult-psychiatrist/?query=fjwf&amp;rid=377088">Adult Psychiatrist</a></div></div><div class="nejm-widget_item"><div><span> Poughkeepsie, New York</span></div><div><span>Obstetrics &amp; Gynecology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/880801/urogynecologist-optum-ny/?query=fjwf&amp;rid=220874">Urogynecologist | Optum NY</a></div></div><div class="nejm-widget_item"><div><span> Fort Smith, Arkansas</span></div><div><span>Anesthesiology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/882217/anesthesiologist-in-fort-smith-arkansas/?query=fjwf&amp;rid=4552">Anesthesiologist in Fort Smith, Arkansas</a></div></div><div class="nejm-widget_item"><div><span> Appleton, Wisconsin</span></div><div><span>Neonatal / Perinatal Medicine</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/883739/neonatologist/?query=fjwf&amp;rid=49812">Neonatologist</a></div></div></div> <!-- content --> <!-- footer --></div> <!-- nejm-widget --></div><script src="https://apps1.nejmcareercenter.org/?width=300&amp;sp=all"></script>




        
        <div class="ng-page_layout-sidebarSpacing"></div>










    
    
        <div data-widget-def="literatumAd" data-widget-id="001e4aa7-b6fe-4b21-9d5b-5bde81227c67" id="ad-article-right-rail-300x250-1">
        



        
        



    
        <div class="pb-house-message adplaceholder exists">
            <a href="/action/clickThrough?id=128743&amp;url=https%3A%2F%2Fstore.nejm.org%2Fsignup%2Fnejm%2Fregister%2Fnotablearticles2024%3Fpromo%3DONFQNAR4%26query%3Dcm-ra%26utm_source%3Dnejm%26utm_medium%3Dcm%26utm_campaign%3Dna24&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2209051&amp;pubId=41284343&amp;placeholderId=101337&amp;productId=1007"><img src="/sda/128743/rightRail--notable24_001.jpg" width="300" height="250"></a>
            
        </div>
    

    

    



        </div>
    





        
        <div class="ng-page_layout-sidebarSpacing"></div>




        
        <script src="https://widgets.nejm.org/onepub-widgets/loader/webcomponents-loader.js" async="" nonce="94d6e9573670da2e-SJC">
<script src="https://widgets.nejm.org/onepub-widgets/loader/polyfill-support.js"  nonce="94d6e9573670da2e-SJC"></script>
<script src="https://widgets.nejm.org/onepub-widgets/more-like-this.js" type="module" nonce="94d6e9573670da2e-SJC"></script>

<more-like-this class="onepub-widget" dataid="onepub-more-like-this" collections="catalyst-article, clinician-article, evidence-article, nejm-ai-article, nejm-article" headertitle="More Like This" maxitems="5"><!----><div class="more-like-this onepub-more-like-this_"><!--?lit$960843500$--><onepub-fonts><wc-fetch></wc-fetch><!--?lit$960843500$--><div class="mlt-wrapper"><div class="mlt-header-container"><div class="mlt-header-content-left"><div class="mlt-header-title-container"><span class="mlt-header-title">More Like This</span></div><!--?lit$960843500$--></div></div><div class="mlt-body"><!--?lit$960843500$--><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$960843500$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$960843500$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$960843500$-->Jan 23, 2025</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2406674?query=recirc_Semantic" target="_self">Abelacimab versus Rivaroxaban in Patients with Atrial Fibrillation</a></div><div class="mlt-article-authors"><!--?lit$960843500$-->C.T. Ruff and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/correspondence" target="_self"><!--?lit$960843500$-->Correspondence</a> <span class="mlt-article-site-label"><!--?lit$960843500$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$960843500$-->Mar 11, 2021</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMc2035891?query=recirc_Semantic" target="_self">Rivaroxaban in Patients with Atrial Fibrillation and a Bioprosthetic Mitral Valve</a></div><div class="mlt-article-authors"><!--?lit$960843500$--></div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$960843500$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$960843500$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$960843500$-->Nov 26, 2020</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2029603?query=recirc_Semantic" target="_self">Rivaroxaban in Patients with Atrial Fibrillation and a Bioprosthetic Mitral Valve</a></div><div class="mlt-article-authors"><!--?lit$960843500$-->H.P. Guimarães and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$960843500$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$960843500$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$960843500$-->Dec 05, 2024</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2407362?query=recirc_Semantic" target="_self">Edoxaban Antithrombotic Therapy for Atrial Fibrillation and Stable Coronary Artery Disease</a></div><div class="mlt-article-authors"><!--?lit$960843500$-->M.S. Cho and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/correspondence" target="_self"><!--?lit$960843500$-->Correspondence</a> <span class="mlt-article-site-label"><!--?lit$960843500$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$960843500$-->Apr 17, 2025</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMc2502454?query=recirc_Semantic" target="_self">Abelacimab versus Rivaroxaban in Patients with Atrial Fibrillation</a></div><div class="mlt-article-authors"><!--?lit$960843500$--></div></div><!----></div><div class="mlt-footer"></div></div></onepub-fonts><style>:host{display:block}@keyframes fadeIn{0%{opacity:0}100%{opacity:1}}.more-like-this{max-width:25rem}.more-like-this *{font-variant-numeric:lining-nums}.mlt-wrapper{animation:fadeIn 1s}.mlt-header-container{border-bottom:#4d4d4d solid .0625rem;border-top:#4d4d4d solid .125rem}.mlt-header-title{color:#1a1a1a;display:block;font-family:var(--sans-serif);font-size:1rem;font-weight:700;letter-spacing:.02rem;line-height:1.5rem;padding-bottom:.94rem;padding-top:.94rem;text-transform:uppercase}.mlt-header-description{color:#333;display:block;font-family:ff-scala-sans-pro;font-size:.75rem;letter-spacing:.05rem;margin-top:-.5rem;padding-bottom:1rem;text-transform:uppercase}.mlt-article-container{border-bottom:#e5e5e5 solid .0625rem;margin-top:1.38rem}.mlt-article-container-header{font-family:var(--sans-serif);font-size:.6875rem;letter-spacing:.04em;line-height:1.125rem;margin:0 0 1rem;text-transform:uppercase}.mlt-article-type{font-weight:700;line-height:1.25rem;letter-spacing:.04rem;text-decoration:none}.mlt-article-type:hover{text-decoration:underline}.nejm{color:#f30}.nejm-ai{color:#006197}.nejm-catalyst{color:#5708a6}.nejm-evidence{color:#69a323}.mlt-article-site-label::after,.mlt-article-type::after{border-right:1px solid #e5e5e5;content:'';display:inline;padding:.1875rem .375rem .125rem 0;margin:0 .375rem 0 0}.mlt-article-pubdate{color:#666;font-style:normal;font-weight:700;line-height:1.25rem;letter-spacing:.04em}.mlt-article-authors{color:#666;font-family:var(--sans-serif);font-size:1rem;font-style:normal;font-weight:400;letter-spacing:normal;line-height:1.5rem;margin-bottom:1.38rem}.mlt-article-site-label{color:#666;font-style:normal;font-weight:700;letter-spacing:.04em}.mlt-article-title{margin-bottom:.5rem}.mlt-article-title>a{background-image:linear-gradient(#f30,#f30);background-position:0 90%;background-repeat:no-repeat;background-size:0 0;color:#1a1a1a;font-family:var(--quadraat-web);font-size:1.25rem;font-style:normal;font-weight:700;letter-spacing:normal;line-height:1.8rem;margin:1.5rem 0 .35rem 0;text-decoration:none;transition:background .25s ease-in-out}.mlt-article-title>a:hover{background-position:0 98%;background-size:100% .125rem;text-decoration:none}.skeleton-card{box-shadow:0 0 4px 1px rgba(0,0,0,.1);margin:1rem 0;padding:1rem}</style></div></more-like-this>




        
        <div><div class="pb-dropzone" data-pb-dropzone="col-0" title="col-0"></div></div>










    
    
        <div data-widget-def="UX3HTMLWidget" data-widget-id="ad06db99-f228-4c92-9ad7-c4ae0fdbdbf1" id="bc-web-rec">
        



        
        <!-- BlueConic TEST empty HTML widget with DIV wrapper with id=bc-web-rec -->

        </div>
    

</aside></article><div data-extent="article-wrapper"><div class="core-container"></div><div class="after-credits"><div class="core-container"><a href="/doi/pdf/10.1056/NEJMoa2209051?download=true" id="downloadPdfUrl" data-doi="10.1056/NEJMoa2209051" data-behavior="trackDownloadEvent" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2209051.pdf"><span>Download PDF</span></a></div></div></div><script id="axel-publication-metadata" type="application/json">{"doi":"10.1056/NEJMoa2209051"}
</script><script type="text/javascript" data-ot-ignore="data-ot-ignore" defer="defer" src="https://static.addtoany.com/menu/page.js" class="optanon-category-C0004 ot-vscat-C0004"></script><div class="articles-nav"></div><template id="figure_nav_template"><nav><a href="#" title="Open in viewer" class="open-in-viewer"><i aria-hidden="true" class="icon-expand"></i></a></nav></template><template id="fv_panel_template" data-sharesocial="Share"><div class="fv__panel js--hidden"><div class="fv__panel__text"><div class="fv__panel__contentTitle"></div><div class="fv__panel__contentText"></div></div></div></template>
<template id="fv_directory_template" data-overlay="View figure"><div class="fv__directory"><div class="fv__header"><nav class="tab__nav"></nav><a href="#" title="Close figure viewer" class="fv__close"><i aria-hidden="true" class="icon-close"></i></a></div><div class="fv__content tab__content"></div></div></template><template id="fv_directory_tabItem_template" data-figures="Figures" data-others="Others" data-tables="Tables"><button role="tab" data-toggle="tab" class="tab__nav__item"></button></template>
<template id="fv_lightbox_template" data-sr-back="Go to figure location within the article" data-sr-closealt="Close" data-sr-download="Toggle download panel" data-sr-download-pptx="Download PPT" data-sr-info="Toggle information panel" data-sr-panel="Close panel" data-sr-share="Toggle share panel" data-sr-zoom="Zoom" data-text-close="Back to article" data-text-nav-figures="All figures" data-text-nav-others="All others" data-text-nav-tables="All tables" data-text-viewall="View all material" data-title-back="Back to article" data-title-closealt="Close" data-title-download="Download" data-title-download-pptx="Download PPT" data-title-info="Info" data-title-share="Share" data-title-zoom="Zoom"></template>
<template id="fv_toolbar_template"><div class="fv__toolbar__info"><strong class="fv__toolbar__contentTitle uppercase"></strong><p class="fv__toolbar__contentText"></p></div></template><template id="toCitationLink" data-citation="Citation" data-footnote="Footnote"><div class="to-citation__wrapper"><a class="to-citation"><i aria-hidden="true" class="icon-return"></i><span>Go to</span></a></div></template><template id="toCitationButton" data-citation="Citation" data-footnote="Footnote"><div class="to-citation__wrapper"><button class="to-citation"><i aria-hidden="true" class="icon-return"></i><span>Go to</span></button></div></template><template id="toCitationAccordion" data-collapse-citation="Hide Citations" data-expand-citation="Show Citations" data-collapse-footnote="Hide Footnotes" data-expand-footnote="Show Footnotes"><div class="to-citation__wrapper"><button aria-controls="aria-controls" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="data-expand-title" data-collapsed-title="data-collapsed-title" class="accordion__toggle__title"></span></button><div role="menu" aria-label="links" class="to-citation__accordion no-separator"><ul></ul></div></div></template><template id="toCitationAccordionItem"><li><a class="to-citation"><i aria-hidden="true" class="icon-return"></i><span></span></a></li></template><template id="citations_truncate_template"><div class="citations-truncation"><button data-label-expand="Show all references" data-label-collapse="Show fewer" data-label-remaining="references remaining" class="btn btn--secondary"><span>Show all references</span></button></div></template><template id="collateral_texts_template" data-references="References" data-figure="Go to Figure" data-media="Go to Media" data-more="More" data-original="Go to original" data-table="Go to Table" data-inviewer="Open in Viewer" data-allinviewer="Open all in viewer"><svg data-tags="copyright" viewBox="0 0 24 24"><path d="M12 20.016q3.281 0 5.648-2.368T20.016 12t-2.368-5.648T12 3.984 6.352 6.352 3.984 12t2.368 5.648T12 20.016zm0-18q4.125 0 7.055 2.93T21.985 12t-2.93 7.055T12 21.985t-7.055-2.93T2.015 12t2.93-7.055T12 2.015zm-.14 7.125q-1.876 0-1.876 2.718v.282q0 2.718 1.875 2.718.704 0 1.172-.398t.469-1.008h1.781q0 1.172-1.031 2.063-.984.843-2.39.843-1.876 0-2.86-1.125t-.984-3.093v-.282q0-1.921.937-3 1.125-1.265 2.906-1.265 1.547 0 2.438.89.984.985.984 2.297H13.5q0-.328-.14-.61-.235-.468-.329-.562-.469-.468-1.172-.468z"></path></svg><span>Request permissions</span><i aria-hidden="true" class="icon-open_in_new"></i></template><template id="collapsible_authors_template"><button aria-expanded="false" data-expandable="all" data-label-expand="Expand All" data-label-collapse="Collapse All" class="collateral-contributors-control"><span>Expand All</span></button></template>
<template id="collapsible_tables_collapse_template"><div class="collapsible-figure-btn__wrapper expanded"><button aria-expanded="true" class="btn collapsible-figure-btn btn--inverse"><i aria-hidden="true" class="icon-arrow-up"></i><span class="text-uppercase">Collapse</span></button></div></template>
<template id="collapsible_tables_expand_template"><div class="collapsible-figure-btn__wrapper collapsed"><button aria-expanded="false" class="btn collapsible-figure-btn btn--inverse"><i aria-hidden="true" class="icon-arrow-down"></i><span class="text-uppercase">Expand Table</span></button></div></template><template id="authorsAffiliationsLink"><a href="#tab-contributors" class="to-authors-affiliations">Authors Info &amp; Affiliations</a></template>

        <div role="navigation" aria-label="Sticky Navigation" class="st-header"><div class="st-header__content"><div class="st-header__item st-header__menu"></div><div class="st-header__current st-header__item"><div class="st-header__label">Now Reading:</div><div class="st-header__title">Rivaroxaban in Rheumatic Heart Disease–Associated Atrial Fibrillation</div></div><div class="st-header__share st-header__item"><div class="share-dropblock dropdown"><a id="sticky-header-dropBlock" href="#" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" class="dropdown-toggle"><span title="" data-toggle="tooltip" data-trigger="hover" data-original-title="Share options"><span class="sr-only">Share</span><i aria-hidden="true" class="icon-share"></i></span></a><div aria-labelledby="sticky-header-dropBlock" data-location="share_tools_article" class="dropdown-menu"><ul class="rlist--inline a2a a2a_kit" style="line-height: 16px;"><li><a href="/#facebook" aria-label="Share on Facebook" data-id="article-share-facebook" rel="nofollow noopener" role="link" target="_blank" title="Share on Facebook" class="btn btn--facebook a2a_button_facebook" data-interactiontype="social"><i aria-hidden="true" class="icon-facebook"></i></a></li><li><a href="/#twitter" aria-label="Share on X (formerly Twitter)" data-id="article-share-twitter" rel="nofollow noopener" role="link" target="_blank" title="Share on X (formerly Twitter)" class="btn btn--twitter a2a_button_twitter" data-interactiontype="social"><i aria-hidden="true" class="icon-twitter"></i></a></li><li><a href="/#linkedin" aria-label="Share on LinkedIn" data-id="article-share-linkedin" rel="nofollow noopener" role="link" target="_blank" title="Share on LinkedIn" class="btn btn--linkedin a2a_button_linkedin" data-interactiontype="social"><i aria-hidden="true" class="icon-linkedin"></i></a></li><li><a href="/#email" aria-label="Share on email" data-id="article-share-email" rel="nofollow noopener" role="link" target="_blank" title="Share on email" class="btn btn--email a2a_button_email" data-interactiontype="content_email_click"><i aria-hidden="true" class="icon-mail"></i></a></li><li><a href="/#bluesky" aria-label="Share on Bluesky" data-id="article-share-bluesky" rel="nofollow noopener" role="link" target="_blank" title="Share on Bluesky" class="btn btn--bluesky a2a_button_bluesky" data-interactiontype="social"><i aria-hidden="true" class="icon-bluesky"></i></a></li></ul></div></div></div><div class="st-header__nav st-header__item"><div class="content-navigation"><a href="/doi/full/10.1056/NEJMoa2208275" aria-label="Previous article" aria-disabled="false" class="content-navigation__prev"><div aria-hidden="true" class="content-navigation__hint"><div class="content-navigation__hint__content"><h6>PREVIOUS ARTICLE</h6><div>Polypill Strategy in Secondary Cardiovascular Prevention</div></div></div><i aria-hidden="true" class="icon-arrow-left"></i><span>Previous</span></a><a href="/doi/full/10.1056/NEJMoa2202884" aria-label="Next article" aria-disabled="false" class="content-navigation__next"><div aria-hidden="true" class="content-navigation__hint"><div class="content-navigation__hint__content"><h6>NEXT ARTICLE</h6><div>Aggressive or Moderate Fluid Resuscitation in Acute Pancreatitis</div></div></div><span>Next</span><i aria-hidden="true" class="icon-arrow-right"></i></a></div></div></div><div class="st-header__track"><div id="progress-tracker" class="st-header__tracker" style="width: 0px;"></div></div></div><div class="fv figureViewer js--has-focus-mode"><div class="fv__directory" data-core-tabs="default" style="display: flex;"><div class="fv__header"><nav class="tab__nav" role="tablist"><button role="tab" data-toggle="tab" class="tab__nav__item active" aria-controls="#tab-pane-figures" aria-selected="true">Figures</button><button role="tab" data-toggle="tab" class="tab__nav__item" aria-controls="#tab-pane-tables" tabindex="-1" aria-selected="false">Tables</button></nav><a href="#" title="Close figure viewer" class="fv__close"><i aria-hidden="true" class="icon-close"></i></a></div><div class="fv__content tab__content"><div class="tab__pane fv__list fv__list--figures" id="tab-pane-figures" aria-label="All figures" tabindex="0" role="tabpanel"><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f0" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2209051_f0.jpg"><img src="/cms/10.1056/NEJMoa2209051/asset/e90d5a28-e029-4528-ac8d-406ff07dcedd/assets/images/large/nejmoa2209051_f0.jpg" height="3416" width="2640" aria-labelledby="f0" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title"></div><div class="fv__item__description"><figcaption>Download a PDF of the <a href="#ap0">Research Summary</a>.</figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f1" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2209051_f1.jpg"><img src="/cms/10.1056/NEJMoa2209051/asset/3eb90917-d9a9-4166-abfd-80f3c1860f7b/assets/images/large/nejmoa2209051_f1.jpg" height="1768" width="2231" aria-labelledby="f1" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title">Figure 1</div><div class="fv__item__description"><figcaption><div class="caption">Cumulative Incidence of the Composite of Stroke, Systemic Embolism, Myocardial Infarction, or Death from Vascular or Unknown Causes (Primary Outcome).</div><div class="notes"><div role="doc-footnote">Vascular causes could be cardiac or noncardiac. The inset shows the same data on an expanded y axis. VKA denotes vitamin K antagonist.</div></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f2" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2209051_f2.jpg"><img src="/cms/10.1056/NEJMoa2209051/asset/9278e3cb-d519-462f-b517-ed012b940adf/assets/images/large/nejmoa2209051_f2.jpg" height="3417" width="2231" aria-labelledby="f2" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title">Figure 2</div><div class="fv__item__description"><figcaption><div class="caption">Cumulative Incidences of Stroke or Systemic Embolism and of Death.</div><div class="notes"><div role="doc-footnote">The insets show the same data on expanded y axes.</div></div></figcaption></div></div></div><div class="tab__pane fv__list fv__list--tables" id="tab-pane-tables" aria-label="All tables" tabindex="-1" role="tabpanel"><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t1" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 1</div><div class="fv__item__description"><figcaption><div class="caption">Characteristics of the Patients at Baseline.<a href="#fv-t1fn1" role="doc-noteref">*</a></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t2" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 2</div><div class="fv__item__description"><figcaption><div class="caption">Intention-to-Treat Analysis of Efficacy Outcomes.<a href="#fv-t2fn1" role="doc-noteref">*</a></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t3" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 3</div><div class="fv__item__description"><figcaption><div class="caption">On-Treatment Analysis of Safety Outcomes and Selected Efficacy Outcomes.<a href="#fv-t3fn1" role="doc-noteref">*</a></div></figcaption></div></div></div></div></div></div><div class="references-pop-up fade" aria-hidden="true"><div class="references-pop-up__heading text-dark d-flex align-items-center"><div class="references-pop-up__title flex-grow-1">Reference <span class="references-pop-up__heading-number">1</span></div><a class="references-pop-up__close text-dark" href="#" title="close pop-up" tabindex="-1" aria-hidden="true"><i class="icon-close" aria-hidden="true"></i></a></div><div class="references-pop-up__items citations to-citation__accordion external-links"></div></div></main>
    

</div>

                    
                        



        
        <div class="ng-page_layout ng-page_layout-fullWidth"><div class="container-fluid"><div class="row"><div class="col-12">



        
        




        
        <div class="ng-page_layout-contentSpacing"></div>










    
    
        <div data-widget-def="oneSearchMultiSearch" data-widget-id="778b3ad8-1a8d-43d8-8196-63b03df4a138" data-location="recirc_inIssue_bottom_article">
        



        
        <div class="os-ms os-ms-more-from-issue"><h3 class="ng-subsection-title"><a href="/toc/nejm/387/11" class="ng-subsection-title_link animation-icon-shift"><span class="ng-subsection-title_text">More from Vol. 387 No. 11</span><span class="ng-subsection-title_icon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-longArrowRight"></use></svg></span></span></a></h3><ul class="os-ms-more-from-issue_list"><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Sep 15, 2022</span></li><li data-toggle="tooltip" data-original-title="Video" class="issue-item_meta-item"><span role="img" aria-label="Video" tabindex="0" class="issue-item_video"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#tooltip-video"></use></svg></span></span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2202884" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Aggressive or Moderate Fluid Resuscitation in Acute Pancreatitis</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">E. de-Madaria and Others</span></div></div></div></div></div></li><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Sep 15, 2022</span></li><li data-toggle="tooltip" data-original-title="Video" class="issue-item_meta-item"><span role="img" aria-label="Video" tabindex="0" class="issue-item_video"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#tooltip-video"></use></svg></span></span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2208275" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Polypill Strategy in Secondary Cardiovascular Prevention</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">J.M. Castellano and Others</span></div></div></div></div></div></li><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Sep 15, 2022</span></li><li data-toggle="tooltip" data-original-title="Video" class="issue-item_meta-item"><span role="img" aria-label="Video" tabindex="0" class="issue-item_video"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#tooltip-video"></use></svg></span></span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2203364" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">A Randomized Trial of Enteral Glutamine for Treatment of Burn Injuries</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">D.K. Heyland and Others</span></div></div></div></div></div></li></ul></div>

        </div>
    

</div></div></div></div>

                    
                        



        
        <div class="ng-page_layout-bottomAd"><div class="container-fluid"><div class="row"><div class="col-12">









    
    
        <div data-widget-def="literatumAd" data-widget-id="7e022d0d-4a48-44a7-af66-033cf5c13eb8" id="ad-article-bottom-FULLx320-1">
        



        
        



    
        <div class="pb-house-message adplaceholder exists">
            <!-- START: Circulation Footer 3 -->
<aside class="g-cta-subscribe">
	<style>
.bads_footer-banner24-ONJQNRF1{background:url(/pb-assets/contextual_messaging/footer-yel-background-2x-1513629627453.jpg) center center no-repeat;padding:20px;display:block;margin:0;min-height:inherit;background-size:cover;text-decoration:none!important;color:#1a1a1a;text-align:left}.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:42px;line-height:44px;letter-spacing:.2px;margin:0 0 20px;font-family:ff-quadraat-web-pro,sans-serif;font-weight:600}.bads_footer-banner24-ONJQNRF1-inner{max-width:1300px;margin:0 auto}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions .a-btn{width:130px;padding-left:12px}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{position:static;color:#000;font-size:18px;line-height:27px;border:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions{margin:20px 0 20px 0;list-style-type:none;padding:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login a{color:#0a68ad}.bads_clearfix:after{visibility:hidden;display:block;font-size:0;content:" ";clear:both;height:0}.bads_clearfix{display:block}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{float:left;width:50%;padding:30px 0}.bads_footer-banner24-ONJQNRF1-inner .bads_device-img{float:left;padding-left:30px;width:50%}.bads_footer-banner24-ONJQNRF1 .bads_device-img>img{display:block;max-width:100%;height:auto}.bads_footer-banner24-ONJQNRF1 .bads_h5{font-size:18px;text-transform:uppercase;line-height:24px;font-weight:600;margin:-15px 0 0;letter-spacing:.2px}@media only screen and (max-width:480px){.bads_footer-banner24-ONJQNRF1-inner .bads_device-img,.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{width:100%;float:none}.bads_footer-banner24-ONJQNRF1-inner .bads_device-img{padding-left:0}.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:20px;line-height:27px;margin-bottom:10px}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding-top:0;padding-bottom:0}.bads_footer-banner24-ONJQNRF1{height:auto}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions{margin:0 0 12px;list-style-type:none}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{line-height:25px;font-size:15px;margin-bottom:10px}.bads_footer-banner24-ONJQNRF1 .bads_device-img{width:280px!important;margin:0 auto}.bads_footer-banner24-ONJQNRF1 .bads_h5{margin:0 0 3px;font-size:14px}}@media only screen and (min-width:480px) and (max-width:1024px){.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:20px;line-height:30px;margin-bottom:15px}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{font-size:14px}.bads_footer-banner24-ONJQNRF1 .bads_h5{font-size:13px;margin-top:0}}@media only screen and (min-width:1025px) and (max-width:1200px){.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding:10px 0}.bads_footer-banner24-ONJQNRF1 .bads_h5{margin:0 0 5px}}@media only screen and (min-width:1401px){.bads_footer-banner24-ONJQNRF1 .bads_device-img>img{float:right}}
	</style>
	<div class="bads_footer-banner24-ONJQNRF1">
	  <div class="bads_footer-banner24-ONJQNRF1-inner bads_clearfix">
		 <div class="bads_subs-btn">
			<p class="g-cta-subscribe__title">Tap into groundbreaking research and clinically relevant insights</p>
			<ul class="g-cta-subscribe__actions">
				<li class="g-cta-subscribe__actions-primary">
				  <a href="/action/clickThrough?id=127716&amp;url=%2Faction%2FstoreProxy%3Faction%3Dsubscribe%26url%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa2209051%26promo%3DONFQNRF1&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2209051&amp;pubId=41284343&amp;placeholderId=101336&amp;productId=1035" class="ng-btn_primary ng-btn_iconRight"><span class="ng-btn_text">Subscribe </span><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#arrows-longArrowRight"></use></svg></span></a>
				</li>
			</ul>
			<p class="g-cta-subscribe__login">Already a subscriber? <a href="/action/clickThrough?id=127716&amp;url=%2Faction%2FstoreProxy%3Faction%3Dactivate%26url%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa2209051%26promo%3DONFQANR4&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2209051&amp;pubId=41284343&amp;placeholderId=101336&amp;productId=1035">Activate</a> your online access.</p>
		 </div>

		<div class="bads_device-img">
		   <img src="/sda/127716/footer-devices-2x.png" alt="Devices">
		</div>
	   </div>
	</div>
</aside>
<!--/END: Circulation Footer 3 -->
            
        </div>
    

    

    



        </div>
    

</div></div></div></div>

                    
                        



        
        <footer class="ng-footer footer__top" style="position: relative;"><div data-location="footer" class="ng-footer_columns"><div class="container-fluid"><div class="row"><div class="col-lg-4 col-md-6 col-sm-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">ARTICLE CATEGORIES</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item">
        <a href="/browse/nejm-article-category/research" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Research</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/review" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Reviews</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/clinical-cases" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Clinical Cases</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/perspective" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Perspective</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/commentary" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Commentary</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/other" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Other</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/medical-article-index" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Browse all Articles</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/toc/nejm/current" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Current Issue</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/loi/nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Issue Index</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">RESOURCES</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/author-center/home" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Authors &amp; Reviewers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/author-center/home" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Submit a Manuscript</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Subscribers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://tools.ovid.com/ovidtools/nejm.html" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Institutional Administrators</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/media" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Media</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/how-to-advertise" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Advertisers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/information-for-subscription-agents" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Agents</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/permissions" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Permissions &amp; Licensing</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/reprints" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Reprints</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmcareercenter.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM CareerCenter</span></a>
    </li>
</ul>
</div></div></div><div class="col-lg-4 col-md-6 col-sm-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title" aria-label="About us">ABOUT US</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/about-nejm/about-nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">About NEJM</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmgroup.org/" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM Group</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Products &amp; Services</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/editors-and-publishers" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Editors &amp; Publishers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/advertising-policies" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Advertising Policies</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/contact-nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text" aria-label="Contact us">Contact Us</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/frequently-asked-questions?#Accessibility" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Accessibility</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/frequently-asked-questions" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">FAQs</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/help" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Help</span></a></li>
    <li class="ng-footer_column-list-item"><a href="mailto:sitefeedback@nejm.org" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Site Feedback</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">SUBSCRIPTIONS</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS3" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Subscribe</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=renew&amp;product=nejm&amp;promo=ONFLNRR3&amp;prc=ONFARN52" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Renew</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=activate&amp;promo=ONFLNAA1" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Activate Subscription</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC4" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Create Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Manage Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=paybill&amp;product=nejm&amp;promo=BNFLPBA1" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Pay Bill</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.wolterskluwer.com/en/solutions/ovid/nejm-complete-collection" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Institutional Sales</span></a></li>    
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org/special-content" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Special Content</span></a></li>
</ul>
</div></div></div><div class="col-lg-4 col-md-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">STAY CONNECTED</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org/emails?section=NEJM" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Email Alerts</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC3" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Create Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Apps</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmcareercenter.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM CareerCenter</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/rss-feed/" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Podcasts</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/rss-feed/" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">RSS Feed</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/institutional-access" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Remote Access</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title" aria-label="Follow us">FOLLOW US</h4>
<ul class="ng-footer_column-list">
<li class="ng-footer_column-list-item"><a href="https://www.facebook.com/TheNewEnglandJournalofMedicine" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-facebook"></use></svg></span></span><span class="ng-footer_column-link-text">Facebook</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://twitter.com/nejm" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-twitter"></use></svg></span></span><span class="ng-footer_column-link-text">X (formerly Twitter)</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.instagram.com/nejm/" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-instagram"></use></svg></span></span><span class="ng-footer_column-link-text">Instagram</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.youtube.com/user/NEJMvideo" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-youtube"></use></svg></span></span><span class="ng-footer_column-link-text">Youtube</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.linkedin.com/company/nejm-group" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-linkedin"></use></svg></span></span><span class="ng-footer_column-link-text">LinkedIn</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://bsky.app/profile/nejm.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-bluesky"></use></svg></span></span><span class="ng-footer_column-link-text">Bluesky</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.tiktok.com/@nejm.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-tiktok"></use></svg></span></span><span class="ng-footer_column-link-text">TikTok</span></a></li>
</ul>
</div></div></div></div></div></div><div data-location="footer" class="ng-footer_journals"><div class="container-fluid"><div class="row"><div class="col-12">



        
        <h4 class="ng-footer_journals-label">JOURNALS</h4>
<ul class="ng-footer_journals-list">
<li class="ng-footer_journals-item"><a href="https://www.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">The New England Journal of Medicine</a></li>
<li class="ng-footer_journals-item"><a href="https://catalyst.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM Catalyst Innovations in Care Delivery</a></li>
<li class="ng-footer_journals-item"><a href="https://evidence.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM Evidence</a></li>
<li class="ng-footer_journals-item"><a href="https://ai.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM AI</a></li>
</ul>
</div></div></div></div><div data-location="legal" class="ng-footer_bottom"><div class="container-fluid"><div class="row"><div class="col-lg-7 col-md-6 ng-footer_bottom-left">



        
        <p>Copyright © 2025 <a href="https://www.massmed.org/" target="_blank" rel="noopener" class="ng-footer_bottom-link"><b>Massachusetts Medical Society</b></a>. All rights reserved, including those for text and data mining, AI training, and similar technologies. Electronic ISSN 1533-4406. Print ISSN 0028-4793.The content of this site is intended for health care professionals.</p>
</div><div class="col-lg-5 col-md-6 ng-footer_bottom-right">



        
        <style>
  #teconsent a {
    color: #666;
    text-decoration: none;
  }
  #teconsent a:hover {
    color: #666;
    text-decoration: underline;
  }
</style>
<ul class="ng-footer_bottom-list">
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/copyright-information.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Copyright</a></li>
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/terms-of-use.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Terms</a></li>
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/privacy-policy.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Privacy Policy</a></li>
<li class="ng-footer_bottom-list-item"><span id="teconsent" consent="undefined" aria-label="Open Cookie Preferences Modal" role="complementary"><a role="link" id="icon-id06517779040573847" tabindex="0" lang="en" aria-haspopup="dialog" aria-label="Cookie Preferences, opens a dedicated popup modal window" class="truste_cursor_pointer">Cookie Preferences</a></span></li>
</ul>
<a href="https://www.nejmgroup.org/" title="NEJM Group" target="_blank" rel="noopener" class="ng-footer_logo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/logo_group.svg" alt="NEJM Group logo" class="ng-footer_logo" loading="lazy" width="103" height="40"></a>
</div></div></div></div><div data-show-after="400" class="back-to-top back-to-top--align-right  "><button data-snap="footer__top" class="back-to-top__action position-relative p-0 m-0 border-0 d-flex flex-column align-items-center justify-content-center"><svg viewBox="0 0 36 36" class="position-relative"><path d="M18 2.0845 a 15.9155 15.9155 0 0 1 0 31.831 a 15.9155 15.9155 0 0 1 0 -31.831" class="back-to-top__action__ring-bg"></path><path d="M18 2.0845 a 15.9155 15.9155 0 0 1 0 31.831 a 15.9155 15.9155 0 0 1 0 -31.831" stroke-dasharray="0, 100" class="back-to-top__action__ring"></path></svg><span class="back-to-top__action-icon position-absolute d-flex"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-up"></use></svg></span></span><span class="sr-only">Back to top</span></button></div></footer>

                    
                        



        
        <!-- TrustArc: Banner -->
<div id="consent_blackbar"><style>  #consent_blackbar{    position:relative;    width:100%;    z-index: 999999;  }    #trustarc-banner-overlay {  background-color: rgb(0, 0, 0);   opacity: 0.3;   position: fixed;   z-index: 1000000;   width: 100%;  height: 100%;   top: 0px;   left: 0px;   overflow: hidden;}.truste-title {  /*font-family: "Source Sans Pro", sans-serif;  font-size: 23px;  font-style: normal;  font-stretch: normal;*/  color: #222;  margin-bottom: 20px;  text-align: center;/*  font-weight:bold;*/}.truste-footer {  margin: 0 auto;      }.truste-left {  margin: 0px 0px 15px 15px;/*font-family: "Source Sans Pro", sans-serif;  font-size: 14px;    */}.truste-banner { margin: 0 auto; }.truste-messageColumn {/*font-family: "Source Sans Pro", sans-serif;  font-size: 14px;*/  color: #666666;  margin: 0px;}#truste-consent-button, #truste-consent-required {    background-color: #FF1E00;    color: #F2F1F1;    padding: 5px 10px;    border: 1px solid #FF1E00;    border-radius: 0px;    cursor: pointer;    text-transform:uppercase;/*    font-family: "Source Sans Pro",sans-serif;    font-size: 15px;*/  }      #truste-show-consent {    background-color: #FF1E00;    color: #F2F1F1;    border: 1px solid #FF1E00;    padding: 5px 10px;    border-radius: 0px;    cursor: pointer;    text-transform:uppercase;/*    font-family: "Source Sans Pro",sans-serif;    font-size: 15px;*/  }div.truste-consent-track-class {  position: fixed;  z-index:9999999;   background: #666;   border: 1px solid #333;    /*padding: 10px 60px;*/    bottom:0px;    right:0px;    left:0px;    margin: 10px;}.truste-left {  margin: 0;}div.text-content {  display: flex;  flex-direction: column;  align-self: baseline;}#truste-consent-text {    /*font-family: "Source Sans Pro", sans-serif;    font-size: 16px;*/    color: #fff;    margin: 15px 0px;}.truste-footer {  padding-top: 15px;}#truste-consent-content {  margin: 0 auto;    padding: 0 10px;    max-width: 1366px;}.truste-consent-footer {  display: none;}.flex-container {  display: block;  align-items: center;  justify-content: space-between;}#truste-consent-buttons {  float: right;  margin: 10px 5px 10px 0px;}#truste-show-consent { background: #F30 !important;}#truste-consent-button, #truste-consent-required { background: #F30 !important; } /* MEDIA QUERIES */  @media screen and (max-width: 500px) {  #truste-consent-track {    padding: 5px 20px;  }  }@media screen and (max-width: 375px) {  .truste-buttonsColumn {    float: none;    margin: 0;  }  #truste-consent-button, #truste-consent-required, #truste-show-consent {    width: 100%;    margin-bottom: 5px;  }          #truste-consent-buttons {  float: none;  margin: 10px 0px 10px 0px;	}}</style><div id="truste-consent-track" style="display: block; opacity: 1;">  <div id="trustarc-banner-overlay"></div>  <div class="truste-consent-track-class">    <div id="truste-consent-content" class="truste-banner">        <div class="flex-container">          <div class="text-content">            <div id="truste-consent-text" class="truste-messageColumn">This site uses cookies and related technologies, as described in our privacy policy, for purposes that may include site operation, analytics, enhanced user experience, or advertising. You may choose to consent to our use of these technologies, or manage your own preferences.                       </div>          </div>          <div id="truste-consent-buttons" class="truste-buttonsColumn">            <button id="truste-show-consent" aria-haspopup="dialog">Manage Settings</button>      <button id="truste-consent-button">Accept</button>      <!-- <button id="truste-consent-required">Decline All</button> -->          </div>        </div>                <div style="clear:both;"></div>    </div>  </div></div><!--emptycomment--></div>
<!-- /TrustArc: Banner -->

                    
                        



        
        <link rel="stylesheet" href="https://cssjs.nejm.org/mmsWidgets.css"><script nonce="94d6e9573670da2e-SJC" type="text/javascript" src="https://cssjs.nejm.org/mmsWidgets.js"></script><script nonce="94d6e9573670da2e-SJC" type="text/javascript">var litSSO = {
    "ucid": null,
    "accessToken": null,
    "authState": null
};

var loginUri = '/action/doSsoLogin';
var logoutUri = '/action/doLogout';

displayAuthenticatedMessage();

mmsWidgets.init({
    clientId: 'qsra7g4d6jwdsgn3zbe6udp6r6278mr9',
    origin: 'NEJM',
    xdReceiver: 'http://www.nejm.org/pb-assets/sso/xd.html',
    isFullPageSignIn: isSignInPage(),
    debug: true,

    onReady: function (e) {
        console.log('<<<<<<<<<< client: received onReady event.');
        $("A.litSsoLogin").click(function (e) {
            if (!$(e.currentTarget).hasClass("noMd") || $(e.currentTarget).parents(".header_sm-login").length === 0) {
                mmsWidgets.signIn(e);
                return false;
            }
        });
        $("A.litSsoLogout").click(function (e) {
            mmsWidgets.signOut(e);
            return false;
        });
        $("A.litSsoCreate").click(function (e) {
            mmsWidgets.showRegModal(e);
            return false;
        });
        $("A.litSsoSubscribe").click(function (e) {
            if (!$(e.currentTarget).hasClass("noMd") || $(e.currentTarget).parents(".header_sm-login").length === 0)
                location.assign(e.currentTarget.href);
            return false;
        });
        if (window.doSSOLogin) {
            window.setTimeout(function () {
                mmsWidgets.signIn();
            }, 500);
        }
        ;
    },
    onLoginSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onLoginSuccess event.' + JSON.stringify(e));

        const redirectUrl = getRedirectUri(window.location.search, location.href.replace(window.location.origin, ""));
        document.cookie = "skipSso=; expires=; path=/";
        if (!litSSO.ucid || e.ucid != litSSO.ucid || !litSSO.accessToken || e.accessToken != litSSO.accessToken) {
            location.assign(loginUri + "?ucid=" + e.profile.ucid
                + "&accessToken=" + e.accessToken
                + "&authState=" + e.authState
                + "&email=" + encodeURIComponent(e.profile.email)
                + "&givenNames=" + e.profile.givenName
                + "&surname=" + e.profile.familyName
                + "&redirectUri=" + redirectUrl
                + "&uccLastUpdatedDate=" + encodeURIComponent(e.profile.uccLastUpdatedDate)
                + "&rememberMe=" + e.rememberMe);
        }
    },
    onAuthStateReady: function (e) {
        console.log('<<<<<<<<<< client: received onAuthStateReady event.' + JSON.stringify(e))

        var isMmsSsoAuthenticated = (e.authState && e.authState !== "anonymous" && e.authState !== "lead" && e.ucid && e.accessToken) ? true : false;
        var isLitSsoAuthenticated = (litSSO.ucid && litSSO.accessToken && litSSO.authState) ? true : false;
        console.log('           isMmsSsoAuthenticated=' + isMmsSsoAuthenticated + ', isLitSsoAuthenticated=' + isLitSsoAuthenticated);

        if (isMmsSsoAuthenticated) {
            if (!isLitSsoAuthenticated || litSSO.ucid != e.ucid) {
                if (window.skipSso)
                    document.cookie = "skipSso=" + encodeURIComponent(e.ucid) + "; expires=; path=/";

                if (!window.skipSso && document.cookie.indexOf("skipSso=" + encodeURIComponent(e.ucid)) == -1) {
                    location.assign(loginUri + "?ucid=" + e.profile.ucid
                        + "&accessToken=" + e.accessToken
                        + "&authState=" + e.authState
                        + "&email=" + encodeURIComponent(e.profile.email)
                        + "&givenNames=" + e.profile.givenName
                        + "&surname=" + e.profile.familyName
                        + "&redirectUri=" + location.href.replace(window.location.origin, "")
                        + "&uccLastUpdatedDate=" + encodeURIComponent(e.profile.uccLastUpdatedDate)
                        + "&rememberMe=" + e.rememberMe);
                } else
                    console.log('**** client: Skip SSO ****');
            } else if (e.accessToken !== litSSO.accessToken)
                updateLitSession(e.ucid, e.accessToken);
        } else if (isLitSsoAuthenticated)
            location.assign(logoutUri + "?redirectUri=" + encodeURIComponent(location.href.replace(window.location.origin, "")));

        if (document.getElementById("ssoerr-ucid"))
            document.getElementById("ssoerr-ucid").innerHTML = e.ucid;

    },
    onRegistrationSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onRegistrationSuccess event.' + JSON.stringify(e))
        document.cookie = "skipSso=; expires=; path=/";
        var uccLastUpdatedDate = '1812-01-01 00:00:00.1 +0000';
        location.assign(loginUri + "?ucid=" + e.profile.ucid
            + "&accessToken=" + e.accessToken
            + "&authState=" + e.authState
            + "&email=" + encodeURIComponent(e.profile.email)
            + "&givenNames=" + e.profile.givenName
            + "&surname=" + e.profile.familyName
            + "&redirectUri=" + location.href.replace(window.location.origin, "")
            + "&uccLastUpdatedDate=" + encodeURIComponent(uccLastUpdatedDate)
            + "&rememberMe=" + e.rememberMe);
    },
    onLogoutSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onLogoutSuccess event.' + JSON.stringify(e))

        document.cookie = "skipSso=; expires=; path=/";
        location.assign(logoutUri);
    },
});

function updateLitSession(ucid, accessToken) {
    $.ajax({
        method: "GET",
        url: "/action/doSsoSessionUpdate",
        data: {ucid: ucid, accessToken: accessToken},
        success: function (callData, textStatus) {
            console.log("Session accessToken updated")
            litSSO.accessToken = accessToken
        },
        error: function (jqXHR, textStatus, errorThrown) {
            alert("Your website session has expired and will now be reset.")
            console.log("Session update failed: " + jqXHR.responseText)
            location.assign(logoutUri + "?redirectUri=" + encodeURIComponent(location.href.replace(window.location.origin, "")));
        }
    });
}

function getRedirectUri(location, fallback) {
    const urlParams = new URLSearchParams(location);
    const uriUrlParam = urlParams.get('uri');
    if (uriUrlParam)
        return encodeURIComponent(uriUrlParam);
    else
        return encodeURIComponent(fallback);
}

function isSignInPage() {
    return document.querySelector('meta[name="pbContext"]').content.indexOf("customPage:string:/sign-in") > -1;
}

function displayAuthenticatedMessage() {
    if (isSignInPage()) {
        var div = document.getElementById('authMsg');
        if ("" === "PersonUser") {
            div.innerHTML += "You are already signed in to " + window.location.origin.replace("https://", "").replace("www.", "") + ". If you would like to sign in with a different email address, please use the form below.";
        } else {
            div.innerHTML = '';
        }
    }
}</script>

                    
                
            </div>
        </div><iframe name="trustarc_notice" id="trustarcNoticeFrame" title="Trustarc Cross-Domain Consent Frame" src="https://consent.trustarc.com/get?name=crossdomain.html&amp;domain=nejm.com" style="display: none;"></iframe><script src="https://consent.trustarc.com/asset/notice.js/v/v1.7-1576" async="async" crossorigin="" importance="high" nonce="94d6e9573670da2e-SJC"></script>
        


        
        

            <script src="/products/mms-nextgen/mms/releasedAssets/js/build.lazyload.bundle-c8c4e7d20884f81951fb.js" nonce="94d6e9573670da2e-SJC"></script>

        <script src="/products/mms-nextgen/mms/releasedAssets/js/main.bundle-3819a02ec7bc2aca01ec.js" nonce="94d6e9573670da2e-SJC"></script>
        


<div id="adModal" tabindex="-1" aria-labelledby="exampleModalCenterTitle" class="ng-modal modal" style="display: none;" aria-hidden="true">
    <div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered ad-promoLayer">
        <div class="ng-modal_content modal-content p-0">
            <div class="ng-modal_body modal-body m-0">
                <div class="ng-modal_header modal-header">
                    <button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#close"></use></svg></span></span>
                    </button>
                </div>

            </div>
        </div>
    </div>
</div>
<script type="text/javascript" src="/wro/1125813~product.js" nonce="94d6e9573670da2e-SJC"></script>








<input id="showLayers" type="hidden" value="true">

    <!-- placeholder id=null, description=ad-layer-config -->
    <!-- placeholder id=null, description=ad-lauchLayer-1 -->
    <!-- placeholder id=null, description=ad-layer-promo-1 -->

    <input id="firstAd" type="hidden" value="">
    <input id="secondAd" type="hidden" value="">

    
    
    

    
    
    <input id="IsInstitution" type="hidden" value="false">
    <input id="IsSubscriber" type="hidden" value="true">
    <input id="CustomerId" type="hidden" value="">


<script type="text/javascript" nonce="94d6e9573670da2e-SJC">
  jQuery.extend(jQuery.mmsLayers.config, {
    rules: [{
      "name": "Launch Layer Ad",
      "frequency": 30,
      "showOnPage": 5,
      "enabled": false,
      "cookieName": "MarketingLaunchLayer",
      "styleClass": "launchLayer"
    },
    {
      "name": "Promo Layer Ad",
      "frequency": 14,
      "enabled": true,
      "cookieName": "PromoLayer",
      "styleClass": "promoLayer"
    },
    {
      "name": "Interstitial Ad",
      "frequency": 7,
      "enabled": false,
      "cookieName": "InterstitialAd"
    },
    {
      "name": "Iperceptions - Ion Layer Ad",
      "showOnPage": 1,
      "enabled": false,
      "test": false,
      "cookieName":"Iperceptions"
    }]
 });
</script>

















    <script type="text/javascript" nonce="94d6e9573670da2e-SJC">
        $(document).ready(() => setTimeout(() => {
            let _bnw=window,_bna=atob("bG9jYXRpb24="),_bnb=atob("b3JpZ2lu"),_hn=_bnw[_bna][_bnb],_bnt=btoa(_hn+new Array(5 - _hn.length % 4).join(" "));
            $.get("/resource/lodash?t="+_bnt);
        },4000));
    </script>












    

    
    

    
    
    
    
        
            
                <script type="text/javascript" src="/wro/1125813~article-metrics.js" nonce="94d6e9573670da2e-SJC"></script>
            
            
            
        
    




<script type="text/javascript" src="/wro/1125813~full-text-analytics.js" nonce="94d6e9573670da2e-SJC"></script>


    


            <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'94d6e95728eada2e',t:'MTc0OTUzNzk4NS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script><iframe height="1" width="1" style="position: absolute; top: 0px; left: 0px; border: none; visibility: hidden;"></iframe><script defer="" src="https://static.cloudflareinsights.com/beacon.min.js/vcd15cbe7772f49c399c6a5babf22c1241717689176015" integrity="sha512-ZpsOmlRQV6y907TI0dKBHq9Md29nnaEIPlkf84rnaERnq6zvWvPUqr2ft8M1aS28oN72PdrCzSjY4U6VaAw1EQ==" data-cf-beacon="{&quot;rayId&quot;:&quot;94d6e95728eada2e&quot;,&quot;serverTiming&quot;:{&quot;name&quot;:{&quot;cfExtPri&quot;:true,&quot;cfEdge&quot;:true,&quot;cfOrigin&quot;:true,&quot;cfL4&quot;:true,&quot;cfSpeedBrain&quot;:true,&quot;cfCacheStatus&quot;:true}},&quot;version&quot;:&quot;2025.5.0&quot;,&quot;token&quot;:&quot;f55e150c7a5f4a4ab9ef82f4a1c9c43c&quot;}" crossorigin="anonymous"></script>

        
        
    

<div style="display:none;" id="signInEmbedded" class="ucc-fullpage-signin ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Sign In</h1>
  </div>    
  <div class="capture_signin">
    {* #signInForm *}
    <div class="ucc-form-inner-wrapper">
      {* signInEmailAddress *}
      {* currentPassword *}
      <div style="padding-top:10px;">
          <div class="capture_form_item capture_form_rememberme">
          <label class="ucc-form-checkbox">                
            <input checked="checked" id="ucc-remember-me-cb-embedded" name="ucc-remember-me-cb-embedded" type="checkbox" value="true">
            <span>Remember Me</span>
          </label>                           
          </div>
          <div class="capture_form_item capture_form_forgotpwd">
            <a role="button" class="ucc-anchor-button" data-capturescreen="forgotPassword">Forgot your password?</a>
          </div>
      </div>
      <div class="capture_form_item">      
        <button id="ucc-sign-in-submit-embedded" class="capture_primary capture-full-width-btn" type="submit">Sign In</button>
      </div>
      <div class="capture_form_item capture_form_footer">
        <div class="ucc-no-acct-msg">Don't have an account?</div>
        <div class="ucc-no-acct-msg-2">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event); mmsWidgets.showRegAuto(event);">Create Account</a>
          <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
        </div>
      </div>
      <div class="capture_form_item capture_form_submit">
        
      </div>      
    </div>
    {* /signInForm *}
  </div>
</div><div style="display:none;" id="forgotPassword" class="ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Forgot Password</h1>
  </div>   
  <div class="ucc-form-inner-wrapper">
  <p style="color:black">Enter the email address associated with your account then click Continue. We will email you a link to a page where you can easily create a new password.</p>
  </div> 
  <div class="capture_forgotpassword">
    {* #forgotPasswordForm *}      
      <div class="ucc-form-inner-wrapper">
        {* forgotPasswordEmailAddress *}
        {* captcha *}
        <div class="capture_form_item" style="padding-top: 20px;">        
          <input id="ucc-widget-forgotpwd-submit" value="Continue" type="submit" class="capture_btn capture_primary capture-full-width-btn">
        </div>
      </div>
    {* /forgotPasswordForm *}
  </div>
  </div><div style="display:none;" id="forgotPasswordSuccess" class="ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Create New Password</h1>
  </div>    
  <div class="capture_forgotpassword">
      <div class="ucc-form-inner-wrapper">
        <p style="padding-top: 30px; padding-bottom: 30px;">We've sent an email with instructions to create a new password. Your existing password has not been changed.</p>        
        <div class="capture_form_item">      
          <button class="capture_btn capture_primary capture-full-width-btn" onclick="janrain.capture.ui.modal.close()">CLOSE</button>
        </div>
      </div>
  </div>
  </div><div style="display:none;" id="resetPassword" class="ucc-widgets-nejm-next">
      <div class="row">      
        <div class="col-md-8 col-md-offset-2 reset-pwd-info"><p>To reset your password, enter a new password twice and click the 'Reset Password' button.</p></div>
      </div>
      <div class="col-md-4 col-md-offset-4">
        {* #changePasswordFormNoAuth *}
          {* newPassword *}
          {* newPasswordConfirm *}     
          <div class="capture_form_item">
            <input value="RESET PASSWORD" type="submit" class="capture_btn capture_primary capture-full-width-btn">
          </div>
          {* /changePasswordFormNoAuth *}
      </div>
    </div><div style="display:none;" id="resetPasswordSuccess">
        <div class="reset-pwd-info">
          <div class="reset-pwd-success-welcome"></div>
          <p class="reset-pwd-success-msg">Your password has been reset. You will need to <a href="/signin" onclick="mmsWidgets.signIn(event)">sign in</a> again using your new password to access site content and features.</p>
          <p class="reset-pwd-success-nav"></p>
        </div>      
    </div><div style="display:none;" id="resetPasswordRequestCode" class="ucc-widgets-nejm-next">
        {* #resetPasswordForm *}
        <div class="capture_form_error">The link that you followed to reset your password has expired.</div>
          <div class="col-md-8 col-md-offset-2">
            <p class="reset-pwd-info">Enter the email address associated with your account then click Continue. We will email you a link to a page where you can easily create a new password.</p>
          </div>
          <div class="col-md-4 col-md-offset-4">
            {* signInEmailAddress *}
            <div class="capture_form_item">
              <input value="continue" type="submit" class="capture_btn capture_primary capture-full-width-btn">
            </div>
          </div>
        {* /resetPasswordForm *}
    </div><div style="display:none;" id="resetPasswordRequestCodeSuccess">
      <div class="reset-pwd-info">
        <p>If the address matches an existing account, you will receive an email with instructions to reset your password.</p>
        <p class="reset-pwd-success-nav"></p>
      </div>
  </div><div id="addtoany" style="position: static;"><div class="a2a_overlay" id="a2a_overlay"></div><div id="a2a_modal" class="a2a_modal a2a_hide" role="dialog" tabindex="-1" aria-label=""><div class="a2a_modal_body a2a_menu a2a_hide" id="a2a_copy_link"><label for="a2a_copy_link_text" id="a2a_copy_link_icon" class="a2a_svg a2a_s_link a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><title>Copy link</title><path fill="#FFF" d="M7.591 21.177c0-.36.126-.665.377-.917l2.804-2.804a1.235 1.235 0 0 1 .913-.378c.377 0 .7.144.97.43-.026.028-.11.11-.255.25-.144.14-.24.236-.29.29a2.82 2.82 0 0 0-.2.256 1.056 1.056 0 0 0-.177.344 1.43 1.43 0 0 0-.046.37c0 .36.126.666.377.918a1.25 1.25 0 0 0 .918.377c.126.001.251-.015.373-.047.125-.037.242-.096.345-.175.09-.06.176-.127.256-.2.1-.094.196-.19.29-.29.14-.142.223-.23.25-.254.297.28.445.607.445.984 0 .36-.126.664-.377.916l-2.778 2.79a1.242 1.242 0 0 1-.917.364c-.36 0-.665-.118-.917-.35l-1.982-1.97a1.223 1.223 0 0 1-.378-.9l-.001-.004Zm9.477-9.504c0-.36.126-.665.377-.917l2.777-2.79a1.235 1.235 0 0 1 .913-.378c.35 0 .656.12.917.364l1.984 1.968c.254.252.38.553.38.903 0 .36-.126.665-.38.917l-2.802 2.804a1.238 1.238 0 0 1-.916.364c-.377 0-.7-.14-.97-.418.026-.027.11-.11.255-.25a7.5 7.5 0 0 0 .29-.29c.072-.08.139-.166.2-.255.08-.103.14-.22.176-.344.032-.12.048-.245.047-.37 0-.36-.126-.662-.377-.914a1.247 1.247 0 0 0-.917-.377c-.136 0-.26.015-.37.046-.114.03-.23.09-.346.175a3.868 3.868 0 0 0-.256.2c-.054.05-.15.148-.29.29-.14.146-.222.23-.25.258-.294-.278-.442-.606-.442-.983v-.003ZM5.003 21.177c0 1.078.382 1.99 1.146 2.736l1.982 1.968c.745.75 1.658 1.12 2.736 1.12 1.087 0 2.004-.38 2.75-1.143l2.777-2.79c.75-.747 1.12-1.66 1.12-2.737 0-1.106-.392-2.046-1.183-2.818l1.186-1.185c.774.79 1.708 1.186 2.805 1.186 1.078 0 1.995-.376 2.75-1.13l2.803-2.81c.751-.754 1.128-1.671 1.128-2.748 0-1.08-.382-1.993-1.146-2.738L23.875 6.12C23.13 5.372 22.218 5 21.139 5c-1.087 0-2.004.382-2.75 1.146l-2.777 2.79c-.75.747-1.12 1.66-1.12 2.737 0 1.105.392 2.045 1.183 2.817l-1.186 1.186c-.774-.79-1.708-1.186-2.805-1.186-1.078 0-1.995.377-2.75 1.132L6.13 18.426c-.754.755-1.13 1.672-1.13 2.75l.003.001Z"></path></svg></label><input id="a2a_copy_link_text" type="text" title="Copy link" readonly=""><div id="a2a_copy_link_copied">✓</div></div><div class="a2a_modal_body a2a_menu a2a_thanks a2a_hide" id="a2a_thanks"><div class="a2a_localize" data-a2a-localize="inner,ThanksForSharing">Thanks for sharing!</div></div></div><div class="a2a_menu a2a_full a2a_localize" id="a2apage_full" role="dialog" tabindex="-1" aria-label="Share" data-a2a-localize="title,Share"><div class="a2a_full_header"><div id="a2apage_find_container" class="a2a_menu_find_container"><label for="a2apage_find" id="a2apage_find_icon" class="a2a_svg a2a_s_find"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" aria-hidden="true"><title>Find any service</title><path fill="#CCC" d="M19.7 18.2l-4.5-4.5c.7-1.1 1.2-2.3 1.2-3.6 0-3.5-2.8-6.3-6.3-6.3s-6.3 2.8-6.3 6.3 2.8 6.3 6.3 6.3c1.4 0 2.6-.4 3.6-1.2l4.5 4.5c.6.6 1.3.7 1.7.2.5-.4.4-1.1-.2-1.7zm-9.6-3.6c-2.5 0-4.5-2.1-4.5-4.5 0-2.5 2.1-4.5 4.5-4.5 2.5 0 4.5 2.1 4.5 4.5s-2 4.5-4.5 4.5z"></path></svg></label><input id="a2apage_find" class="a2a_menu_find a2a_localize" type="text" autocomplete="off" title="Find any service" data-a2a-localize="title,FindAnyServiceToAddTo"></div></div><div class="a2a_full_services" id="a2apage_full_services" role="presentation"></div><div class="a2a_full_footer"><a href="https://www.addtoany.com" title="Share Buttons" rel="noopener" target="_blank"><span class="a2a_svg a2a_s__default a2a_s_a2a a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><g fill="#FFF"><path d="M14 7h4v18h-4z"></path><path d="M7 14h18v4H7z"></path></g></svg></span>AddToAny</a></div></div><div id="a2apage_dropdown" class="a2a_menu a2a_mini a2a_localize a2a_hide" tabindex="-1" aria-label="Share" data-a2a-localize="label,Share"><div class="a2a_mini_services" id="a2apage_mini_services"></div><div id="a2apage_cols_container" class="a2a_cols_container"><div class="a2a_col1" id="a2apage_col1"></div><div id="a2apage_2_col1" class="a2a_hide"></div><div class="a2a_clear"></div></div><div class="a2apage_wide a2a_wide"><a href="#addtoany" id="a2apage_show_more_less" class="a2a_more a2a_localize" title="Show all" data-a2a-localize="title,ShowAll"><span class="a2a_svg a2a_s__default a2a_s_a2a a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><g fill="#FFF"><path d="M14 7h4v18h-4z"></path><path d="M7 14h18v4H7z"></path></g></svg></span><span class="a2a_localize" data-a2a-localize="inner,More">More…</span></a></div></div><div style="height: 1px; width: 1px; position: absolute; z-index: 100000; top: 0px; visibility: hidden;"><iframe id="a2a_sm_ifr" title="AddToAny Utility Frame" aria-hidden="true" src="https://static.addtoany.com/menu/sm.25.html#type=core&amp;event=load" style="height: 1px; width: 1px; border: 0px; left: 0px; top: 0px; position: absolute; z-index: 100000; display: none;"></iframe></div></div><pkm-cyumtnhwdvuz></pkm-cyumtnhwdvuz><div role="status" aria-live="assertive" aria-relevant="additions" class="ui-helper-hidden-accessible"></div><script type="text/javascript" src="https://api.altmetric.com/v1/internal-556fdf0f/doi/10.1056/nejmoa2209051?callback=_altmetric.embed_callback&amp;domain=www.nejm.org&amp;cache_until=3-10"></script><div id="janrainEngageEmbed" style="display: none;"><div class="janrainContent" style="width: 380px !important; height: 156px !important; padding-left: 5px !important; padding-right: 5px !important; box-sizing: content-box !important; background-color: rgb(255, 255, 255) !important; border: 1px solid rgb(192, 192, 192) !important; border-radius: 10px !important; overflow: hidden !important; position: relative !important;"><div id="janrainView"><div class="janrainHeader" style="background-color: rgb(255, 255, 255) !important; font-size: 14px !important; color: rgb(102, 102, 102) !important; position: relative !important; height: 20px !important; left: -5px !important; padding: 5px 5px 0px !important; white-space: nowrap !important; width: 380px !important; z-index: 100 !important; border-radius: 10px 10px 0px 0px !important; text-align: left !important;"><div style="padding-left: 1px !important; font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important;">Sign in using your account with</div></div><div id="janrainProviderPages" style="padding-top: 5px; left: 5px; position: absolute;"><div class="janrainPage" pageindex="0"><ul class="providers" id="janrainProviders_0" style="float: left !important; list-style-type: none !important; margin: 0px !important; padding: 0px !important;"><li id="janrain-aol" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="1" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-aol" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-aol" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">AOL</span></a></li><li id="janrain-openid" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="3" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-openid" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-openid" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">OpenID</span></a></li></ul><ul class="providers" id="janrainProviders_1" style="float: left !important; list-style-type: none !important; margin: 0px !important; padding: 0px !important;"><li id="janrain-yahoo" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="2" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-yahoo" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-yahoo" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">Yahoo!</span></a></li></ul></div></div><div style="background-color: rgb(255, 255, 255) !important; width: 380px !important; height: 10px !important; position: absolute !important; left: 0px !important; padding-left: 5px !important; padding-right: 5px !important; padding-bottom: 5px !important; bottom: 0px !important; font-size: 10px !important; text-align: left !important; color: rgb(102, 102, 102) !important; font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; border-radius: 0px 0px 10px 10px !important;"><div style="padding-left: 1px !important;"><a href="http://janrain.com/products/engage/social-login?utm_source=mms.rpxnow.com&amp;utm_medium=Partner&amp;utm_campaign=attribution" target="_blank">Social Login by Janrain</a></div></div></div></div></div><iframe name="captureIFrame_7agftlxqs0w16hn9dtmybz534tm1vtuqpulqhu1k" data-transactionid="7agftlxqs0w16hn9dtmybz534tm1vtuqpulqhu1k" id="captureIFrame_7agftlxqs0w16hn9dtmybz534tm1vtuqpulqhu1k" src="about:blank" class="" data-captureiframeloadeventbound="yes" style="display: none;"></iframe><div id="janrainModalOverlay" style="inset: 0px; position: fixed; background-color: rgb(0, 0, 0); opacity: 0.4; display: none; z-index: 1000;"></div><div id="janrainModal" style="width: 380px; height: 131px; position: absolute; z-index: 1000; display: none;"><a href="#" class="janrain_modal_closebutton" style="position: absolute; cursor: pointer; z-index: 1000;">X</a><div style="display: block;" id="signIn" class="ucc-widgets-nejm-next janrain-capture-ui capture-ui-content capture_screen_container" data-capturescreenname="signIn" data-captureventadded="true">
    <div class="capture_header">
      <h1>Sign In</h1>
    </div>    
    <div class="capture_signin">
      <form id="capture_signIn_signInForm" name="signInForm" data-capturefield="signInForm" action="https://mms.us.janraincapture.com/widget/traditional_signin.jsonp" class="capture_form capture_signInForm" method="POST" novalidate="novalidate" data-transactionid="7agftlxqs0w16hn9dtmybz534tm1vtuqpulqhu1k" target="captureIFrame_7agftlxqs0w16hn9dtmybz534tm1vtuqpulqhu1k" accept-charset="UTF-8" next="{&quot;noop&quot;:&quot;&quot;}"><div id="capture_signIn_signInForm_defaultSavedProfileMessage"></div><div id="capture_signIn_signInForm_errorMessages"></div><input id="capture_signIn_utf8" data-capturefield="undefined" value="✓" type="hidden" class="capture_utf8" name="utf8"><input id="capture_signIn_screen_7agftlxqs0w16hn9dtmybz534tm1vtuqpulqhu1k" data-capturefield="undefined" value="signIn" type="hidden" class="capture_screen_7agftlxqs0w16hn9dtmybz534tm1vtuqpulqhu1k" name="capture_screen"><input id="capture_signIn_js_version_7agftlxqs0w16hn9dtmybz534tm1vtuqpulqhu1k" data-capturefield="undefined" value="d445bf4" type="hidden" class="capture_js_version_7agftlxqs0w16hn9dtmybz534tm1vtuqpulqhu1k" name="js_version"><input id="capture_signIn_transactionId_7agftlxqs0w16hn9dtmybz534tm1vtuqpulqhu1k" data-capturefield="undefined" value="7agftlxqs0w16hn9dtmybz534tm1vtuqpulqhu1k" type="hidden" class="capture_transactionId_7agftlxqs0w16hn9dtmybz534tm1vtuqpulqhu1k" name="capture_transactionId"><input id="capture_signIn_form_7agftlxqs0w16hn9dtmybz534tm1vtuqpulqhu1k" data-capturefield="undefined" value="signInForm" type="hidden" class="capture_form_7agftlxqs0w16hn9dtmybz534tm1vtuqpulqhu1k" name="form"><input id="capture_signIn_flow_7agftlxqs0w16hn9dtmybz534tm1vtuqpulqhu1k" data-capturefield="undefined" value="standard" type="hidden" class="capture_flow_7agftlxqs0w16hn9dtmybz534tm1vtuqpulqhu1k" name="flow"><input id="capture_signIn_client_id_7agftlxqs0w16hn9dtmybz534tm1vtuqpulqhu1k" data-capturefield="undefined" value="qsra7g4d6jwdsgn3zbe6udp6r6278mr9" type="hidden" class="capture_client_id_7agftlxqs0w16hn9dtmybz534tm1vtuqpulqhu1k" name="client_id"><input id="capture_signIn_redirect_uri_7agftlxqs0w16hn9dtmybz534tm1vtuqpulqhu1k" data-capturefield="undefined" value="https://www.nejm.org" type="hidden" class="capture_redirect_uri_7agftlxqs0w16hn9dtmybz534tm1vtuqpulqhu1k" name="redirect_uri"><input id="capture_signIn_response_type_7agftlxqs0w16hn9dtmybz534tm1vtuqpulqhu1k" data-capturefield="undefined" value="code" type="hidden" class="capture_response_type_7agftlxqs0w16hn9dtmybz534tm1vtuqpulqhu1k" name="response_type"><input id="capture_signIn_flow_version_7agftlxqs0w16hn9dtmybz534tm1vtuqpulqhu1k" data-capturefield="undefined" value="20240514181256512029" type="hidden" class="capture_flow_version_7agftlxqs0w16hn9dtmybz534tm1vtuqpulqhu1k" name="flow_version"><input id="capture_signIn_settings_version_7agftlxqs0w16hn9dtmybz534tm1vtuqpulqhu1k" data-capturefield="undefined" value="" type="hidden" class="capture_settings_version_7agftlxqs0w16hn9dtmybz534tm1vtuqpulqhu1k" name="settings_version"><input id="capture_signIn_locale_7agftlxqs0w16hn9dtmybz534tm1vtuqpulqhu1k" data-capturefield="undefined" value="en-US" type="hidden" class="capture_locale_7agftlxqs0w16hn9dtmybz534tm1vtuqpulqhu1k" name="locale"><input id="capture_signIn_recaptcha_version_7agftlxqs0w16hn9dtmybz534tm1vtuqpulqhu1k" data-capturefield="undefined" value="2" type="hidden" class="capture_recaptcha_version_7agftlxqs0w16hn9dtmybz534tm1vtuqpulqhu1k" name="recaptchaVersion">
      <div class="ucc-form-inner-wrapper">
        <div id="capture_signIn_form_item_signInEmailAddress" class="capture_form_item capture_email capture_form_item_signInEmailAddress" data-capturefield="undefined"><label for="capture_signIn_signInEmailAddress">Email Address</label><input id="capture_signIn_signInEmailAddress" data-capturefield="signInEmailAddress" value="" type="email" class="capture_signInEmailAddress capture_required capture_text_input" placeholder="Email Address" name="signInEmailAddress"><div class="capture_tip" style="display:none;"></div><div class="capture_tip_validating" data-elementname="signInEmailAddress">Validating</div><div class="capture_tip_error" data-elementname="signInEmailAddress"></div></div>
        <div id="capture_signIn_form_item_currentPassword" class="capture_form_item capture_password capture_form_item_currentPassword" data-capturefield="undefined"><label for="capture_signIn_currentPassword">Password</label><input id="capture_signIn_currentPassword" data-capturefield="currentPassword" value="" type="password" class="capture_currentPassword capture_required capture_text_input" placeholder="Password" name="currentPassword"><div class="capture_tip" style="display:none;"></div><div class="capture_tip_validating" data-elementname="currentPassword">Validating</div><div class="capture_tip_error" data-elementname="currentPassword"></div></div>
        <div style="padding-top:10px;">
            <div class="capture_form_item capture_form_rememberme">
                <label class="ucc-form-checkbox">                
                    <input checked="checked" id="ucc-remember-me-cb" name="ucc-remember-me-cb" type="checkbox" value="true">
                    <span>Remember Me</span>
                </label>          
            </div>
            <div class="capture_form_item capture_form_forgotpwd">
              <a role="button" class="ucc-anchor-button" data-capturescreen="forgotPassword">Forgot your password?</a>
            </div>
        </div>
        <div class="capture_form_item">
          <button id="ucc-sign-in-submit" class="capture_primary capture-full-width-btn" type="submit">Sign In</button>
        </div>
       
        <div class="capture_form_item">
          <div class="ucc-no-acct-msg">Don't have an account?</div>
          <div class="ucc-no-acct-msg-2" id="signInModalCreateAccountLink">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event); mmsWidgets.showRegAuto(event);">Create Account</a>
            <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
          </div>

          <div class="ucc-no-acct-msg-2" id="signInModalCloseLink" style="display:none">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event);">Create Account</a>
            <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
          </div>

        </div>
     
        <div class="capture_form_item capture_form_submit">
          
        </div>      
      </div>
      </form>
    </div>
  </div></div></body></html>